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Summary 
Integrins are metazoan heterodimeric receptors for cell adhesion and interaction 
with  extracellular matrix. Nowadays 18 integrin alpha chains and 8 beta chains are 
known in human cells, forming 24 different heterodimers specific for wide array of 
ligands, including collagens, laminins, and fibronectin. Dynamic assembly and 
disassembly of ligand-bound integrins as well as rearrangement of unengaged integrins 
on a cell surface depends on the intracellular trafficking. It is crucial for the processes 
related to cell adhesion, spreading, and migration, such as neutrophil migration or 
metastasis development in cancer.  
Number of studies addressed endocytosis and recycling of integrins, yet, the 
comprehensive model of integrin trafficking is still missing as the pathways of integrin 
retrograde trafficking can differ depending on the integrin activation status, binding to the 
ligand, growth factors presence. An additional level of complexity dealt in the integrin 
trafficking studies is a certain promiscuity in integrin α and β chain interactions, therefore 
the knowledge on the specificity of a trafficking pathway for a certain heterodimer is 
often lacking.  
This study focused on internalization regulators of integrin α2β1, which is a 
ubiquitously expressed receptor of collagens, mainly collagen I, one of the most abundant 
extracellular matrix proteins, which is known as a metastasis suppressor in human cancer. 
Studies on α2β1 endocytosis are sparse and mostly focused so far on the trafficking of 
α2β1 clustered by addition of virus or ligand.  
To identify and characterize novel regulators of internalization of non-clustered 
integrin α2β1, we established a quantitative fluorescent-microscopy-based integrin α2 
internalization assay. We demonstrated that bulk internalization of endogenously 
expressed non-clustered integrin α2 in HeLa cells is dependent on both clathrin and 
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caveolin1, and occurs via Rab5-, Rab4- and Rab11-positive endosomes. Next, we used 
RNAi to screen 386 cytoskeleton and cytoskeleton-associated genes for their involvement 
in integrin α2 internalization. We identified 122 primary screening hits as potential 
regulators of integrin α2 trafficking, number of which were previously known as 
regulators of endocytosis, focal adhesion formation, and cell migration, and as direct 
interactors of integrins. In the validation assays we could reproduce the results of the 
primary screening for 43% of expressed hits in the two groups of hits selected for 
validation (14 molecules that were targeted by multiple siRNAs in the primary screening, 
and 12 kinesin molecular motors). 
Three validated kinesin hits have never previously been associated with endocytic 
trafficking events. To get an insight in the function of kinesins in integrin internalization, 
we further characterized the role of KIF15 in the trafficking of integrin α2. It was 
identified as a strong inhibitor of the early steps of integrin α2 endocytosis, but not 
transferrin or EGF. We demonstrated that knock-down of KIF15 lead in re-location of the 
integrin-specific clathrin adaptor Dab2 from the plasma membrane, which is likely to be 
the reason for the block of integrin α2 internalization. 
Taken together, this study establishes the methods to address the internalization of 
non-clustered integrin α2β1, identifies the number of novel regulators of integrin 
trafficking, and provides insight into the role of KIF15 molecular motor in the integrin α2 
internalization.  
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Zusammenfassung 
Integrinen sind metazoische heterodimerische Rezeptoren für die Adhäsion der 
Zellen und ihre Wechselwirkung mit der Matrix. Zur Zeit sind 18 Alphaketten und 8 
Betaketten der Integrinen in der humanen Zelle bekannt, die 24 unterschiedliche 
Heterodimeren bilden. Diese Heterodimeren sind für eine umfangreiche Reihe von 
Liganden spezifisch, wie zum Beispiel Kollagene, Laminine und Fibronektin. 
Dynamische Zusammenbildung und Zerlegung von Integrinen, die zu einem Ligand 
gebunden sind, sowie die Umstellung von ungebundenen Integrinen auf der 
Zellenoberfläche hängt von dem intrazellularen Traffiking ab. Das ist essentiel für die 
Prozesse, die mit Zellenadhäsion, Verbreitung und Migration verbunden sind, so wie 
Migration von Neutrophilen und das Entstehen von den Metastasen in Krebs. 
Einige Studien gehen das Endozytosis und Recycling von Integrinen an, trotzdem 
fehlt es an einem umfassenden Model von Traffiking von Integrinen, weil der Verlauf von 
dem rückläufigen Traffiking von Integrinen je nach Aktivierungsstatus von Integrin, 
Ligandbindung, und die Präsenz von Wachstumsfaktoren sich unterscheiden kann. Ein 
zusätzliches Niveau der Komplexität, mit dem die Integrinstudien zu tun haben, bezieht 
sich auf eine gewisse Vermischtheit von Wechselwirkungen zwischen Alpha- und 
Betaketten; als Ergebnis davon fehlt es oft an Wissen über der Spezifität von den 
Traffikingverläufen von gewissen Heterodimeren. 
Diese Studie ist auf die Internalisierungsregulatoren von Integrin α2β1 fokussiert, 
das ein allgegenwärtig exprimierter Kollagenrezeptor, hauptsächlich von dem Kollagen I, 
und ein der meist reichlichen extrazellularen Matrixproteinen ist. Studien über  das 
Endozytosis von α2β1 sind knapp und hauptsächlich auf das Traffiking von α2β1 
gesammelt durch eine Zufabe von Viren oder Liganden fokussiert. 
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Um die neuen Regulatoren von der Internalisierung von dem ungesammelten 
Integrin α2β1 zu identifizieren und zu beschreiben, wir haben ein Assay etabliert, das auf 
die quantitative Fluoriszenzmikroskopie basiert ist. Wir haben gezeigt, dass der Grossteil 
von der Internalisierung des endogen extremierten nicht gesammelten Integrins α2 in 
HeLa Zellen sowohl von Klathrin als auch von Kaveolin1 abhängt, und durch Rab5-, 
Rab4- und Rab11-positiven Endosomen stattfindet. Wir haben dann RNAi benutzt, um 
386 Zytoskeleton- und zytoskeletonwerwandten Genen auf ihre Beteiligung an die 
Internalisierung von Integrin a2 zu screenen. Wir haben 122 primäre Screening-Hits als 
potentielle Regulatoren von dem Traffiking von Integrin α2 identifiziert, ein Anteil von 
denen bereits als Regulatoren von Endozytosis, Entstehen der fokale Adhäsion, 
Zellenmigration und direkte Interaktoren von Integrinen bekannt waren. In einem 
Validierungsassay konnten wir die Ergebnisse von dem primären Screening für 43% vom 
dem exprimierten Hits aus zwei Gruppen von für die Validierung ausgewählten Hits (14 
Molekülen, die von mehreren siRNAs in dem primären Screening addressiert wurden, 
und 12 Kinesin-Molekularmotoren) nachvollziehen. 
Drei validierte Kinesin-Hits wurden nie mit dem endozytotischen Traffiking 
früher assoziiert. Um einen Einblick in die Funktion von Kinesinen in der 
Integrininternalisierung zu erwerben, haben wir weiter die Rolle von KIF15 in dem 
Traffiking von Integrin α2 charakterisiert. Es wurde als ein starker Inhibitor von den 
frühen Schritten von Endozytosis von dem Integrin α2, aber nicht von Transferrin oder 
EGF identifiziert. Wir haben nachgewiesen, dass ein Knockdown von KIF15 zu einem 
Verlust von einem Integrin-spezifischen Klathrinadaptor Dab2 von der Plasmamembran 
führt, dass wahrscheinlich der Grund für die Blockierung von der Internalisierung dem 
Integrin α2 ist. 
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Also haben wir die Methoden für das Adressieren von der Internalisierung von 
dem nicht gesammelten Integrin α2 entwickelt, eine Reihe von neue Regulatoren von dem 
Trafficking des Integrins identifiziert, und einen Einblick auf die Rolle von dem 
Molekularmotor KIF15 in der Internalisierung das Integrin α2 geleistet. 
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1. Introduction 
1.1. Integrins 
Integrins are metazoan heterodimeric receptors involved in cell adhesion and 
interaction between cell and extracellular matrix (ECM). The first integrin heterodimers 
VLA-1 and VLA-2 (very late antigen-1 and -2, integrin α1β1 and α2β1 respectively) were 
identified in 1985 as protein complexes appearing on differentiated activated T-
lymphocytes (Hemler, Jacobson, Brenner, Mann, & Strominger, 1985). Nowadays 18 
integrin alpha chains and 8 beta chains are known in human cells, forming 24 different 
heterodimers specific for wide array of ligands, including collagens, laminins, and 
fibronectin (Takada, Ye, & Simon, 2007) (Figure I.1). Integrins provide physical 
attachment of cells to ECM and mediate outside-in and inside-out signaling on the 
adhesion status of the cell. On the cellular level, integrins control sensing of mechanistic 
properties of the substrate, cell proliferation and cell death, as proper attachment is crucial 
for cell division of adherent cells (Hynes, 2002; Pellinen et al., 2008; Schwarz, 2010), and 
loss of it leads to apopthosis (Taddei et al., 2012). On the level of organism they are 
involved in cell migration during development , differentiation, immunity, tumorigenesis 
and metastasis, haemostasis (Hynes, 2002). Integrin knock-out mouse models display a 
range of phenotypes, from embrionic lethality for knock-out of β1 integrin (Fässler and 
Meyer, 1995), defects in mesoderm development and vascularization and apoptosis of 
cranial neural crest cells upon knock-out α5 integrin (Yang et al., 1993; Goh et al., 1997) 
to abnormal platelet aggregation and osteosclerosis in mice lacking β3 integrin (Hodivala-
Dilke et al., 1999; McHugh et al., 2000). Moreover, integrins can serve as co-receptors 
for viral entry (Stewart and Nemerow, 2007), i.e. integrin α2β1 is used for cell attachment 
and entry by rotavirus and EV1 (Bergelson et al., 1992; Fleming et al., 2010), whereas 
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αvβ3 is exploited by EV9, CA9, adenovirus, rotavirus and others (Roivainen et al., 
1994)(Hamilton et al., 1997) (Nelsen-Salz et al., 1999) (Guerrero et al., 2000).  
Figure I.1. Ligand specificity of mammalian integrin heterodimers. Adapted from (Margadant et 
al., 2011) 
 
1.2. Integrin structure and function 
Integrin receptors consist of two transmembrane non-covalently associated chains, 
which have large N-terminal extracellular region, responsible for interaction with ligand, 
single transmembrane domain, and short C-terminal cytoplasmic tail. Ligand-binding 
affinity of integrins depends on their conformation. Active conformation (“open” or 
extended) is characterized by stretched N-terminal head domain and spacial separation 
between tails and transmembrane domains of two chains. It has higher affinity to the 
ligand than inactive (“closed” or bent) or intermediate conformation (Kim et al., 2003).  
Inside-out integrin signaling is supported by interactions of integrin cytoplasmic 
tails with number of effectors, aactivating or de-activating integrins. The key regulators of 
this process are known. Talins (Calderwood, 1999; Calderwood et al., 2002), and kindlins 
(Moser et al., 2008; Montanez et al., 2008; Harburger et al., 2009) activate integrins by 
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binding to the cytoplasmic tail of beta chains. Integrin activation can be attenuated by 
number of proteins sharing phosphotyrosine-binding (PTB) domain, that compete with 
talin for beta tail binding, as was shown for filamins (Kiema et al., 2006), ICAM1 
(Millon-Frémillon et al., 2008) and Dok-1 (Calderwood et al., 2003).  
Figure I.2. Outside-in signaling of integrins elicits number of cellular responces. Ligand binding 
leads to separation of integrin tails and recruitment of FAK and Src, which phosphorylate scaffold protein 
paxillin and P130Cas. Phosphorylated P130Cas recruits guanine exchange factors DOCK, and leads to Rac 
activation. Rac and RhoA function oppositely during cell migration. ILK is recruited to b integrin 
cytoplasmic domain and promotes Akt activity. Src also activates Akt and can furthermore promote cell 
proliferation Adapted from (Hu and Luo, 2013) 
 
Although most of existing evidence is for regulation of integrin inside-out 
activation through binding to its beta chains, recent data suggested, that interactors of α 
chains can also be involved, as this was demonstrated for  integrin α chains-binding 
protein SHARPIN, that prevents talin and kindlin binding and thus maintains integrin in 
inactive state (Rantala et al., 2011).  
Outside-in integrin signalling depends on integrin binding to to their ligands. 
There is no clear-cut answer, whether activation of integrin is a prerequisite of ligand-
binding (“switchblade model” (Luo et al., 2007)) or inactive integrin can also bind ligand 
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and subsequently get activated (“deadbolt model” (Xiong et al., 2003). At any rate, ligand 
binding to integrin induces cascade of cellular responces (Figure. I.2) . Activated 
integrins cluster, recruit the signalling scaffolds paxillin, vinculin, CRK and integrin-
linked kinase (ILK) (Schaller, 2001; Brown and Turner, 2004; Wickström et al., 2010; 
Carisey and Ballestrem, 2011), kinases focal adhesion kinase (FAK) and Src (Klinghoffer 
et al., 1999), and activate the small GTPases Rho and Rac, which serve as master 
regulators of actin cytoskeleton (Burridge and Wennerberg, 2004). Rac is activated by 
complex of paxillin and focal adhesion protein pCas130 (Humphries et al., 2007). They 
stimulate the formation of lamellopodia at the leading edge of migrating cells by inducing 
actin polimerization through WAVE/Scar and Arp2/3 (Schaller and Parsons, 1995; Yeo 
and Song, 2008). Thus, initiation of cell adhesion co-incides with activation of Rac and 
Cdc42 signalling, which enhances actin-dependent protrusions, cell migration and cell 
spreading. Activity of RhoA and Rho-dependent actomyosin contractility is 
concomitantly down-regulated (Zaidel-Bar et al., 2005). On the contrary, Rho is 
responsible for stabilization of the adhesive sites, halting cell migration and formation of 
actin stress fibers.  Increase of Rho activity and phophorylation of myosin light chain 
induces formation of stress fibers and prevents cell migration (Ridley et al., 1992; Miki et 
al., 1998, 2000; Eden et al., 2002).  
Integrins organize in several kinds of complexes at the PM. Nascent adhesions 
form at the broad actin-rich edges of migrating cells called lamellopodia. Nascent 
adhesions are linked to actin cytoskeleton, but myosin independent. Actin crosslinking 
with myosin II allows them to mature to focal complexes (Choi et al., 2008). Focal 
complexes are small dot-like integrin complexes (about 2 µm in diameter) similar in 
composition to the mature focal adhesions (DePasquale, 1987; Rinnerthaler et al., 1988). 
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Focal complexes require on Cdc42 and Rac-GTPase activity, and can be matured to focal 
adhesions upon activation of Rho (Nobes and Hall, 1995; Rottner et al., 1999). The 
mature focal adhesions accommodate clustered ligand-bound integrins in the elongated 
structures sized and 3-10µm in length. At the cytosolic side of PM focal adhesions are 
connected to the acto-myosin stress fibers (reviewed in (Burridge and Fath, 1989; Rottner 
et al., 1999; Schwartz, 2010),  
Focal adhesion complexes encompass number of proteins that directly and 
indirectly interact with integrin cytoplasmic tails, ensuring integrin signalling and 
physical association to the cytoskeleon. This dynamic complex of proteins is referred as 
an “integrin adhesome”, and currently lists more than 150 proteins, including 24 
cytoskeletal components, 25 adaptors, 18 kinases, 21 GTPases and their regulators 
(Zaidel-Bar et al., 2007). The main components of focal adhesion complexes, besides 
integrins and talins, are the polyvalent adaptors vinculin and paxillin that are able to 
directly recruit actin filaments, and serve as signalling platforms  (Brown, 1996; Brown 
and Turner, 2004; Humphries et al., 2007)  
Focal adhesions are dynamic structures, constantly formed, remodelled, and 
disassembled according to cellular needs. They persist at the PM for up to 40 min and 
then can be disassembled or matured into more stable fibrillar adhesions (Kaverina et al., 
1999). Targeted delivery of integrins to the newly formed adhesion sites in migrating cells 
and disassembly of focal adhesions depends on the microtubules targeted to the focal 
adhesions and on the integrins endocytosis and recycling (Kaverina et al., 1999; Choi et 
al., 2008; Ezratti et al., 2005; Chao and Kunz, 2009; Theisen et al., 2012)  
Integrin binding to ECM, signalling, and transduction of mechanical forces 
eventually results in the ECM remodeling by several mechanisms. First, integrin 
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signaling and attachment to substrate controls the levels of expression and extracellular 
assembly of ECM proteins such as fibronectin, collagen, and tenascin (Löer et al., 2008; 
Torgler et al., 2004; Clark et al., 2003; Zervas et al., 2001; Brown et al., 2002). Second, 
integrins can mediate ECM proteolytic degradation, as serve as receptors to several 
proteases, including matrix metalloproteases (MMP). By direct binding to the MMP, 
integrin can modulate activities of MMPs, and, thus, levels of substrate degradation 
(Pierini et al., 2000) (Maier et al., 2008; Lindahl et al., 2002; Liu et al., 2000; Chiquet et 
al., 2009; Tamariz and Grinnell, 2002; Ilić et al., 2004; Jülich et al., 2009; Pankov, 2000; 
Schiller et al., 2004; Canty et al., 2006). Induction of MMPs expression by integrins have 
was demonstrated for integrin α2β1 and MMP-1, a3b1 and MMP-2, aVb6 and MMP-2 
and MMP-9 (Brooks et al., 1996) (Brooks et al., 1998)  (Chintala et al., 1996; Parks, 
1999; Thomas et al., 2001). And finally, integrins can directly mediate the internalization 
of ECM proteins from the extracellular space and target them to lysosomal degradation 
(Du et al., 2011; Dozynkiewicz et al., 2011; Shi and Sottile, 2008). 
Besides their function in the cell attachment, spreading and migration, integrins 
are involved in the control of cell cycle and cell death and survival decisions. Integrin-
dependent Rho- and ERK signalling via cyclin D results in cell cycle pogression 
(reviewed in (Assoian and Klein, 2008). Proper integrin-binding to the ECM protects the 
cells from apoptosis via activation of NFκB, ERK, and Akt/PI3K -dependent survival 
pathways by FAK and ILK. On the contrary, loss of attachment results in activation of 
several apoptotic mechnisms, including  death receptor- and caspase 8-dependent 
apoptosis (reviewed in  (Stupack, 2002; Taddei et al., 2012)).  
Thus, integrins serve as both receptors for cellular environment, and the effectors 
for modulating of this environment and performing a range of crucial cellular functions, 
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such as regulation of cytoskeleton organization, cell motility, and cell cycle control. 
Integrins are regulated in number of ways, the principle of them are control of activation 
status, and modulation of integrin availability and distribution on the PM. The latter 
largely depends on the intracellular trafficking of integrins.  
 
1.3. Intracellular trafficking pathways 
Number of interconnected pathways link intracellular membrane compartments. 
The proteins destined to function at plasma membrane are generally synthesized in ER, 
then exported through ERGIC to Golgi, pass cis-, medial- and trans-Golgi, and trans-
Golgi network (TGN), and finally are delivered to the cell surface (De Matteis and Luini, 
2008; Gillon et al., 2012). Endocytosis, on contrary brings membranes and extracellular 
material from the surface to cell inside (Doherty and McMahon, 2009). The internalized 
cargo is sorted into the early endosomes (EE) and then can be driven to degradation in 
lysosomes via late endosomes and multivesicular bodies (MVB) or recycled back to the 
PM (Gruenberg and Stenmark, 2004; Grant and Donaldson, 2009) (Figure I.3). Due to 
the scope of this dissertation project, the further analysis will focus on the endocytosis 
and recycling pathways of the cell.  
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Figure I.3. The endomembrane compartments of the endocytic pathway in 
mammalian cells are outlined (solid arrows). Interconnections with the secretory pathway 
are shown with dashed arrows. Membrane invaginations and internal vesicles are shown 
in red, which highlights the tubular–cisternal and/or multivesicular regions of early and 
late endosomes. The outline  indicates, using solid arrows, that recycling to the cell 
surface occurs through both an indirect (slow) route through recycling endosomes and a 
direct (rapid) route, and that trafficking routes also connect the Golgi apparatus to early 
and late endosomes and the plasma membrane. Modified from (Gruenberg and Stenmark, 
2004) 
 
There is number of entry pathways known by now, providing the endocytic flow 
of material, including (but not limited to) clathrin-mediated endocytosis (CME), caveolin-
dependent, flotillin-dependent, Arf6-dependent, and macropinocytosis (Doherty & 
McMahon 2009). CME is the best studied endocytosis pathway. It is required for 
internalization of number of cellular receptors including transferrin receptor and G-
protein coupled receptors. During CME, the endocytic cargo is packed into membrane 
pits coated with clathrin triskelions on cytoplasmic side of the membrane. This process is 
mediated by array of adaptor proteins, often cargo-specific, that can drive cargo proteins 
into clathrin-coated pits (CCP) (Traub, 2005; Kirchhausen, 2009). Upon assembly of 
clathrin on the cytosolic surface of growing pit, the large GTPase dynamin2 is recruited 
to the neck of the forming vesicle and performs a GTP-dependent scission of the vesicle 
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(Van der Bliek et al., 1993; Damke et al., 1994; Bashkirov et al., 2008; Pucadyil and 
Schmid, 2008). 
Much more limited information on the clathrin-independent endocytosis (CIE) is 
available, if to compare to CME. One of the best studied CIE is caveolin-dependent 
endocytosis. Caveolae are flask-shaped invaginations on the plasma membrane. They are 
more stabile than CCP and provide the signalling plathform for number of pathways 
including integrin signalling (Parton and Simons, 2007). Formation of caveolae depends 
on scaffold protein caveolin1 (CAV1) and its orthologues CAV2 and CAV3 and mediates 
the internalization of so called lipid rafts or cholesterol enriched membrane microdomains 
(CEMMD) (Chidlow and Sessa, 2010). 
After scission from the PM, the newly-formed vesicles lose their clathrin coat 
(Lemmon, 2001) and can further undergo homotypic fusion to form EE or fuse with 
existing EE (Nielsen et al., 1999). The formation of the early endosomes derived from 
clathrin-coated vesicles requires membrane recruitment of small GTPase Rab5 (Bucci et 
al., 1992; Zeigerer et al., 2012), but existing data suggests, that internalized caveolae and 
macropinosomes are targeted to Rab5 EE (Pelkmans et al., 2004; Zoncu et al., 2009)  
Rab proteins have been long recognized as the master regulators of membrane 
trafficking  They cycle between the active, GTP-bound and inactive GDP-bound form 
with help of accessory proteins that promote GTPase activity of Rabs (GTPase activating 
proteins, GAPs), displace GDP with GTP and thus activate Rabs (guanine nucleotide 
exchange factors, GEFs). Inactive Rabs can be retained in the GDP-bound form in the 
cytoplasm by guanine nucleotide dissociation inhibitors (GDI)  (Zerial and McBride, 
2001) (Mizuno-Yamasaki et al., 2012). GTP-bound Rab GTPase can be recruited to the 
cellular membranes, and, in turn, recruit specific effectors, altogether determining the 
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identity and function of membrane compartment (Figure I.4). The mechanism called 
“Rab conversion” was proposed to explain transformation of one compartment to another. 
It was initially described for maturation of Rab5-positive EE to Rab7-positive LE. With 
“Rab conversion” the Rab5-positive early endosomes, containing the cargo destined to 
degradation loose Rab5 and recruit Rab7 in a coordinated manner, which depends on 
Rab5 interaction with Vps/HOPS complex, working as Rab7 GEF (Rink et al., 2005). In 
C. elegans replacement of Rab5 with Rab7 is regulated by Rab7 GEF SAND-1, which is 
recruited by Rab5 GEF Rabex5, present on the EE in complex with Rab5, and, in turn,  
and physically recruits Rab7 to the endosomes via direct interaction with HOPS (Peralta 
et al., 2010; Poteryaev et al., 2010). Other small GTPases cascades are known, suggesting 
this is a general mechanism of membrane compartment identity acquisition (reviewed in  
(Mizuno-Yamasaki et al., 2012)).  
The fate of internalized cargo is determined by the signals and post-translational 
modifications it is bearing. Whereas polyubiquitination with chains of at least four 
ubiquitin moieties is a signal for proteosomal degradation of ubiquitinated protein, 
monoubiquitination is sufficient to drive the membrane proteins for internalization, as 
was shown for receptor tyrosine kinases (Thrower et al., 2000). Ubiquitinated cargo is 
further sorted to the lysosomal pathway via ubiquitin-interacting ESCRT complex 
(Schields and Piper, 2011). Yet, for internalization and of number of proteins, including 
EGF receptor, ubiquitination is redundant or not required (Lombardi et al., 1993; Haglund 
et al., 2003; Huang et al., 2007).  
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Figure I.4. Rab proteins determine the trafficking compartments identitiy. Adapted from 
(Stenmark, 2009)RAB1, located at endoplasmic reticulum (ER) exit sites and the pre-Golgi intermediate 
compartment (IC), mediates ER–Golgi trafficking. RAB2, located at the IC, might also regulate Golgi–ER 
trafficking. The Golgi-localized RAB6, RAB33 and RAB40 mediate intra-Golgi trafficking. RAB33, 
together with RAB24, also regulates the formation of autophagosomes. RAB8 mediates constitutive 
biosynthetic trafficking from the trans-Golgi network (TGN) to the plasma membrane and also participates 
in GLUT4 vesicle translocation (with RAB10 and RAB14) and ciliogenesis (with RAB17 and RAB23). 
RAB3, RAB26, RAB27 and RAB37 mediate various types of regulated exocytic events and RAB27 also 
mediates the translocation of melanosomes to the cell periphery. RAB32 and RAB38 are involved in the 
biogenesis of melanosomes and RAB32 also controls mitochondrial fission. RAB13 regulates the assembly 
of tight junctions between epithelial cells. RAB18 controls the formation of lipid droplets. RAB22 mediates 
trafficking between the TGN and early endosomes and vice versa. RAB5, which is localized to early 
endosomes, phagosomes, caveosomes and the plasma membrane, mediates endocytosis and endosome 
fusion of clathrin-coated vesicles (CCVs), macropinocytosis (with RAB34) and maturation of early 
phagosomes (with RAB14 and RAB22). RAB21 mediates integrin endocytosis. RAB11 and RAB35 
mediate slow endocytic recycling through recycling endosomes, whereas RAB4 mediates fast endocytic 
recycling directly from early endosomes. RAB15 is involved in the trafficking from early endosomes to 
recycling endosomes and in the trafficking from apical recycling endosomes to the basolateral plasma 
membrane. RAB17 and RAB25 control trafficking through the apical recycling endosomes to the apical 
plasma membrane. The late endosome-associated RAB7 mediates maturation of late endosomes and 
phagosomes, and their fusion with lysosomes. Another late endosomal GTPase, RAB9, mediates trafficking 
from late endosomes to the TGN. 
 
There are several main protein degradation pathways in the cell: proteosomal 
degradation, autophagosomal, and lysosomal degradation (Ciechanover, 2005; Wong and 
Cuervo, 2010). The chains of at least four ubiquitin  Lysosomal degradation is the usual 
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route for the endocytic cargo destined for decay. Along this pathway, the internalized 
cargo, that is delivered into the EE, is sorted to the multivesicular bodies (MVB) and then 
delivered to the Rab7- and Rab9-positive late endosomes (LE) (Riederer et al., 1994; 
Feng et al., 1995). The cargo of late endosomes recruits ESCRT protein compex which 
induces inward invagination and leads to endosomes maturation into multivesicular 
bodies (MVB) which have characteristic appearance due to the vesicles enclosed into 
outer membrane (Gruenberg and Stenmark, 2004). Autophago-lysosomal degradation 
serves for removal of cell organelles and cytoplasm. The hallmark of this pathway is 
characteristic double membrane that appears from engulfing of the cell of its own content. 
In resemblance to MVB, the autophagosomes fuse to the lysosomes in order to degrade 
their cargo.  
Variety of endocytic cargo, including number of receptors, is not degraded but 
recycle back to the PM. Two main pathways of recycling from endosomes to the PM are 
widely recognized in eukaryotic cells. One is so called “short-loop” recycling that occurs 
directly from the EE. This process is Rab4-dependent  (Van der Sluijs et al., 1992). 
Alternatively, the recycled cargo is delivered to Rab11-positive recycling endosomes 
(Ullrich et al., 1996). The Rab4- and Rab11-positive membranes appear in the cell as the 
microdomains in the Rab5-positive EE (Sönnichsen et al., 2000), but Rab11 endosomes 
also form distinct compartments, localized in the perinuclear area (perinuclear recycling 
compartment, PRC) (Ullrich et al., 1996) or apical recycling endosomes in the polarized 
cells (Wang et al., 2000). Transferrin, being the cellular endocytic recycling cargo can 
pursue either recycling pathway, but with different dynamics. In HeLa cells, internalized 
transferrin accumulates in EE as early as in 5 min and is delivered to the RE 30 min after 
internalization (Peden et al., 2004). 
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The Rabs mentioned above are the main players in the organization of endocytosis 
and recycling pathways, which were discovered the earliest, characterized the best, and 
are conserved between different species, from yeast to human (Segev, 2001). Yet, as the 
family of Rabs is numerous, additional players of the trafficking pathways emerge. For 
instance, in human cells members of Rab5-subfamily Rab5a, b, c, Rab21, and Rab22 
function in internalizaiton pathway at the level of early endosomes. The members of 
Rab11-subfamily Rab11a, b, and Rab25 are involved in recycling, and Rab 35 shares with 
Rab4 the function of short-loop recycling from EE (reviewed in (Scharwz et al., 2007)  
The membrane fusion in all the trafficking steps is mediated by SNAREs (soluble 
N-ethylmaleimide-sensitive factor attachment protein receptors). They are the single 
transmembrane domain proteins, present on the donor and acceptor membranes, and are 
assembled into the tertiary complex of Q-SNAREs (Qa, Qb. And Qc) on one membrane 
and an R-SNARE at the opposing membrane (Jahn and Scheller, 2006). The energy 
required for the membrane fusion is released by assembly of SNAREs cytosolic domains 
into quaternary complex. There are 36 SNARE proteins present in humans mediating 
particular steps in the intracellular trafficking  (reviewed in (Jahn and Scheller, 2006)). 
 
1.4. Cytoskeleton in membrane trafficking  
Cellular cytoskeleton consists of three types of structures: microtubules formed by 
tubulin polimers, actin microfilaments, and intermediate filaments. Cytoskeletal elements 
are crucial players in the intracellular trafficking, as they provide support and anchorage 
for individual compartments of the cell, and physical link between them, including tracks 
for vesicles and protein trafficking. Both actin and microtubular cytoskeleton are required 
for that, although their function is substantially different. Microtubules are crucial for 
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long-range traffic, chromosome organization in mitosis, and cell division (Vale, 2003; 
Manneville and Manneville, 2006; Meraldi, 2011). Actin filaments serve as tracks for 
short-range traffic, and organize the cortex of the cell – the dense meshwork of the actin 
fibers localized immediately beneath the PM, which plays the crucial role in the events of 
vesicle budding and fusion at the PM (Dominguez and Holmes, 2011). The physical 
movement of the cargo along the cytoskeleal tracks, and maintaining of cytoskeleton 
organization is provided by cytoplasmic molecular motors, that can convert chemical 
energy into mechanical, as they change conformation by hydrolyzing ATP. Microtubule-
dependent molecular motors belong to kinesin and dynein families of molecular motors. 
The actin-dependent motors are myosins (Foth et al., 2006).  
Microtubules are the polymers of α and β tubulins assembled as a hollow tube of 
25 nm in diameter. For formation of microtubule, α- and β-tubulin dimerize, and then 
form linear protofilaments (Weisenberg, 1972). They posess an intrinsic polarity due to 
the polar organization of tubulin α and β dimers, so that one end of the protofilament 
exposes only one type of tubulin: α at the (-)-end of microtubules and β at the (+)-ends. 
The organization of microtubule arrays can differ dramatically depending on the cell type 
and cell state. In non-polarized animal interphase cells microtubules typically start 
nucleating at the microtubule organizing center (MTOC) in the perinuclear area and grow 
towards the PM, so that microtubular (+)-ends are found mostly at the  cell periphery, and 
(-) ends in the perinuclear area (Manneville and Etienne-Manneville, 2006).   
Kinesins superfamily of proteins performs numerous functions in organization of 
cytoskeleton, cell division, and intracellular transport of vesicles, protein complexes, and 
RNA. This variety of roles is provided by high diversification of kinesins in the evolution. 
Yeast genome encodes for 6 kinesins, which are involved in mitosis (Hildebrandt and 
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Hoyt, 2000). Yet mammalian cells encompass 45 members of this family, which can, in 
addition, produce multiple splice variants (Hirokawa et al., 2009). Mammalian kinesins 
are divided into 15 families, which can be grouped into three categories according to their 
structure: N-kinesins have the amino-terminal motor domain and, C-kinesins, that contain 
exclusively members of kinesin family 14A and 14B, have the motor domain at carboxy-
terminus, and M-kinesins have the motor domain in the middle (Figure I.5). Kinesins, 
generally, move along the microtubules in the polarized manner. N-kinesins exhibit 
microtubule (+)-end directed movement, whereas C-kinesins drive microtubules (-)-end 
directed movememnt. M-kinesins act as microtubule depolymerases (reviewed in 
(Hirokawa et al., 2009). Yet, recent studies revealed that yeast mitotic kinesin Cin8 
(member of kinesin-5 family of proteins), that belongs to kinesin-5 family of N-terminal 
kinesins, can switch directions, depending on whether it works alone or in the group of 
molecules (Roostalu et al., 2011).  
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Figure I.5. The structure and phylogeny of major mouse kinesins. (A) A 
phylogenetic tree of all 45 kinesin superfamily (also known as KIF) genes in the mouse 
genome, which are classified into 15 families the major kinesins. In general, kinesins 
comprise a kinesin motor domain and a coiled-coil domain. (B) The 15 families of 
kinesins can be broadly grouped into N-kinesins, M-kinesins and C-kinesins, which 
contain their motor domain at the amino terminus, in the middle or at the carboxyl 
terminus, respectively. N-kinesins drive microtubule plus end-directed transport, C-
kinesins drive minus end-directed transport and M-kinesins depolymerize microtubules. 
The three types of kinesin are grouped as indicated. Only the kinesin 13 family contains 
M-kinesins and only the kinesin 14A and kinesin 14B families contain C-kinesins. All 
other families consist of N-kinesins. aa, amino acids; PX, Phox homology. Adapted from 
(Hirokawa et al., 2009). 
 
Dyneins are multimeric motors driving microtubule (-)-end directed transport. 
There are 14 dyneins encoded in human genome, but 13 of them (axonemal dyneins and 
cytoplasmic dynein-2)  have specific function in motility of cilia and flagella and 
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intraflagellar transport. The bulk intracellular transport is carried out by cytoplasmic 
dynein-1, that is found in all microtubule-containing cells. Dynein-1 is a giant 
macromolecular complex consisting of heavy chains, that contain motor domains, 
required for microtubule-based motility, several intermediate chains, responsible for cargo 
binding, and at least three classes of light chains, thought to mediate dimerization of 
dyneins, and light intermediate chains binding to heavy chains independently (reviewed 
in (Sakakibara and Oiwa, 2011; Rapali et al., 2011; Allan, 2011). Cytoplasmic dynein-1 is 
crucial for the retrograde transport of numerous cellular cargoes, organization of 
intracellular compartments (i.e. Gogli, endosomes) and microtubule organization in the 
cell (Palmer et al., 2009; Allan, 2011; Hunt and Stephens, 2011). 
Actin filaments consist of globular monomeric actin (G-actin), that can 
polymerize to form  microfilaments (F-actin). Similar to microtubules, actin 
microfilaments are polar, with faster polymerization at the barbed ends and slower at the 
pointed end. F-actin can exist in the form of meshwork, that is typical for the cortex 
organization, or highly crosslinked anti-parallel bundles and stress fibers (Dominguez and 
Holmes, 2011)  
Myosins are actin-dependent motors, providing short-range traffic along actin 
filaments, supporting cell shape, and organizing actin cytoskeleton. Myosins share the 
common strucural features: N-terminal actin-binding ATPase motor domain, a neck 
domain, containing light-chain-binding IQ motifs, and a C-terminal tail. Mammalian cells 
have up to 40 myosins belonging to ~20 different classes (Foth et al., 2006). Number of 
them are directly implicated in the transport of cargo along the actin filaments (i.e. 
myosin V, VI) (Desnos et al., 2007; Frank et al., 2004), and others can be required for 
reorganization of actin cortex during endocytosis and secretion to allow vesicles through 
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the dense network of actin fibers present below the PM (Bond et al., 2007). Most of the 
myosins are “plus”- (barbed) end directed, whereas myosin VI represents a single known 
exclusion so far, as it is “minus”- (pointed) end directed (Sweeney and Houdusse, 2010) 
The role of intermediate filaments in the intracellular trafficking has been 
overlooked for a long time, yet, newly emerging data suggest they might directly interact 
with clathrin adaptor complex AP-3, mediate lysosomes positioning in the cells (Styers et 
al., 2004), and/or directly interact with kinesins (Helfand et al., 2004) or myosins (Rao et 
al., 2002). 
 
1.5. Integrin trafficking  
Integrins, being surface-resident receptors, have to be properly delivered to the 
PM, and their delivery, localization, and rearrangement depend on the intracellular 
vesicular trafficking.  
There is very limited information available on the anterograde trafficking of 
integrins. Integrin heterodimers assemble in ER, and this is a prerequisite for correct 
chains folding (Huang et al. 1997) and integrin export from ER (Heino et al. 1989). There 
is evidence that other conponents of focal adhesions could regulate delivery of integrins 
to the PM, as talin associates with integrin complex already in ER and facilitates integrin 
complex exit from ER (Martel et al. 2000) Upon assembly alpha beta complex acquires 
inactive confirmation and is transported to Golgi and PM (Tiwari et al. 2011). In 
polarized cells integrins are sorted to the basolateral membranes, and this sorting requires 
protein kinases D 1 and 2 (PKD1 and PKD2) (Yeaman et al., 2004).  
Being delivered to PM, integrins undergo rounds endocytosis and recycling and, to 
lesser extent can be driven into degradation pathway. Unlike the receptors internalized by 
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ligand-induced endocytosis (i.e. EGF or Tf), integrins do not require ligand-binding to 
trigger internalization, and can undergo endocytosis and recycling both in free and ligand-
bound states (Sottile and Chandler, 2005; Shi and Sottile, 2008; Rintanen et al., 2011; 
Arjonen et al., 2012). Yet, the pathways of integrin retrograde trafficking can differ 
depending on the particular heterodimer, integrin activation status, binding to the ligand, 
growth factors presence. Although the comprehensive model of integrin trafficking in 
different conditions is still missing, a large number of regulators of different steps in 
integrin endocytosis and recycling are already known. The individual regulators are listed 
in the table I.1, and the outlines of the pathways of integrin trafficking they are organizing 
are discussed in more detail below. 
Table I.1. Regulators of integrin trafficking.  
Integrin 
trafficking 
regulator  
Integrin  Controlled process References 
GTPases and their interactors 
Arf6 β1 Recycling of β1 integrin upon 
cells stimulation 
(Powelka et al., 2004) 
Arf5/BRAG2 α5β1 Internalization of β1, co-
localizes with AP-2 and CCP 
at the PM  
(Moravec et al., 2012) 
Dnm2 β1 Required for focal adhesions 
disassembly but not for 
internalization of clustered α2 
(Ezratty et al., 2005; 
Karjalainen et al., 2008) 
Rab1/p115 β1 Required for anterograde 
trafficking of β1 to the lipid 
rafts 
(Wang et al., 2010) 
Rab5 β1, α5β1 Integrin internalization and 
trafficking in EE 
(Pellinen et al., 2006; 
Valdembri et al., 2009; 
Arjonen et al., 2012)  
Rab4 β1, αVβ3 Fast-loop recycling of αVβ3 
integrin upon stimulation with 
PDGF; recycling of active β1 
(Roberts et al., 2001) 
Woods et al., 2004; 
Arjonen et al., 2012)  
Rab7 β1 Active β1 is found in the Arjonen et al., 2012)  
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Rab7-positive endosomes 
Rab11 β1, α5β1 Long-loop recycling of 
integrins 
(Powelka et al., 2004; 
Woods et al., 2004; Veale 
et al., 2010; Arjonen et 
al., 2012) ) 
Rab21/ 
p120RabsGAP 
α1, α2, α5, 
α6, α11, β1 
Rab21 binds a and b chains 
and regulates rapid 
internalization of integrins, 
but not transferrin. 
P120RabsGAP displaces 
Rab21 from tail of α  integrin, 
promoting integrin recycling 
(Pellinen et al., 2006) 
(Pellinen et al., 2008) 
(Mai et al., 2011)  
Rab25 β1 Binds β1 tails and regulates 
recycling  
(Caswell et al., 2007; 
Dozynkiewicz et al., 
2011) 
Kinases 
Akt/GSK3 αVβ3, 
α5β1 
Promotes recycling of 
integrins, but not transferrin, 
by phosphorylation of 
glycogen synthase kinase 3 
(Roberts et al., 2004) 
PRKCα β1, α5β1 Induces endocytosis and 
recycling of active β1; 
triggers caveolin-dependent 
endocytosis of α5β1 upon 
working in SDC4-RhoG 
pathway 
(Ng et al., 1999; Bass et 
al., 2011) 
PKD1 αVβ3, 
a3b1, β1 
Required for Rab4-dependent 
recycling of αVβ3 and 
basolateral sorting of β1 
integrins in TGN 
(Woods et al., 2004; 
Yeaman et al., 2004; 
Onodera et al., 2012) 
PKD2 β1 Together with PKD1 
participates in sorting of β1 
integrins to basalateral 
membranes in TGN 
(Yeaman et al., 2004) 
PAK1 Clustered 
α2β1 
Required for sorting of 
clustered α2β1 to the caveolae
(Karjalainen et al., 2008)
aPKC β1 Negatively regulates integrin 
internalization by 
phosphorylation of Numb 
(Nishimura and 
Kaibuchi, 2007) 
PKCε β1 Phophorylates vimentin to 
promote integrin recycling 
(Ivaska et al., 2005) 
Integrin-binding proteins 
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ACAP1 β1 Stimulation-dependent β1 
recycling in migrating cells 
(Li et al., 2005) 
AP2 β1 Clathrin adaptor required for 
disassembly of FA 
(Chao and Kunz, 2009) 
ARH β1 Adaptor protein required for 
β1 internalization in 
migrating cells 
(Nishimura and 
Kaibuchi, 2007) 
Dab2 α1, α2, α3, 
β1 
Adaptor proteins required for 
disassembly of focal 
adhesions and bulk 
internalization of integrin  β1 
(Ezratty et ak., 2005; 
Teckchandani et al., 
2009, 2012) 
Numb β1, b3, 
α5β1 
Adaptor protein required for 
β1 internalization in 
migrating cells 
(Nishimura and 
Kaibuchi, 2007; 
Teckchandani et al., 
2009) 
NRP/GIPC1 α5β1 Internalization at the endge of 
fibronectin-positive fibrillar 
structures 
(Valdembri et al., 2009) 
SNX17 β1 Promotes integrin recycling  (Böttcher et al., 2012) 
Molecular motors 
KIF1C α5β1 Supports the stabilization of 
trailing edge in migrating 
cells by targeted delivery of 
α5β1 
(Theisen et al., 2012) 
Myosin-X β1 Relocalization of β1 integrin 
to phylopodia 
(Zhang et al., 2004) 
Myosin VI/GIPC α5β1 Promotes internalization of 
active α5β1 
(Valdembri et al., 2009) 
SNAREs 
VAMP3/ SNX4/ 
SNAP23 
α5β1 SNARE complex required for 
delivery of α5β1 integrin 
from RE to PM in the leading 
edge of migrating cells 
(Veale et al., 2010) 
SNAP29 β1 Regulates recycling of β1 
integrin and transferrin 
(Rapaport et al., 2010) 
STX6/VAMP3 a3b1; α5β1 Recycling of α5β1; a3b1 
recycling through TGN 
during chemotactic cell 
motility  
(Tiwari et al., 2011; 
Riggs et al., 2012) 
VAMP2 α5β1 Trafficking of α5β1 to the PM (Hasan and Hu, 2010) 
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1.5.1. Early steps of integrin endocytosis 
Cytoplasmic tail of β1 integrin contains 3 sequence stretches that are known to be 
involved in integrins localization to FA (Reszka et al., 1992). Two of them have a 
conserved NPXY motif, which is known to mediate internalization of low-density 
lipoprotein receptor (Chen et al., 1990), megalin (Takeda et al., 2003), insulin and insulin 
growth factor-like receptor (Rajagopalan et al., 1991; Hsu et al., 1994), EGF receptor,  β-
amyloid precursor protein (Perez et al., 1999), but not in transferrin receptor. NPXY 
works as a binding site for such endocytic adapters as Dab2, AP-2, Numb (Nishimura and 
Kaibuchi, 2007). However, the presence of this motif might not be sufficient to trigger 
cargo internalization, as introduction of it into the recombinant transferrin receptor did 
not promote NPXY-dependent internalization, but a longer amino acid stretch was 
required  (Collawn et al., 1991). Moreover mutations of NPXY motifs present in β1 chain 
of α5β1 integrin did not block integrin internalization, as expected (Vignoud et al., 1994). 
Number of adaptor proteins are known to be involved in CME of integrins. The 
role in internalization of integrins was shown for Dab2, ARH, Numb, AP2 (Ezratty et al., 
2005; Nishimura and Kaibuchi, 2007; Chao and Kunz, 2009; Teckchandani et al., 2009, 
2012) The described integrin internalization pathway mediated by Dab2 still has lots of 
controversies: it has been shown that in human fibrosarcoma HT1080 cells Dab2 
mediates disassembly of integrin β1-containing FA (Chao & Kunz, 2009), which should 
normally accumulate active integrin. Yet Teckchandani et al (2009, 2012) demonstrated 
that in HeLa cells Dab2 preferentially co-localizes with the β1 integrin on the dorsal 
surface of the cell, which is not engaged in the interaction with ligand. The requirement 
for AP-2 adaptor complex was demostrated along with the requirement of Dab2 for β1 
integrin internalization (Chao & Kunz, 2009; Teckchandani et al., 2009). 
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Despite the plethora of data on the clathrin-dependent internalizaiton of β1 
integrin, alternative entry routes for integrins are also known. In myofibroblast cells 
siRNA experiments demonstrated that internalization of α5β1 integrin and its ligand 
fibronectin in fibroblasts depended on caveolin-1 (Sottile and Chandler, 2005; Shi and 
Sottile, 2008). It has been described recently, that internalization of αVβ3 integrin can 
occur via membrane ruffles at the dorsal surface of the cell (Gu et al., 2011). Intracellular 
trafficking regulators can take part in shifting of integrin towards one or another 
internalization pathway.  over-expression of Rab21 in SAOS cells promotes clathrin-
independent internalization of α5β1 and αVβ3, although normally they are internalized 
via CME in this cell line (Pellinen et al., 2008). Experiments on α2β1 integrin 
demonstrated that it can be clustered by its natural ligand collagen I, by EV1 virus 
binding or by incubation with primary anti-α2 chain antibodies followed by addition of 
appropriate secondary antibodies ,so that internalization of clustered α2β1 occurs via 
caveolae and is independent of clathrin in SAOS cells  (Upla et al., 2004; Rintanen et al., 
2012). Remarkably, the features of clustered α2β1 trafficking are clearly distinct from the 
constitutive internalization of non-clustered α2β1 and does not correspond to the 
conventional internalization pathway (see below).  
Following internalization, integrins are delivered to the EE positive for Rab5 and 
its effectors (Pellinen et al., 2006; Valdembri et al., 2009; Arjonen et al., 2012) . From the 
EE they can be recycled back to PM via Rab21 and Rab4-dependent pathway (Roberts et 
al., 2001; Woods et al, 2004; Pellinen et al., 2008 ; Arjonen et al., 2012) or sorted into 
long-loop recycling (Powelka et al., 2004; Arjonen et al., 2012) or degradation pathways  
(Lobert et al., 2010). It has been shown that stimulation of the cells with PDGFβ results in 
fast Rab4-dependent recycling of αVβ3 integrin, but not of α5β1 (Roberts et al., 2001). 
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Integrin β1 was also efficiently recycled to the PM upon serum addition via Arf6 and 
Rab11 pathways (Powelka et al., 2004).  
 
1.5.2. Integrin recycling 
After internalization integrins are predominantly recycled back to the PM. The 
recycling pathway employed can differ depending on particular heterodimer, activation 
status of integrin or stimulation of the cell with growth factors. Rab4- (short-loop 
recycling) and Rab11-dependent (long-loop recycling) pathways are the best 
characterized, although the full understanding of the integrin recycling regulation is 
missing. Rab4-dependent pathway is used by integrin αVβ3, in contrast to α5β1, upon 
stimulation with PDGF (Roberts et al., 2001). Nevertheless, analysis of integrin β1 
trafficking revealed that both active and inactive conformation of integrin β1 co-localized 
with Rab4, yet only recycling of inactive β1 was affected by expression of Rab4 
dominant-negative mutant (Rab4S22N) (Arjonen et al., 2012). Both conformations could 
be found in the Rab11-positive PRC (Arjonen et al., 2012), and were recycled to the cell 
surface in Arf6 and Rab11-dependent manner upon the stimulation of cells with serum 
(Powelka et al., 2004).  
In contrast to studies the report of Dozynkiewicz et al. (2011) which demonstrated 
involvement of member of Rab11 family, Rab25, in the recycling of ligand-occupied in 
A2780 from late endosomes, no co-localization of either active or inactive integrin β1 to 
Rab25 was found in MDA-MB-231 cells (Arjonen et al., 2012) 
Recycling of integrins was shown to be driven by the competitive binding of 
regulators to the integrin tails. So, the efficient recycling of β1 depends on the 
displacement of Rab21 from the integrin heterodimer by p120RasGAP, and in the absence 
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of p120RasGAP the integrin is retained in the Rab21- and EEA1-positive endosomes 
(Mai et al., 2011). The re-routing of internalized β1 to the recycling compartment requires 
interaction of NXXY-motif in β1 tail with sorting nexin 17 (SNX17), and when SNX17 is 
depleted, α5β1 integrins are ubiquitilated and driven to ESCRT-mediated degradation 
(Böttcher et al., 2012). 
Besides Rab proteins, several SNARE complexes were identified as regulators of 
integrin recycling. The first work indicating that SNAREs are involved in integrin 
recycling was done using the general inhibitor of SNARE function TeTx, application of 
which blocked cell spreading. This could be rescued by expression of toxin-insensitive 
VAMP3 (Skalski and Coppolino, 2005). Further insight in the role of VAMP3 in recycling 
of integrins was obtained from work of Veale and colleagues (2010), who demonstrated 
than the complex of R-SNARE VAMP3 and Q-SNAREs SNX4 and SNAP23 was 
required for delivery of α5β1 from the recycling compartment to newly forming 
lamellopodium in migrating cells. SNAP29 regulates recycling of β1 integrin through the 
recycling pathway shared by transferrin (Rappaport et al., 2010). In addition, the delivery 
of internalized α5β1, but not α2β1 or a3b1 integrin to the PM is dependent on VAMP2 
(Hasan and Hu, 2010). 
Regulation of integrin recycling depends on interaction of cytosolic proteins with 
integrins C-terminal domain. Interaction of catalytically-active protein kinase D (PKD1) 
with C-terminal b3 domain of  αVβ3 integrin was required for Rab4-dependent recycling 
of internalized integrin to the nascent focal adhesions (Woods et al., 2004).  
 
1.5.3. Integrin degradation 
The degradation of integrins is by far less understood than their recycling. 
38 
 
Generally, the binding to the ligand can drive a fraction of internalized integrin-ligand 
complex to the lysosomal degradation. The degradation of integrins in the conventional 
lysosomal pathway is by far less efficient than their recycling: half-life of the α5β1 
integrin in the lysosomal pathway is 18h (Lobert et al., 2010), whereas the cycle of 
endocytosis and recycling of the same heterodimer takes only 30 min (Roberts et al., 
2001, 2004). The sorting of fibronectin-bound α5β1 into the MVBs and, subsequently, 
lysosomes depends on ubiquitination of a5 chain and requires the interaction of ESCRT 
complex with α5β1 (Lobert et al., 2010). In addition, the analysis of relation between 
integrin β1 activation state and the pursued trafficking pathway revealed that only active 
β1 is found in Rab7-positive endosomes, whereas EE and recycling compartments are 
occupied by both active and inactive forms (Arjonen et al., 2012).  
However, different degradation pathway was recently described for clustered α2β1 
integrin. There, the heterodimer clustered by EV1 virus, addition of collagen I, or 
sequential application of primary and secondary antibodies against α2 is efficiently 
internalized from the PM to the intracellular structures that does not co-localize neither to 
EE marker EEA1 (Rab5 effector, early endosome antigen 1) in the early steps of 
internalization (upon 5 and 15 min of internalization), nor to the conventional late-
endosome-dependent degradation labeled by Rab7, CD63, LAMP1 at the later steps of 
internalization (30 min, 1h, 2h, 6h). The clustered integrin does not recycle to the PM, but 
is instead delivered to the integrin-specific MVBs and degraded by calpain proteases 
(Upla et al., 2004; Rintanen et al., 2012). 
 
1.5.4. Cytoskeleton in integrin trafficking  
Although integrin function is tightly interconnected with organization of 
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cytoskeleton, the role of cytoskeletal structural proteins like actin and tubulin, and 
cytoskeleton regulators in the integrin trafficking remains elusive. Several works 
identified the requirement for actin cytoskeleton in integrin recycling. Stimulation-
dependent recycling of integrin β1 from the PRC requires intact actin and, presumably, 
Arf6-dependent actin rearrangments (Powelka et al., 2004). Treatment with actin-
depolymerizing drug cytochalasin D specifically blocks recycling of inactive β1 integrin 
from PRC, but does not affect trafficking of active β1 (Arjonen et al., 2012). In addition, 
Q-SNARE complex SNX4/SNAP23, required for recycling of α5β1, was required for F-
actin-rich lamellopodia formation in migrating macrophages, but causal relationship 
between F-actin enrichment in lamellopodia and delivery of α5β1 integrin to these 
locations was not investigated  (Veale et al., 2010). Involvement of actin in the integrin 
trafficking implies the role for actin-based motors, and this was demonstrated for two of 
them. Myosin X (Myo10) was shown to directly interact with NPXY motifs in β1 integrin 
tail and to induce relocalization of integrins to extending filopodia (Zhang et al., 2004). 
Unconventional myosin VI (myo6) interacted with GIPC and Nrp to promote 
internalization of active α5β1 (Valdembti et al., 2009).  
The requirement of microtubules for the directed migration of the cells has been 
demonstrated early (Vasiliev et al., 1970). Direct observations revealed link between 
microtubules and FA in goldfish fibroblasts (Kaverina et al., 1998) and indicated that 
mictotubules occurrence at FA site correlated with FA disassembly (Kaverina et al., 
1999). Indeed, it has later been shown that dynamin-dependent dissassembly of FA is 
induced by regrowth of microtubules after their disruption with tubulin-depolymerizing 
drug nocodazole (Ezratty et al., 2005). In turn, microtubules reaching adhesion sites 
exhibit higher dynamics and multiple switching between growth and catastrophe, which 
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might depend on FA components paxillin and FAK (Palazzo et al., 2004; Schober et al., 
2007; Efimov et al., 2008). One of the FAK downstream effectors which serve as factors 
of dynamic microtubule-dependent FA disassembly at the leading edge of migrating cells 
is a microtubule-associated kinase SLC (Wagner et al., 2008) 
Kinesins were barely studied in the context of integrin trafficking. KIF1C was 
recently shown to mediate integrin α5β1 delivery to the rear adhesion site in the migrating 
epithelial cells and stabilization of the tail of migrating cells, which was required for 
maintenance of migration directionality (Theisen et al., 2012). Kinesins KIF5b and 
KIF3a/3b can indirectly mediate FA turnover by delivering an MT1-MMP (matrix 
metalloprotease) to the adhesion sites (Wiesner et al., 2010), where it is required for ECM 
degradation and integrin and fibronectin endocytosis (Takino et al., 2007; Shi and Sottile, 
2011) 
At last, sparse data indicate that there may also be a role for intermediate filaments 
in the integrin traffic. It has been shown that intermediate filaments are required for cell 
migration (Eckes et al., 1998). Moreover, phosphorylation of one of the intermediate 
filaments components vimentin promotes integrin β1 recycling (Ivaska et al, 2005).  
 
1.6. Integrin α2β1 
Integrin  α2β1 is a receptor for collagens which are the most abundant ECM 
proteins in the human body (Myllyharju and Kivirikko, 2001). This heterodimer was 
initially identified as a surface glycoprotein complex on activated T-lymphocytes (Hemler 
et al. 1984; Hemler et al. 1985). Its main ligands are collagen I, and, to lesser extent, 
collagen IV (Kramer & Marks 1989). Suprisingly, although being the receptor for one of 
the most abundant ECM proteins, α2 integrin does not cause in major phenotype in vivo 
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when knocked out. Mice lacking α2β1 integrin were born, developed normally, and could 
reproduce. No gross abnormalities were recorded in most of the organ systems, but the 
mammary gland branching was diminished, and the platelet aggregation in response to 
collagen was delayed, although not completely blocked (Chen et al., 2002). In wound 
healing, α2β1 integrin was necessary for vascularization of the wound, but otherwise its 
role in the healing was dispensible. The reason for the lack of phenotype in integrin α2 
knock-out is a matter of debate (Parks, 2007).  
Integrin α2β1 is required for echovirus (EV1) and rotaviruses infection (Bergelson 
et al., 1992; Londrigan et al., 2003; Fleming et al., 2010). Both EV1 and rotaviruses 
utilize integrin α2 I-domain for binding, but, interestingly, their binding prefereces for 
activation state of integrin differ. Rotaviruses require for binding to α2 the residues 
similar to the ones exploited by collagen I, and more avidly bind to the active 
conformation of α2β1 (Londrigan et al., 2003; Fleming et al., 2010). Yet, EV1 
preferentially binds to inactive α2 at the position distinct from the collagen-binding site 
and does not induce integrin  activation (Jokinen et al., 2010).   
So far little is known about intracellular trafficking pathways of α2β1. Recently a 
prominent pool of information emerged, characterizing the trafficking of α2 integrin 
clustered by addition of collagen I, EV1, or sequential treatment of living cells with 
primary anti-α2 antibodies and appropriate secondary antibody in SAOS cells (Upla et al., 
2004; Karjalainen et al., 2008, 2011; Rintanen et al., 2012). Under these conditions, α2 
gets internalized soon after clustering via caveolae, in 1h leaves the PM completely and is 
not recycled back upon internalization (Rintanen et al, 2012). Strikingly, pursuing this 
degradation pathway, internalized clustered α2 does not co-localize neither with markers 
of clathrin-dependent internalization pathway EEA1 nor with markers of late 
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endosomal/lysosomal pathway Rab7, LAMP1, and CD63, but is driven to the integrin-
specific MVBs, and than degraded by calpains (Karjalainen et al., 2008, 2011; Rintanen 
et al., 2012).  
The information on the trafficking of non-clustered is very sparse. In SAOS cells 
overexpressing α2β1, non-clustered α2 integrin upon internalization pursues recycling 
pathway (Rintanen et al., 2012). In HeLa and MDA-MB-231 cells α2 chain was shown to 
interact with Rab21, which is required for endocytosis and recycling of β1 integrins 
(Pellinen et al., 2006, 2008). Additionally, the involvement of Dab2 endocytic adaptor in 
the internalization of α2β1 heterodimer was suggested, as the surface levels of α2 and β1 
integrins increased upon knock-down of Dab2 in HeLa cells, and Dab2 was further 
demostrate to play role in β1 internalization (Teckchandani et al., 2009, 2012) 
Although plenty of data is available for the trafficking of non-clustered β1 
integrin, the α2 binding partner, it can not be readily transferred to understand the 
trafficking of α2β1 integrin, as β1 forms heterodimers with 12 α chains, that can pursue 
different endocytosis pathways.  
1.7. Integrin trafficking in disease  
Abnormal integrin function has long been associated with diseases and integrins 
are successfully used as therapeutic targets. Over-expression of number of integrins, their 
ligands, and ECM-degrading MMPs is a cause for rheumatoid arthritis, although the 
primary reason for that seems to be the integrin signaling rather than trafficking (Lowin 
and Straub, 2011).  
Integrin antagonists (i.e. RGD peptides) are used as therapeutics to prevent 
platelet aggregation and blood clot formation (Meyer et al., 2006). Antibodies against α4 
integrin are used to block the leucocyte trafficking through the blood-brain barrier and 
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therefore control the inflammation in the multiple sclerosis (O’Connor, 2007). However, 
one of the most prominent medicine-related function of integrin is their association with 
cancer.  
The development of solid cancers is often associates with dissemination of 
transformed cells which actively migrate from the primary tumor and invade to the 
adjacent tissues to form new tumor masses (Ramsay et al., 2007). Integrins can be 
involved in the cancer development through different mechanisms, e.g. by regulating 
cytokinesis of dividing cells (Pellinen et al., 2008), changing the MMPs expression 
profiles (Silletti et al., 2001) or altering migratory properties of the cells (Shin et al., 
2012).  
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2. Objectives 
Trafficking of integrins is of great relevance for understanding of normal and 
pathological cellular behaviour. The number of integrin heterodimers expressed in human 
cells, and the fact that integrins trafficking pathways can change according to integrins 
activity and ligand-binding status,  introduces a vast complexity to the existing data on 
the subject. The current model of integrin trafficking is far from being comprehensive. 
Previous studies identified number of integrin-specific trafficking regulators, but many 
groups of proteins, known or expected to contribute to traffic specificity (i.e. molecular 
motors) have never been systematically explored in the context of integrin traffic.  
For these reasons we decided to systematically search for the regulators of non-
clustered  α2 integrin retrograde trafficking. 
To achieve this, the following goals were pursued:  
1. establish a quantitative assay that could be applied to medium- or large-
scale analysis of α2 integrin internalization; 
2. perform RNAi screening for systematic analysis of α2 integrin 
internalization regulators; 
3. validate the screening results and  
4. characterize the role of selected hits in the α2 integrin traffic.  
 
The following approaches were undertaken: 
1.  The quantitative fluorescent microscopy-based assay was established to 
measure the internalization of integrin α2 in a small- and medium scale. The 
quantification of the assay was developed to achieve an adequate representation of the 
observed experimental results and high dynamic range of the assay.  
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2. The library of 1084 siRNAs targeting 386 genes known or predicted to be 
involved in the cytoskeleton organization was used for RNAi screening for α2 integrin 
internalization regulators. The results were bioinformatically analyzed and compared to 
published relevant datasets to characterize the screening hits. 
3. In order to verify the primary screening results, the reproducibility of the 
effect of the primary screening hits in the modified experimental conditions was assessed 
for selected group of hits. The presence of false-negatives among the screening results 
was tested. To eliminate the influence of secondary effects of hits knock-down, the 
changes in total α2 integrin expression were estimated for genes taken into validation, and 
the effect of local cell density changes on the α2 integrin endocytosis and expression. 
4. To further dissect the role of novel α2 integrin endocytosis regulator 
KIF15 in intracellular trafficking, the effect of its knock-down on the trafficking of other 
endocytic cargoes and cellular distribution of integrin-specific clathrin adaptor Dab2 was 
tested. The specificity of hit effect was verified by Western Blotting and rescue by overe-
expression of siRNA-resistant cDNA.  
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3. Materials and Methods 
3.1 Materials, antibodies, plasmids, reagents 
The following antibodies were used in this study: mouse monoclonal against 
human α2 integrin (clone P1E6, Merck-Millipore), mouse monoclonal against human α5 
integrin (clone NKI-SAM1, Merck-Millipore), mouse monoclonal agains integrin β1 
(clone TS2/16, BioLegend) rabbit monoclonal ant-Dab2 (H-110, Santa Cruz), mouse 
monoclonal antibody against Dab2 (clone 52/p96, BD Biosciences), anti-KIF15 
antibodies reactive with human and mouse KIF15 (Tanenbaum et al., 2009) , anti-α-
tubulin (Cell Signalling, clone DM1A),  goat anti-mouse and anti-rabbit antibodies 
coupled to Alexa-488 and Alexa-647 (Invitrogen), anti-rabbit HRP-coupled (GE 
Healthcare), anti-mouse HRP-coupled (R&D). LipofectamineTM2000 (Invitrogen) was 
used for tranfection. Transferrin-Alexa568 and EGF-Alexa555 conjugates were purchased 
from Invitrogen. peGFP-C1 plasmid was purchased from Clontech. GFP-MmKIF15 
plasmid was obtained from R. Medema (Tanenbaum et al., 2009). GFP-Rab5, GFP-
Rab7a, mCherry-Rab11b, and mCherry-Rab4a were a kind gift of Dr. Brady. 
Micropatterned coverglasses (Starter's CYTOOchips) with fibronectin-Alexa550 
coating were obrained from Cytoo.  
 
3.2 Cell culture 
All experiments were performed in human epithelial carcinoma cells (HeLa, 
ATCC CCL-2). were grown in Minimum Essential Medium (Eagle) (MEM, Sigma-
Aldrich) supplied with 10% (v/v) fetal calf serum (PAA Laboratories), 2mM L-glutamine 
(Invitrogen), 50g/ml streptomycin and 50U/ml penicillin (Invitrogen)., buffered with 
30mM HEPES, pH 7,2-7,4. Cells were cultured in 10 cm cell-culture dishes in the 
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incubator maintaining 37 °C and humidified atmosphere with 5% CO2, and split every 3 
days in ratio 1:8 using 0.25% trypsin-EDTA (Invitrogen).  
For serum-starvation the growth medium was replaced with MEM supplied with 
2mM L-glutamine and 0,01% (w/v) BSA (Roth) (MEM-BSA). For transfection Opti-
MEM (Invitrogen) without supplements was used for the first 4h of incubation of cells 
with transfection complexes (see Transection with siRNAs and cDNAs) which was 
further replaced with MEM supplied with 10% fetal calf serum (PAA Laboratories) and 
2mM L-glutamine (Invitrogen).  
 
3.3 Transfection with siRNA and cDNA 
For delivery of siRNAs or cDNAs in the HeLa cells we used liquid-phase direct 
transfection or reverse tranfection. For individual and small-scale experiments liquid-
phase direct transfection with siRNAs or cDNA was performed using Lipofectamine 2000 
reagent (Invitrogen) according to manufacturer's protocol. For single tranfection of cells 
growing in 24-well plate or in 8-well chambered coverslip 20 pmol of siRNA of was 
used. For cDNA tranfection amount of cDNA used was 800 ng per transfection in 24-well 
plate and 200 ng in 8-well chambered coverslip. Unless otherwise is stated, tranfection of 
the cells with siRNA occurred 48h before respective assay, and with cDNA – 24h before 
the assay. Reverse tranfection on cell arrays was used for delivery of siRNAs in large-
scale screening format, as described (Erfle et al., 2007, 2011). In brief, 5 µl of siRNA 
from 30 µM stock was mixed with solution of 3,5 µl Lipofectamine 2000 and 3 µl Opti-
MEM containing 0,4M sucrose and incubated for 20 min at RT. Thereafter it was mixed 
with 7,25 µl of 0,2% gelatine (w/v) in 0,01 % fibronectin (v/v), and transferred to contact 
printing on LabTek using eight solid pins PTS 600, which gives the spot size of approx. 
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400 µm. The spot-to-spot distance was set to 1125 µm, which allowed to fit on a single 
LabTek 384 spots organized in 12 columns and 32 rows. The whole library of 1084 
siRNAs was spotted on 4 LabTeks, with 6-12 Scramble negative control spots distributed 
across each layout. Additional row of positive control siRNAs targeting DNM2 and 
CLTC was spotted on each LabTek several weeks prior the start of the screening. The 
printed cell arrays were dried for 24h at RT, and then stored at RT until cell plating on the 
spotted cell array 48h before performing the integrin endocytosis assay.  
 
3.4 Western Blotting 
For analysis of KIF15 knockdown and overexpression, HeLa cells were plated in 
12-well plate, and tranfected with siRNA and cDNA for 48 and 24 h, respectively. Then 
cells were rinced with PBS and lysed with 80 µl of hot (95 °C) Laemmli buffer (Laemmli, 
1970) supplemented with 100 mM DTT and Protease Inhibitor Coctail (Roche). The 
nucleic acids in lysate were sheared by adding to the sample 0,2 µl  benzoase nuclease for 
10 min at RT. The proteins were separated at 8% PAA gel. PVDF Immobilion-P 
membrane was used for protein blotting. The membrane was blocked with 5% non-fat dry 
milk in PBST (PBS-0,1% Tween). KIF15 was detected using anti-KIF15 antibodies 
reactive with human and mouse KIF15 (Tanenbaum et al., 2009) diluted 1:300, incubated 
at 4 °C ON. After short washes with PBST secondary HRP-coupled anti-rabbit antibody 
(Amersham, 1:20000 dilution in PBST) was added. The signal was detected by ECL 
system (GE Healthcare). Luminescence was recorded by Chemiluminescence Detection 
System (Intas) and quantified by ImageJ software (NIH, Abramoff et al., 2004). For 
analysis of changes of Dab2 amount upon KIF15 knockdown, the mouse p96/Dab2 (BD) 
antibodies were used in dilution 1:500 following detection with HRP-coupled anti-mouse 
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antibodies (R&D, 1:1000 dilution). Tubulin specific band at 55 kDa detected by anti-α-
tubulin (clone DM1A9, Cell Signaling, 1:4000 dilution) was used for normalization of 
KIF15 or Dab2 signal.  
 
3.5 RT-PCR 
Preparation of total cellular RNA was made using TRIzol reagent (Invitrogen) 
according to manufacturer's protocol. cDNA was prepared with MMVL-reverse 
trancriptase (Ambion) and oligo-dT. The primer pairs used to assess the expression of 
genes of interest are listed in Appendix IV. Primer specificity was determined by 
nucleotide BLAST analysis against human genome and trancriptome. Primers were 
designed using Primer BLAST (NCBI) or the primer pairs published in (Jaulin et al., 
2007) were used. 
 
3.6. Non-clustered and clustered α2 integrin internalization assay 
For α2 integrin internalization assays the cells were serum-starved for 14h before 
the assay, or, in case of cDNA tranfection, 6h before the assay. Internalization of non-
clustered α2 integrin was previously published in (Erfle et al., 2011). For the assay, the 
primary antibody against α2 integrin (P1E6) was diluted in MEM-BSA to the final 
concentration 10 µg/ml and cooled on ice. The cells growing in multi-well plates were 
overlayed with 80-100 µl of antibody solution and placed on metal plate on ice. For the 
cells growing on coverslips, the antibody solution was pipeted in 50 µl droplets on 
parafilm-wrapped metal plate placed on ice, and the coverslips were flipped on them. The 
cells were kept on ice with antibody solution for 50 min, then shortly washed twice with 
ice-cold MEM-BSA to remove the excess of antibody, and then incubated with pre-
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warmed MEM-BSA at 37 °C in humidified 5% CO2 atmosphere for indicated time. After 
the incubation the cells were rinsed with PBS, stripped with acetic buffer (0,5% (v/v) 
acetic acid, 0,5M NaCl, pH 2,6) for 30-40 s, rinsed again with PBS and fixed with 2% 
PFA for 20 min at RT. The stripping step could be omitted, if indicated, for assessment of 
surface α2 integrin. After fixation the PFA was washed with PBS and quenched by 
incubation with 30mM glycin for 5 min. The cells were permeabilized with 0,2% (w/v) 
saponin in 10% (v/v) FCS in PBS and then were incubated for 1h with secondary anti-
mouse antibodies (Alexa488 or Alexa647 coupled, Invitrogen) in permeabilisation 
solution. and the nuclei were counterstained with Hoechst 33342 dye (0,1 µg/ml). For 
experiments aiming for the surface α2 integrin visualization, 10% (v/v) FCS in PBS was 
used instead of permeabilisation solution. 
Clustering and subsequent internalization of α2 integrin was induced as described 
in (Rintanen et al., 2012) by sequential incubation of living cells with primary anti-α2 
(P1E6) antibodies and then with secondary anti-mouse antibodies coupled to Alexa647. 
Cells were incubated on ice with 10 µg/ml P1E6 as described for non-clustered integrin 
assay, then rinsed twice with ice-cold MEM-BSA, and then incubated for 50 min with 
secondary anti-mouse – Alexa647 antibodies on ice. Corresponding non-clustering 
control was incubated on ice with MEM-BSA without addition of secondary antibody. 
Then cells were shortly washed twice with ice-cold MEM-BSA and incubated with pre-
warmed MEM-BSA at 37 °C in humidified 5% CO2 atmosphere for indicated time. After 
the incubation the cells were rinsed with PBS and fixed with 2% PFA for 20 min at RT. 
The nuclei were counterstained with Hoechst 33342. Corresponding non-clustered control 
was subsequently stained with secondary anti-mouse antibody as previously described. 
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3.7. Non-clustered integrin α2 internalization on CYTOOchips 
The cells were grown on plastic in multi-well plates and transfected with siRNAs 
(liquid phase transfection, as described earlier) 48 h before the integrin internalization 
assay. Next day after transfection the cells were trypsinized, counted, and 60000 cells 
were seeded on the Starter's CYTOOchip, that was beforehand briefly washed with 70% 
ethanol and kept in PBS. For seeding the cells were resuspended in the normal growth 
medium. The cells were allowed to sediment for 10 min at RT, then were gently 
transferred to 37 °C, 5% CO2  for another 20 min to allow cell attachment. The the non-
attached cells were washed by two-times partial replacement of the growth medium. 4h 
after seeding the cells on chip (which corresponds approx. 14H before the integrin α2 
internalization assay), the growth medium was replaced by MEM-BSA. The integrin 
internalization was further performed as described previously. 
 
3.8. EGF and Transferrin endocytosis assays 
EGF endocytosis assay was performed as described in (Schmidt-Glenewinkel et 
al., 2009). Cells were serum-starved for 14 hours before the assay; then EGF-Alexa555 
was added to the medium to final concentration of 100ng/ml and cells were incubated for 
indicated amount of time at 37 °C, stripped with acidic buffer (50 mM glycine, 150 mM 
NaCl, pH 3.0), and fixed with 3% PFA 20 min at RT. 
For transferrin endocytosis assay cells were serum-starved for 1h, then tranferrin-
Alexa568 was added to the medium to the final concentration of 25 µg/ml, and cells were 
incubated for indicated time at 37 °C, shortly rinsed with PBS and directly fixed with 3% 
PFA 20 min at RT.  
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3.9. Microscopy 
Wide-field fluorescent microscopy was done with Olympus IX81 Scan^R 
automated inverted microscope (Olympus Biosystems) controlled by Scan^R acquisition 
software. Generally, imaging was made using 20x/0.75 NA air objective lens 
(UPlanSApo; Olympus Biosystems). For screening 10x/0.4 NA air objective lens 
(UPlanSApo; Olympus Biosystems) was used. Stabilised 150W Hg/Xe light source and 
combination of the following excitation/emission filters was used for the imaging of the 
fluorophores: excitation wavelength = 450-490 nm and emission wavelength 500 - 550 
nm was used to to image integrin α2, excitation wavelength = 426-446 nm, emission 
wavelength = 460-500 nm - to image EGF-Alexa555, and 545-580 nm excitation and 
610-700 emission wavelength - to image transferrin-Alexa568. Excitation wavelength = 
325-375 nm, emission wavelength = 435-475 nm was used to image nuclei in all assays. 
Confocal imaging was performed with confocal laser scanning microscope TCS 
SP5 (Leica Microsystems) using a 63x oil immersion objective lens. An argon (λ = 
488nm) laser was used to excite GFP or Alexa-488 dye, diode laser (λ = 561 nm) was 
used to excite Alexa-568 dye or mCherry, and a helium/neon (λ = 633nm) laser was used 
to excite Alexa 647 dye.  
TIRF was performed on Nikon Eclipse Ti TIRF microscope with Nikon Apo TIFR 
60x NA 1.49 objective. 488 and 640 nm laser lines were used for excitation of Alexa488 
and Alexa647, respectively, with following filters: excitation wavelength = 485-485nm, 
emission wavelength = 500-545 nm, and emission wavelength = 621-643, excitation 
wavelength = 672 - 712nm.  
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3.10. Image analysis and statistical data analysis for small-scale 
experiments 
For experiments performed in 96-well plates, 8-chamber µ-slides, or on coverslips 
in 24-well plates, 30 to 42 images were analyzed. Images obtained by wide-field 
fluorescent automated screening microscopy were processed by Scan^R Analysis 
software (Olympus). The nuclei of individual cells were identified by intensity module of 
built-in Scan^R object finder using an intensity threshold to identify objects border. The 
threshold was set manually for each individual experiment. To measure the mean intensity 
of the perinuclear area, the outline of nuclei was expanded by 10 µm. Besides the mean 
intensity of imaged channels, the imaged position in which the cell was located, and the 
coordinates of nucleus center were recorded. 
Quality control and statistical analysis of image analysis raw data were done using 
the following pipeline. First, all the images underwent visual control to exclude those of 
insufficient quality (i.e. out of focus, too little cells, scratches or other artefacts present); 
second, 2% of the cells with the highest fluorescence intensities were excluded to ensure 
that abnormal or apoptotic cells don't interfere with analysis.  Further analysis depended 
on the assay. 
For the integrin internalization assay in the multiwell plates a threshold, separating 
α2 integrin internalizing cells from non-internalizing was determined visually for each 
experiment. Percentage of internalizing cells was multiplied to the mean intensity of 
internalizing cells resulting in integrin endocytosis parameter per well (equation 1): 
endocytosis= (mean intensity abovethreshold )(number of cellsabove threshold )
(total number of cells)
[1] 
In the non-clustered α2 integrin endocytosis assay, for negative control siRNA-
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transfected cells the number of internalizing cells was usually about 30%. The resulting 
“endocytosis” parameter was normalized to the corresponding negative control. 
The similar calculation method was used for tranferrin, EGF, and clustered α2 
integrin internalization assay. Due to the nature of these assays, the percentage of 
internalizing cells in the control experiments was usually close to 100%.  
For quantification of rescue of human KIF15 knockdown with over-expression of 
GFP-mKIF15, the individual cells measurements were binned according to level of 
expression of GFP-mKIF15. The scale of binning was linear for low-level of expression 
(intensities from 0 to 100 A.U.), and logarithmic for high expression  (higher then 100 
A.U.). Three bins containing at least 20 cells/bin with highest GFP-mKIF15 signal were 
selected and mean intensity of internalized integrin was averaged.  
For the assessment of α2 integrin expression, after removal of 2% of brightest 
cells, mean intensity of total cell population was calculated and then normalized to the 
corresponding negative control. 
Statistical significance of difference between experiments mean was tested by 
Student's two-tailed t-test for samples with uneven variance. P-value less than 0,05 was 
considered significant.  
 
3.11. Image analysis and statistical data analysis for RNAi screening on 
cell arrays 
By imaging the cell arrays with 10x objective, each siRNA spot was fitted to an 
individual image. Central area of each image, corresponding to siRNA spot (represented 
with outline in Fig. 1), was selected by Scan^R software (Olympus) and the  individual 
cells within it were detected by nuclear staining. One siRNA spot on cell arrays 
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accomodated 100-400 HeLa cells. Amount of internalized integrin represented by mean 
intensity of integrin staining in perinuclear region was measured for individual cells.  
Statistical analysis of the primary screening raw data was done using the statistical 
language R (R Development Core Team. R: A language and environment for statistical 
computing, 2011) and the package cellHTS (Boutros et al., 2006) from Bioconductor  
http://www.bioconductor.org). Prior statistical analysis, all the images were subject to 
visual control to exclude those of insufficient quality, as described for smalle-scale 
experiments; then 2% of the cells with the highest fluorescence intensities were excluded 
for each imaged spot. The remaining cell intensities were averaged, and B-score 
normalization (Brideau et al., 2003) was applied to them, to calculate a correction factor 
for each well which would account for spatial effects and between-plate artifacts. In each 
well the computed correction factor was subtracted from the remaining cell intensities to 
obtain normalized single-cell data. The the normalized intensities of the whole cell 
population from the single cell array was pooled and Gaussian Mixture Model (Knapp et 
al., 2011) was fitted to it to automatically cluster the cells into two subpopulations that 
would correspond to internalizing and non-internalizing cells. The median signal 
intensitity and cell number of each of two clusters was calculated for single imaged 
positions (corresponding to single siRNA transfections). The median signal intensity of 
the internalizing cells was multiplied to the number of internalizing cells and divided by 
the total cell count in each well. This ratio was normalized against the median of the  
negative controls on each cell array by subtracting the median of the negative controls 
from each well and dividing the result through the median absolute deviation (MAD) of 
the negative controls (equation 2). 
z= median(well) - median(negative control)
        MAD(negative control) [2] 
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Replicate measurements were summarized by taking the median. Z=±1 was 
selected as a threshold for determining hit siRNAs. The cell arrays, on which positive 
controls average did not reach the threshold were excluded from analysis. After all the 
quality control steps, 5 to 8 replicates remained for 95% of tested siRNAs. One-sided, 
one-sample Welch's t-test was used to compute significance values for each well where 
more than three replicates were available.  
 
3.12. Co-localization analysis 
Co-localization of the intracellular structures in the multi-channeled single confocal plane 
images was done in Image J (NIH, (Abramoff et al., 2004). For this, the images 
background was subtracted using rolling ball algorithm (radius 30px), the Gaussian Blur 
filter was appllied (σ = 0,75 – 1 µm), the channels were thresholded to detect individual 
vesicles and binarized. The resulting binary images were  processed using “Image 
calculator” function (“AND” operator) for pairwise comparison of two images and 
creating the additional image on which only co-localizing pixels were present (co-
localization image). The number and parameters of particles present in binarized channel 
images and co-localization image were analyzed by “Particle analysis” plugin. To exclude 
both the small stuctures and co-localization due to high density of vesicles (which is 
likely to occur in the perinuclear area) only particles of the size 10-100 µm2 were taken 
into account. The number of particles in the co-localization image was divided by the 
number of particles of one of the channels of original image to get the percentage of co-
localizing particles.  
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3.13. Bioinformatic analysis of screening results 
Results of the screenings were compared to other high-throughput assays and gene 
annotations: genes from the adhesome (Zaidel-Bar et al., 2007), TFR and EGFR 
endocytosis (Collinet et al., 2010) (genes from phenotypic groups 1, 2, 12, 14 considered 
as affecting exclusively TFR endocytosis; groups 9, 10, 11, 13 as affecting exclusively 
EGFR endocytosis; groups 3, 4, 5, 6, 7, 8 as affecting both), MHC II antigen presentation 
machinery (Paul et al., 2011), focal adhesion formation (Winograd-Katz et al., 2009), 
mitosis (Neumann et al., 2010), epithelial cell migration (Simpson et al., 2009) (hits of 
medium and high confidence), integrin association (Humphries et al., 2009), β1-integrin 
activity (Pellinen et al, 2012) and binding to β1-integrin tail (Böttcher et al., 2012). 
Networks were prepared based on protein-protein interaction collected in SysBiomics 
(which contain data from the main PPI databases: DIP, BIND and HPRD). Network 
analysis was performed in Cytoscape 2.8.3. 
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4. Results 
4.1. Fluorescent-microscopy-based α2 integrin internalization 
assay  
To address the regulation of α2β1 integrin endocytosis, we developed the 
fluorescent-microscopy-based assay that would allow to visualize and quantify 
internalized integrin the individual cells and across the large cells population. Antibody-
based assays are widely used to address internalization of various surface proteins, 
including different integrins and MHCII (Gao et al., 2000; Powelka et al., 2004; Ma et al., 
2012). In such assays, antibodies targeting the extracellular epitope of the protein of 
interest are incubated with living cells (often upon block of internalization, i.e. by 
incubation at low temperature), then the excess of antibody is washed away, and the cells 
are returned to permissive conditions for internalization of protein-antibody complexes. 
The cells can be further subjected to immunostaining to visualize the internalized protein-
antibody complex. 
We have set such an experiment to to visualize and quantify α2β1 integrin 
endocytosis in human cells upon various conditions. For experimentation we selected 
HeLa cell line, that expresses high levels of endogenous α2β1 integrin (Fleming et al., 
2010). Monoclonal antibody targeting extracellular I-domain of α2 chain of α2β1 
heterodimer was used (Jokinen et al., 2010). As integrin α2 chain forms a unique 
heterodimer with β1 integrin (Hynes, 1992, 2002), we could follow a particular 
heterodimer by labeling the α2 chain only.  
Integrin signalling and trafficking was shown to cross-talk with signalling of 
growth factors (Riikonen et al., 1995), therefore we performed the integrin internalization 
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assays in the cells after 14h of serum starvation to avoid interference of growth factors 
present in the full medium. To visualize α2 integrin endocytosis, live HeLa cells were 
incubated with P1E6 antibody for 50 min on ice (Figure R.1A), briefly washed with ice-
cold medium, then supplied with pre-warmed serum-free medium and returned to 37°C 
for various periods of time (Figure R.1B).  
By staining of total and surface α2-integrin bound primary antibodies, we found 
that after 1h about 70% of antibody-bound integrin could be found on the PM, indicating 
only partial endocytosis and/or efficient recycling of α2 integrin. (Figure R.1B, R.2B). 
The assesment of α2 integrin endocytosis by parallel staining of surface and total integrin 
nevertheless presents a problem of dealing with two sets of samples per condition, and 
low dynamic range. Therefore we used short stripping with acidic buffer to remove the 
surface bound P1E6 antibodies after integrin internlization. This allowed to specifically 
visualize the pool of internalized α2 integrin (Figure R.1C, R.2A) by staining with 
secondary antibodies.  
Figure R.1. Antibody-based integrin endocytosis assay. (A) Cells are incubated with antibodies 
against extracellular domain of integrin α2 on ice for 50 min. (B) The antibody-bound integrin α2 is 
allowed to get internalized over 60 min. (C) The surface-bound antibody is stripped and only internalized 
antibody-bound integrin is visualized. Scale bar = 20µm 
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For assessment of the amount of internalized integrin, we used automated wide-
field fluorescent microscopy, as it combines precise measurements of individual cell 
phenotypes with possibility of high-throughput experimentation and analysis (Tuckwell et 
al., 1995). 
Allowing the cells to internalize antibody-bound α2 integrin, we saw that, after 1h 
Figure R.2 Endogenous integrin α2 in 
HeLa cells changes internalization features 
when clustered by treatment with primary 
anti-integrin α2 and secondary antibodies. 
(A)  Internalized non-clustered integrin α2. 
The integrin labelling was performed as 
described in (A), but prior fixation and 
staining the antibodies remaining on the 
surface were stripped, the cells were fixed, 
permeabilized, and stained with secondary 
Alexa647-coupled antibodies for 
internalized integrin alpha2. (B) Surface 
non-clustered integrin α2. Surface integrin 
alpha2 in HeLa cells was labeled on ice 
with primary anti-integrin alpha2 antibody 
(P1E6), left for internalization for 1h, and 
6h, or fixed immediately after labelling 
(0h). Integrin alpha2 remaining on the cells 
surface was stained with secondary 
Alexa647-coupled antibodies. (C) 
Clustered integrin α2. Surface integrin 
alpha2 in HeLa cells was labeled on ice 
with primary anti-integrin alpha2 antibody 
(P1E6) followed by clustering with 
secondary Alexa647-coupled antibodies 
and left for internalization for 1h, and 6h, 
or fixed immediately after labelling (0h). 
Scale bar 20 µm (D) Quantification of the 
mean intensity of clustered integrin alpha2 
after 6h of internalization. Bars represent 
mean intensity of clustered integrin 
(normalized to 1h of internalization) from 
three independent experiments ± SEM. (* p 
< 0,05, statistical significance measured 
with Student’s t test, unpaired, unequal 
variance). 
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of internalization, intracellular pool of α2 integrin reached steady-state and persisted till 
two hours (Figure R.2D). At prolonged incubation of 6h and 24h integrin-specific 
fluorescence was strongly diminished (63% and 30% of 1h, correspondingly), most likely 
indicating degradation of antibody-bound integrin. Therefore, it was decided to perform 
futher measurements of intracellular α2 integrin after 1h of internalization. Additionally, 
attempts to establish comparable protocols for internalization of integrin β1 and integrin 
a5 chains were made. For this we used the stimulating anti-β1 antibodies (clone TS2/16) 
and anti-a5 antibodies (clone NKI-SAM1). However, application of different acidic 
stripping methods (30s stripping with acetic acid buffer at RT, stripping with glycine 
buffer for 30s at RT or 5 min on ice) did not result in complete removal of surface-bound 
antibodies (data not shown), therefore these protocols were not used.  
 
4.1.1. Quantification of microscopy-based integrin internalization assay 
The quantitative assessment of integrin α2 internalization was done by automated 
fluorescence microsopy and single cell-based analysis (Erfle et al., 2011). The individual 
cells were identified through the nuclei counterstaining, and the mean integrin-specific 
fluorescence was measured in the perinuclear area. We found high variety of  
internalization level of the endogenous α2 integrin in HeLa cells (Figure R.3), that is, 
most likely due to variability of integrin expression, which can have 10-folds difference 
between 10% of dimmest and brightest cells stained for total α2 integrin (data not shown). 
Comparable difference between the 10% of brightest and dimmest cells was observed for 
internalized integrin (Figure R.3A).  
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We found that about 60% of the cells contain low amount of intracellular integrin 
after 1h of internalization even in negative control siRNA  
Figure R.3. Cell-to-cell variability in integrin internalization (A) Immunostaining of total integrin 
α2 chain in HeLa cells. Scale bar = 20 µm. (B) Distribution of integrin α2 staining intensity over the whole 
cell population in a single representative experiment. (C) Quantification of internalized integrin mean 
intensity after transfection with control siRNAs. Integrin internalization assay was performed 48 h after 
transfection with negative control (siCTRL) and integrin endocytosis effectors (CLTC, DNM2 and CAV1) 
siRNAs. Bars represent mean fluorescent intensity of intracellular integrin α2 after 1h of internalization 
from three independent experiments ± SEM. **p< 0,01; statistical significance measured with Student’s t 
test, unpaired, unequal variance. 
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treatment (Figure R3.B) or no treatment (data not shown). Presence of a big 
unresponsive population of cells smooths the observed effects on integrin internalization. 
Having to deal with that, we have probed several quantification procedures to obtain a 
good dynamic range of our assay. By averaging the internalized α2 integrin intensity of 
all cells in a population, only 40% difference to control could be measured  when 
dynamin-2, caveolin 1 and CLTC were down-regulated for 48h (Figure R3.C). Therefore 
we established the quantification procedure that would take  into consideration a varying  
proportion of cells  that demonstrate internalization of α2 integrin, defined by an 
experiment-dependent threshold (see Methods),  Using this method, we could score the 
inhibition of α2 integrin internalization from 70% (upon down-regulation of caveolin-1) 
to 80% (down-regulation of dynamin-2) (Figure R.4B). As strong inhibition calculated 
by this method corresponds well to the little appearance of intracellular α2 integrin under 
Figure R.4..Integrin α2 endocytosis in HeLa cells
is inhibited by treatment by siRNAs targeting
dynamin 2, clathrin heavy chain, and caveolin-1.
(A) HeLa cells were transfected with corresponding
siRNAs, and after 48h integrin internalization assay
was performed. Treatment with siRNAs targeting
dynamin2, CLTC and caveolin-1 led to strong
reduction of integrin internalization (representative
example of cells transfected with Dnm2 and
negative control siRNAs downregulation is shown).
Scale bar = 20 µm. (B) Quantification of the siRNA
effect on integrin internalization. Bars represent
mean endocytosis rate normalized to control
siRNA-treated cells from two independent
experiments ± SEM. (**p< 0,01; statistical
significance measured with Student’s t test,
unpaired, unequal variance). 
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these conditions (Figure R.4B), we have used this method for the majority of 
experiments in this study unless stated otherwise. 
 
4.2. Clustered and non-clustered integrin α2β1 pursues different 
internalization routes 
We have initially tested whether endocytic trafficking of endogenous α2β1 in 
HeLa cells shares similar features as to SAOS cells over-expressing α2  (Rintanen et al., 
2011; Karjalainen et al., 2008; Upla et al., 2004). At first, clustering of α2 integrin was 
induced by sequential addition of the primary and secondary antibodies (see Methods). 
Similar to the data obtained by Rintanen et al., 2011 in SAOS-α2β1 cells, an efficient 
accumulation of endogenous α2 integrin in cytoplasmic punctuate structures was 
observed after 1h of incubation (Figure R.2C). After longer incubation times α2 integrin 
was accumulated at a juxtanuclear area, and a reduction up to 70% of clustered α2 
integrin was recorded after prolonged incubation times up to 6h (Figure R.2C). Hardly 
any PM localization of the clustered integrin α2 was observed already after 1h of 
incubation. In contrast, after internalization of non-clustered α2 integrin (Erfle et al., 
2011), the larger fraction of α2 integrin was localized at PM even at longer incubation 
times (Figure R2.B). Thus, trafficking of clustered and non-clustered endogenous 
integrin α2 strongly resembles that of the over-expressed protein (Rintanen et al., 2012).  
 
4.2.1. Non-clustered α2 integrin traffics through Rab5-Rab4-Rab11 
positive pathway 
To test, to which internalization pathway non-clustered α2 integrin is driven, we 
have co-localized it after 1h with Rab5, Rab4, Rab7, and Rab11, determinants of early, 
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late, and recycling endosomes, correspondigly (reviewed in (Stenmark., 2009)  
It has previously been shown, that internalized β1 integrin, the binding partner of 
α2, is delivered to the Rab5- and EEA1-positive early endosomes, and then targeted to 
recycling via Rab4 or Rab11 endosomes (Powelka et al., 2004; Pellinen et al., 2006; 
Arjonen et al., 2012), or, in case of activated or ligand-bound β1, to Rab7-dependent 
pathway, from which it can be driven to degradation (Arjonen et al., 2012) or recycle 
back to PM . 
After 1h of internalization we found substantial co-localization between integrin 
and  overexpressed Rab5, Rab4 and Rab11 in the perinuclear area and peripheral vesicles 
(Figure R.5A, B, C). The co-localization between α2 integrin and GFP-Rab7  was 
considerably less even in the perinuclear area and almost absent at the cell periphery  
(Figure 5D, insert). As the density of the vesicles in the perinuclear area of the cells is 
very high, we have used only peripheral vesicles to quantify co-localization and found 
60% and 68 % of integrin-containing vesicles on the cell periphery co-localized with 
Rab5 and Rab11, correspondigly. Co-localization of internalized integrin with over-
expressed Rab4 was 32%, but it is worthy to mention, that almost all the Rab4-positive 
vesicles (95% of them) contained internalized α2 integrin. Only 6% of peripheral 
integrin-containing vesicles were Rab7-positive. This would indicate that non-clustered 
α2 integrin following internalization via Rab5-dependent pathway, is driven to Rab11-
positive recycling compartment. In contrary, clustered integrin α2 in SAOS-α2β1 cells 
bypassed conventional clathrin-dependent internalization route and did not co-localize 
with early endosomal marker EEA1 and Rab7 (Rintanen et al., 2012).  
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Thus, we demonstrate that, internalized non-clustered α2 integrin is driven to 
conventional Rab5-, Rab4- and Rab11-positive endocytic recycling route, and, to lesser 
Figure R.5. Internalized integrin α2 co-
localizes with Rab5a, Rab11b, and Rab4a
but not Rab7a in HeLa cells. Co-
localization with overexpressed GFP-
Rab5 (A), mCherry-Rab11 (B), mCherry-
Rab4a (C) and GFP-Rab7 (D) (green) and
internalized integrin α2 (red) after 1h of
internalization. Integrin α2 endocytosis
assay was performed as described 30h
after transfection of HeLa cells with
corresponding plasmids. Confocal single
sections are presented. Arrows point to
internalized integrin co-localizing with
corresponding Rab, arrowheads indicate
the structures where no co-localization
occures. Scale bar = 10 µm. Scale bar of
inserts = 5 µm.  
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extent, to Rab7-positive late endocytic compartment, in contrast to published data on 
trafficking of clustered α2 integrin. 
 
4.1.2. Endocytosis of non-clustered α2 integrin depends on clathrin and 
caveolin 
 Previous studies demonstrated by RNAi and proteomic analysis, that endocytosis 
of β1 integrin chain, the binding partner of α2 integrin, occurs via clathrin/Dab2-
dependent (Chao and Kunz, 2009; Teckchandani et al., 2009, 2012) and caveolin-
dependent pathways (Shi & Sottile, 2008). However, internalization of over-expressed 
clustered and ligand-bound α2 integrin was demostrated by fluorescence and electron 
microscopy to occur via caveolae (Upla et al., 2004; Rintanen et al., 2012). It was not 
inhibited by overexpression of clathrin adaptror AP180 C-terminus or dominant-negative 
EPS15, and did not co-localize with early endosomal maker EEA1 (Upla et al., 2004; 
Rintanen et al., 2012). Yet, hardly any data are available about the endocytic trafficking of 
non-clustered α2 integrin. Localization of internalized α2 integrin to Rab5-positive 
endosomes suggests that canonical clathrin-dependent (Bucci et al., 1992) or caveolin-
dependent (Lucas et al., 2004) internalization pathways are involved. To test that, we have 
down-regulated the key components of clathrin-dependent and caveolae-dependent 
pathways (clathrin heavy chain (CLTC) and caveolin-1) and dynamin-2 which is required 
for both pathways (Hansen and Nichols, 2009, Doherty and McMahon, 2009, Parton and 
Simons, 2007, Caswell and Norman, 2006), and assessed integrin α2 endocytosis under 
these conditions (Figure R.4). 
 The siRNAs  used for this experiment were previously published (Gregory, Hale, 
Perlmutter, & Houghton, 2012; Spoden et al., 2008) and were validated by manufacturer 
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(reported downregulation efficiency was more than 80% by qRT-PCR). We have 
confirmed downregulation of target transcripts by more than 50% by RT-PCR. Down-
regulation of each of the the three components of endocytosis machinery resulted in 
strong reduction of intracellular integrin upon 1h of internalization compared to control, 
seemingly reflecting block in early steps of endocytosis (Figure R.3). 
 Thus we demonstrated that, in agreement to previously published data on 
trafficking of β1 integrin (Chao & Kunz, 2009; Teckchandani et al., 2009; Shi & Sottile, 
2008), down-regulation of clathrin heavy chain, dynamin-2, and caveolin 1 strongly 
inhibits internalization of non-clustered α2 integrin, indicating that both clathrin-
dependent and caveolae-dependent pathways are involved. Dependency on clathrin 
divercifies the internalization pathway of non-clustered α2 integrin from that of clustered 
α2.  
 
4.3. Fluorescent microscopy-based RNAi  screen identifies potential 
regulators of non-clustered α2 integrin endocytic trafficking   
1084 siRNAs targeting 386 genes with known or predicted roles in cytoskeleton 
organization were chosen for the analysis (Appendix 1, RNAi library provided by R. 
Pepperkok, EMBL, Heidelberg). The gene set included 94 molecular motors (44 kinesins, 
13 dynein subunits, and 37 myosins), 28 small Ras and Rho GTPases, 53 GAPs and 62 
GEFs of these GTPases, 41 actin-associated and 14 microtubule-associated proteins, 34 
kinases and 9 phosphatases, 5 different integrin β chains and, 23 scaffold and adaptor 
proteins as well as a number of proteins belonging to diverse functional groups. Products 
of 81 genes in this library were previously shown to constitute integrin adhesome (Zaidel-
Bar et al., 2007).    
For the primary screening we used format of reverse transfection in cell array 
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(Erfle et al., 2007) (see Methods). The cell arrays had a surface coating with fibronectin 
and gelatin. Unlike the collagen I (as demonstrated in (Ritanen et al., 2012), gelatine 
coating did not induce clustering of  integrin and allowed us to follow the internalization 
of non-clustered α2 integrin. In agreement to our experiments with dynamin2 
downregulation in cells grown on plastic, treatment with siRNAs targeting Dnm2 
inhibited α2 integrin internalization by 80% in cells grown on mixture of gelatin and 
fibronectin (data not shown). Similar to the experiments in the conditions of the direct 
transfection, siRNAs targeting CLTC, dynamin-2 and caveolin-1 induced a strong 
inhibition of α2 integrin trafficking on cell arrays (Appendix II), therefore, they were 
used as the positive controls.  
Data collection was made on a wide-field microscope and intracellular integrin 
α2-specific fluorescence  was quantified for single cells. After a thorough quality control 
including manual image quality check, cell densities and performance of the controls, five 
to eight replicas were statistically analysed for 95% of all siRNAs. The statistical analysis 
was performed by B. Knapp (AG Kaderali, BioQuant, Heidelberg, currently TU Dresden, 
Dresden). As manual setting of the threshold to separate cells with high and low 
internalization levels of α2 integrin for every experiment could be biased depending on 
the experimenter, a mixture model has been applied to separate cells with the high and 
low internalization levels of α2 integrin automatically (see Methods). For each siRNA 
spot the percentage of internalizing cells as well as amount of internalized integrin (as 
defined by mean intensity of the internalized integrin staining) was calculated.  
Z-scores (see Methods) of individual siRNAs on the labtek were normalized to the 
z-score of negative controls averaged across each labtek. Thus average z-score of 
scrambled negative control siRNA was 0 (Figure R.6A). CLTC siRNA had average z-
70 
 
score -1,54 (p-value = 7,45E-29), and dynamin 2 siRNA had -1.49 (p-value = 2,24E-13) 
(Figure R.6A, B). Caveolin 1 siRNA had weaker effect (average z-score -1,14, p-value = 
0,01). In our screen we have considered as primary hits those siRNAs, which had 
absolute z-scores > 1. Positive z-scores indicate acceleration and negative z-scores show 
inhibition of integrin α2 trafficking ( Table 2). The gene was considered a primary hit in 
case one out of two tested siRNAs gave an effect on integrin internalization (for pool of 
genes tested with 2 siRNAs per gene), or  if at least 2 siRNAs (for pool of genes tested 
with 4 or 6 siNRAs) or at least 3  siRNAs had consistent effect on integrin internalization. 
Altoghether we found 122 primary hits: 115 inhibitors and 7 accelerators of integrin 
internalization (Appendix II). Out of them, 28 were targeted by 2 or more siRNAs. In 
total, 31 primary hits had individual siRNAs absolute z-scores more than 1,5. 
Interestingly, the positive control siRNAs that in preliminary experiments in multi-well 
plates were blocking the integrin endocytosis by 70-80% (Figure R.3), in the screening 
have performed rather like mild inhibitors (z scores = -1,54; - 1,49; -1,14  for DNM2, 
CLTC, and caveolin 1 correspondingly) with number of hit siRNAs outperforming them 
(Appendix II).Among the screening hits we found molecules that could be expected to 
have an effect on integrin internalization: i.e. knockdown of  integrin β1  (hit with 4 out 
of 12 siRNAs, z = -1.32), actin (1 out for 2 siRNAs, z = -1,11), β-tubulin (2 out of 2 
siRNAs, z= -1,08) inhibited the α2 internalization, and ASAP1 (GAP for Arf6 involved in 
recycling of β1 integrin (Onodera et al., 2012) accelerated it (z = 2,26). The top scoring 
primary hits included trafficking regulator ARF1 (z= -1,62) (Gu, 2000), regulator of β1 
integrin endocytosis syndecan 4 (Bass et al., 2011) (z=-1,78), actin-binding RhoA GAP 
ARHGAP6 (z=-2,11) (Prakash et al., 2000), kinesin molecular motor KIF18a (z = -1,76) 
(Mayr et al., 2007) (Figure R.6B).  
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4.3.1. Bioinformatic analysis of the primary screening results   
The following bioinformatic analysis was performed in collaboration with D. 
Matelska (AG Russell, BioQuant, Heidelberg). 
Having classified the screening hits to functional classes according to Gene 
Ontology (GO) terms, we did not find enrichment of any functional groups among the 
screening hits compared to the screened library. This is likely a consequence of thorough 
preselection of genes included in the library. 
Figure R.6. Results of the primary
screening for regulators of integrin α2
endocytosis (A) Hit z-scores of the most
effective siRNAs tested in the screening.
Mild hit siRNAs (1 < absolute z-scores
< 1,5) are highlighted in green. Strong hit
siRNAs (absolute z-scores > 1,5) are
highlighted in red. (B) Examples of
integrin α2 endocytosis assay on cell
arrays. No changes in integrin α2
endocytosis was observed following
incubation of HeLa cells with the
negative control (left column). Treating
cells with siRNA targeting dynamin2
(DNM2) induced a strong reduction of
internalised integrin α2 (middle column).
Similar effect was observed when
KIF18a was down-regulated for 48h.
White outlines represent spots containing
individual siRNAs. Integrin α2 specific
fluorescence was measured within spot
boundaries. Scale bar = 100 µm. (C)
Regulators of integrin endocytosis in
comparison to known regulators of
transferrin and EGF endocytosis
(Collinet et al., 2010), focal adhesion
formation (Winograd-Katz et al., 2009)
and epithelial cell migration regulators
(Simpson et al., 2008).  
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We compared the results of our screening with other RNAi screening data. One of 
the most interesting datasets for us was the recent genome-wide screening for regulators 
of transferrin (Tf) and epidermal growth factor (EGF) endocytosis (Collinet et al., 2010). 
The list of our hits overlaps by 32% with the published endocytosis regulators (39 of our 
hits were found as the regulators of either Tf or EGF endocytosis). We have found that 
among the genes used in our screening, the hit rate was comparable with the screening of 
(Collinet et al., 2010). The latter collected 81 Tf endocytosis regualators (21%) and 89 
EGF endocytosis regulators (23%) out of 386 cytoskeleton-associated genes, whereas our 
screening found 122 potential integrin endocytosis regulators (32%) ( Figure R6.C). 
Majority of overlapping hits (25 of 39) regulated all three endocytic cargoes. Minority of 
hits was shared between integrin endocytosis and specific regulators of Tf or EGF 
endocytosis (7 regulators overlap with either Tf and EGF endocytosis). Hits overlapping 
with Tf endocytosis regulators (FARP2, PTPN1, MYH1, SDC4, VAV2, CAV1, 
DYNC1H1, ARHGEF2) include 2 integrin-interacting proteins (SDC4  and  and 2 
molecular motors. Regulators of EGF endocytosis include 4 kinases (LIMK2, PIK3CA, 
ROCK1, PRKCA) all of which, except LIMK2 are known as components of adhesome 
(as listed in (Zaidel-Bar et al., 2007)),  GTPase-regulating protein  CHN2, actin-binding 
protein LASP1, and integrin-interacting protein CIB.  The observation that majority of 
integrin endocytosis regulators are specific for integrin, and the other big group overlaps 
with regulators of both Tf and EGF, suggests that regulators of integrin endocytosis either 
belong to general internalization machinery (shared by transferrin, EGF, integrin and, 
perhaps, other endocytic cargos) or integrin specific, but not more related to either 
transferrin or EGF internalization pathways. 
Next, we have compared our results with the recent RNAi screenings for 
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regulators of focal adhesion formation (Winograd-Katz et al., 2009) and cell migration 
(Simpson et al., 2008), both using the same RNAi library (Figure R6.C). These 
screenings were not genome-wide, but covered three different libraries: kinases, 
phosphatases, and genes involved in cell adhesion and migration or suspected to play role 
in these processes. The gene set had a substantial overlap of 161 genes with our 
cytoskeleton-associated genes library. Out of these, 52 (33% of the libraries overlap 
subset) were found as primary hits in our integrin endocytosis screening. 80 (50% of the 
subset) genes were found as hits in the focal adhesion formation screening, and 24 of 
them were also found as integrin endocytosis regulators (including CDC42, PTEN, 
PTPN11). In the migration screening the hit rate was smaller: 29 of 161 tested genes 
(18%) were found as hits. Out of them  9 primary hits overlapped with the hits of integrin 
endocytosis screening (including CRK, ITGB1, LIMS1, ASAP1). Thus, both in case of 
focal adhesion formation screening and cell migration screening, the overlap with integrin 
endocytosis screening hits was about 30%.  3 hits  were common between all the three 
screenings: ACTB, CRK, , and kinase PRKCA. Yet, 12 of these 26 proteins are known as 
components of integrin adhesome. 
Recent biochemical screening for integrin α2 interactions (Uematsu et al., 2011) 
showed only minor overlap of 2 hits with our screening hits (MYH9 and GAPDH) This 
study was performed by nano-flow liquid chromatography/mass-spectrometry of the 
proteins co-precipitated with Flag-tagged α2 integrin chain over-expressed in HT1080 
fibrosarcoma cells and identified in total 70 proteins only two of which were previously 
known as components of adhesome (Zaidel-Bar et al., 2007). Also, this study did not 
identify trafficking regulator Rab21 binding to integrin α2 (Pellinen et al., 2006), 
indicating that used methodology might not suit to detect trafficking-related interactions 
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which can be transient and or indirect. On the contrary, quantitative  mass-spectrometry 
analysis of the protein complexes associated with ligand-bound integrins α5β1 and a4b1  
in human leukemia K562 cell line stably expressing a4 integrin (Humphries et al., 2009), 
identified number of molecules that were subsequently found as regulators of integrin α2 
endocytosis The total overlap between this hits study and the integrin endocytosis 
screening hits presented 19 proteins, including ARF1, dynamin 2, PTPN11 and molecular 
motors MYH9, KIF2C, and DYNC1H1.  
Recent genome-wide RNAi screening for regulators of MHCII antigen 
presentation (Paul et al., 2011) had only a minor overlap with our screening results ( 3 
hits in common). In the context of intracellular traffic, MHCII antigen presentation 
depends on the anterograde trafficking from ER to  the PM (Bénaroch et al., 1995;  
Neefjes et al., 1990). High overlap of our screening results with the endocytotic 
regulators, and small overlap with the potential biosynthetic regulators indicates 
specificity of our screening to the endocytic pathway. 
As no genome-wide or large-scale data are available for the cell entry of viruses 
using integrin α2  as a co-receptor ( i.e. EV1 (Bergelson, Shepley, Chan, Hemler, & 
Finberg, 1992)or rotavirus (Fleming, Graham, Takada, & Coulson, 2010). Only negligible 
overlaps was obtained upon comparison of our screening with the genome-wide analyses 
of HIV (Brass et al., 2008) or HCV (Q. Li et al., 2009) replication, as neither of these 
viruses uses α2β1 integrin as a co-receptor.  
The analysis of the primary screening results revealed a vast overlap of the 
screening hits with the published datasets of regulators of relevant processes: endocytosis, 
focal adhesion formation, and cell migration. On the contrary, the datasets on the 
processes not related directly to integrin endocytosis (i.e. anterograde trafficking or 
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MHCII or the entry of viruses which do not use integrin α2 as a co-receptor) was only 
minor. This indicates reliability of screening results even at the level of primary 
screening.  
 
4.3.2. Validation 
For the validation of primary screening results and further analysis we selected 26 
primary hits (1/5 of primary hits).  
Altogether 15 kinesins were identified as hits in the primary screening (KIF1B, 
KIF2A, KIF2C, KIF3B, KIF3C, KIF6, KIF15, KIF16B, KIF18A, KIF19, KIF22, KIF23, 
KIF24, KIF26A, KIF26B). For hit kinesins represented by two isoforms, one isoform was 
futher analyzed.  Thus, in total 12 were tested in the validation assays (KIF1B, KIF2A, 
KIF3B, KIF6, KIF15, KIF16B, KIF18A, KIF19, KIF22, KIF23, KIF24, KIF26B). For 3 
of them (KIF6, KIF19, KIF26b) we did not find evidence of expression in HeLa cells 
(Appendix III). Validation assays were performed using 2 siRNAs from Ambion similar 
to the ones used in the primary screening, and two additional siRNAs from Qiagen. In 
most cases siRNAs were functional and led to knockdown of target transcript by 40-90%. 
For KIF22 the knockdown induced by siRNAs was minimal (about 10%), and, therefore, 
the effect on integrin α2 endocytosis, induced by siRNA treatment, was considered 
unspecific. Hit genes were considered as effectors of α2 integrin endocytosis if 
knockdown of corresponding transcripts with at least two siRNAs consistently resulted in 
more than 40% difference in integrin endocytosis compared to negative control siRNA 
when measured in multiwell format. The summarized results of the validation assays are 
presented in Table R.1.  
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Table R.1. Validated screening hits  
 
Gene name Integrin endocytosis1 Integrin expression 1 Cell count 1 
Negative control 
siRNA 
100 100 100 
DNM2 27,2 ± 6,63 82,45 ± 13,77 98,56 ± 6,88 
ARF12 49,17 ± 7,43 99,11 ± 17,67 99,16 ± 37,85 
ABL2 52,78 ± 9,94 56,84 ± 4,49 72,05 ± 18,6 
ARHGAP6  42,03 ± 6,35 43,14 ± 4,33 75,59 ± 7,24 
ITGB1 7,38 ± 3,4 54,12 ± 7,1 99,93 ± 17,32 
KIF152 27,8 ± 4,45 96,5 ± 2,3 106,44 ± 7,75 
KIF18A 51,12 ± 9,54 97,64 ± 16,74 98,64 ± 31,44 
KIF23 25,4 ± 6,36 92,69 ± 33,23 49,11 ± 22,74 
Myo1A 36.43 ± 17.79 64,72 ± 4.04 126,42 ± 46,71 
NF2 35,59 ± 3,1 95,89 ± 13,64 85,77 ± 3,19 
PTPN11 39,11 ± 5,19 76,83 ± 3,72 66,07 ± 28,1 
Data show results of validation experiments for selected representative siRNA. for the 
whole set of data see Appendix V. 
1 Values show  % of control ± SEM 
2 Hits affecting trafficking, but not total integrin expression are highlighted in green. 
 
Among the 9 hit kinesins expression of which in HeLa cells we detected, 3 were 
validated as inhibitors of integrin α2 endocytosis: KIF15, KIF18a, KIF23. None of them 
was previously associated with endocytic trafficking, and only one recent screening for 
regulators of VSV-G secretion (Simpson et al., 2012) identified them as hits. Given that 
only few primary hit kinesins were previously associated with intracellular trafficking 
pathways, and many known traffic-regulating kinesins didn't show up in the screening, we 
additionally tested 17 known traffic-related kinesins  in the validation screening together 
with the primary screening hits (listed in Appendix IV). For them, 2 Qiagen siRNAs per 
gene were tested, and, if one ot them had effect, 2 siRNAs from Ambion, same as used in 
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the primary screening. We have confirmed expression of 13 genes from this group in 
HeLa. From them, only KIF13a, that was previously known to organize endocytic 
recycling (Delevoye et al., 2009), showed effect on integrin endocytosis under conditions 
of validation screening (only with additional siRNAs but not with siRNAs used in the 
primary screening, therefore it couldn't be considered a hit).  
As our library included variety of other molecules among which were 81 
components of integrin adhesome, in the validation assays we also tested heterogenous 
group of 14 other hits, that were targeted by at least 2 different siRNAs in the primary 
screening. Among these were 8 adhesome components. For these genes 2 additional 
siRNAs from Qiagen were ordered, and hit was considered validated, if at least one of 
them gave effect on α2 integrin endocytosis, matching the primary screening effect. 7 
genes of this group were validated,. Among these hits ARF1 was a general trafficking 
regulator known to recruit components of COPI coat on the transport vesicles in 
biosynthetic and endocytic pathways (Gu and Gruenberg, 2000; Kumari and Mayor, 
2008). It was shown to mediate paxillin recruitment to the focal adesion sites and to 
potentiate RhoA-dependent actin stress fibers assembly (Norman et al., 1998). Another 5 
molecules were known as integrin adhesome components or their interactors (ARF1, 
ABL2, ITGB1, NF2, PTPN11) (Zaidel-Bar, Itzkovitz, Ma’ayan, Iyengar, & Geiger, 
2007).  Neurofibromin 2 (NF2) directly interacts with integrin beta1 (Cabodi et al., 2010; 
Obremski et al., 1998). Non-receptor protein tyrosine phosphatase 11 (PTPN11) is a 
component of adhesome, where it dephosphorilates paxillin (Ren et al., 2004). Two 
validated hits regulates actin cytoskeleton organization via RhoA pathway: kinase ABL2, 
which was shown to be upstream mediator of RhoA (Shimizu et al., 2008) and and RhoA 
GAP ARHGAP6 (Prakash et al., 2000). Finally, MYO1A one is an actin-based molecular 
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motor involved in membrane movement along the actin cytoskeleton in enterocyte 
microvili and formation of lumenal vesicles in the interstine (Mooseker and Coleman, 
1989; McConnell et al., 2009).  Downregulation of all the listed hits,  was inhibiting α2 
integrin endocytosis by more than 40%.  
Thus we could reproduce the primary screening result for 10 of the 23 expressed 
genes (43%) tested in the validation assays.  
 
4.3.3. Expression of α2 integrin is affected by knockdown of number of 
hits 
Given the fact, that knockdown of integrin β1 strongly inhibited integrin α2 
endocytosis, and integrin α2 chain have previously been shown to be transcriptionally co-
regulated with β1 integrin (Heino et al., 1989), we asked ourselves, if the decreased 
amount of internalised integrin can be due to downregulation of total α2 integrin resulting 
from knockdown of some genes selected for validation. To discriminate between the hits 
affecting integrin trafficking specifically and those influencing integrin expression, we 
stained for total α2 integrin upon hits knockdown. For  5 validated hits alterations in α2 
integrin trafficking did not coincide with alterations in α2 expression: ARF1,  NF2, 
KIF15, KIF18a, KIF23 (the difference was less than 25% compared to the negative 
control) (Table R.1, highlighted green). Yet, number of other genes tested in validation 
dramatically reduced or increased integrin expression in the cells, and in many cases it 
coincided with the effect on amount of internalized integrin (Figure R.7, Appendix IV). 
To resolve the other cases and show if the decrease of internalized integrin amount was 
due to blockage in trafficking machinery or only due to decrease of surface integrin, or 
both, more direct measurements of integrin endocytosis would be required. 
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Figure R.7. Fig.5. Integrin endocytosis rate correlates with level of integrin expression for number 
of hits. Representative examples of siRNA effect of selected hits on integrin endocytosis and expression is 
shown: knockdown of KIF13a reduces both integrin internalization and expression, whereas knockdown of 
KIF15 inhibits only integrin α2 internalization, buut not expression. (A) Examples of integrin α2 
endocytosis and expression stainings in HeLa cells. Cells were seeded on multiwell plates and transfected 
next day. 48h after transfection integrin endocytosis assay was performed. (B) Corresponding total integrin 
α2 expression staining examples. For measurement of integrin expression cells were fixed, permeabilized 
and stained for total integrin. SiRNAs affecting endocytosis but not expression were selected as trafficking 
hits. Bar 20 µm.  
 
4.3.4. Endocytosis and expression of α2 integrin does not depend on 
local cell densities 
All the three validated kinesin hits were known to play role in mitosis. KIF15 is 
involved in mitotic spindle organization (Tanenbaum et al., 2009; Vanneste et al., 2009) . 
KIF18a regulates chromosome congression in mitosis (Mayr et al., 2007). KIF23 is 
required for cytokinesis (Zhu et al., 2005). Two latter kinesins were also found as hits in 
the recent screening for mitosis regulators (Neumann et al., 2010). Question is, if this can 
be due to block in cell cycle progression, or a secondary effect resulting from lower cell 
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densities after knockdown of mitotic machinery, as, according to published data, local cell 
densities can influence internalization of other endocytic cargoes, namely tranferrin and 
EGF (Snijder et al., 2009).  
To answer this question, we tested correlation of integrin α2 expression or integrin 
traffic with local cell densities to find out, it there could be a dependency (such as was 
shown for endocytosis of transferrin and EGF) (Snijder et al., 2009). Local cell densities 
were estimated from the coordinates of individual nuclei localizing to the same or 
neighbouring 15x15 µm position on the image (as described in (Knapp et al., 2011)). We 
could find no or little correlation neither of integrin expression nor integrin endocytosis 
with local cell densities (data not shown). Correlation coefficient between mean intensity 
of internalised α2 integrin per cell and the local cell density of the environment this cell 
belonged was -0,05± 0,03 for negative control siRNAs and -0,05± 0,02 for positive 
control siRNA targeting DNM2. For some individual siRNAs greater correlation was 
found, but it never exceeded 0,15. The same was true for integrin expression level of 
individual cells.  
Selection of 15 kinesins, known or expected to be involved in traffic, included 
genes that have known mitotic function: KIF11 (Blangy et al., 1995; Kolluet al., 2009) 
and KIFC1 (Zhu et al., 2011). We have shown that KIF11 and KIFC1 had no effect on 
integrin internalization (101,8 ± 11,8 and 102,3 ± 25,4% of control, respectively), 
although knockdown of KIF11 led to dramatic decrease of cell counts per imaged position 
(50,8 ± 14,7% of control) (Appendix IV), as expected given its role in mitosis. This 
suggests that the inhibition of integrin endocytosis by hit kinesins involved in mitosis is 
independent of their mitotic function.   
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4.4. KIF15 is a novel regulator of membrane trafficking  
In the validation screening KIF15 knockdown resulted in a strong inhibition of α2 
integrin endocytosis. Unlike the other kinesin hits of our screening, KIF15 was not 
identified in the Mitocheck project (Neumann et al., 2010) as a master regulator of 
mitosis, which agrees with the knowledge that its function in maintenance of bipolar 
mitotic spindle is redundant with Eg5(KIF11) (Tanenbaum et al., 2009; Vanneste et al., 
2009) .  
However, it was also shown that rat KIF15 can have function beyond  mitosis, as 
it is expressed in postmitotic neurons (Snijder et al., 2009), where it can contribute to the 
microtubule stability and microtubules-actin interactions (Neumann et al., 2010). We 
decided to further investigate the interphase role of KIF15 that could explain the strong 
inhibition of α2 integrin endocytosis upon its knockdown (Table R.1).  
 
4.4.1. KIF15 specifically regulates α2 integrin internalization 
To assess the specicity of KIF15 effect on integrin α2 endocytosis, we first 
confirmed KIF15 knockdown on the protein level and found that 48h after transfection 
with siRNAs KIF15 was downregulated by at least 75% (Figure R.8A, C).  
Next, we  attempted to rescue it by overexpression of siRNA-resistant murine 
KIF15 tagged with GFP (GFP-mKIF15) (Tanenbaum et al., 2009) in the background of 
control of KIF15 siRNAs transfection. Murine and KIF15 shares 86% identity at protein 
level. GFP-mKIF15 localized similar to the endogenous human KIF15 and could rescue 
the mitotic phenotype of human KIF15 knockdown, as demonstrated by (Tanenbaum et 
al., 2009).  
According to our observations, GFP-mKIF15 localized mostly in the cytoplasm, 
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but, occasionally, to PM, cytoplasmic punctate structures and to the microtubules 
(although the latter two phenotypes were not predominant) (Figure R. 9). 
The overexpression level of GFP-mKIF15 construct was reported to be close to 
endogenous (Tanenbaum et al., 2009), and the comparable -3,3-fold KIF15 
overexpression we saw upon overexpression of GFP-mKIF15 (Figure R.8B, D).  
To rescue the phenotype of KIF15 knockdown we have downregulated human 
KIF15 with siRNAs 48 hours before integrin endocytosis assay, and overexpressed GFP-
mKIF15 or cytoplasmic eGFP 30h before the assay. To score the results of resque 
experiment, the total cells population was binned according to the GFP fluorescence  
intensity per cell. We found that overexpression of GFP-mKIF15 led to dose-dependent 
increase of internalized α2 integrin. Therefore only cells with high level of GFP-mKIF15 
expression was taken for analysis. For overexpression of cytoplasmic eGFP, that was used 
as a negative control, the total cell population was taken into account, as it had no dose-
dependent effect on integrin α2 internalization. 
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Figure R.8. Efiiciency of KIF15 knockdown and over-expression (A)HeLa cells were transfected 
with corresponding siRNAs for 48 hours and lysed. The amount of KIF15 in the whole-cell lysate was 
determined by protein gel blot.  Efficiency of KIF15 down-regulation by RNAi (A, C)  ectopic over-
expression (B, D) , and effect of KIF15 down-regulation on Dab2 expression (E, F) in HeLa cells. Whole 
cell lysates were collected following 48h  after siRNAs treatment and following 24h after transfection with 
cDNA encoding a full-length GFP-tagged KIF15. α-tubulin was used as a loading control for  all 
experiments. The expression levels of endogenous KIF15 after treatment with the respective siRNAs (A, C) 
were normalized to the expression level of KIF15 when cells were treated with the negative control. The 
over-expression level of ectopic GFP-tagged KIF15 was normalized to the expression level of the 
endogenous KIF15 in cells expressing GFP (B, D). Expression level of Dab2 upon KIF15 knock-down was 
normalized to the negative control siRNA treatment (E, F). Bars represent means of normalized expression 
and the error bars indicate s.e.m. derived from at least 3 independent experiments. *, p≤0,05, **, p≤0,01.  
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Figure R.9. Murine GFP-KIF15 localization in HeLa cells. Over-expressed KIF15 localizes 
predominantly in the cytoplasm (left), but also appears in speckles and microtubule-like pattern in 2-4% of 
cells (right). 
 
 
Figure R.10 Over-expression of murine GFP-
KIF15 resques KIF15 knock-down in HeLa
cells. (A) Knock-down of KIF15  prevents
internalization of integrin α2 and this effect is
lessened by the over-expression of GFP-tagged
KIF15, but not GFP. Asterisks indicate cells
expressing high levels of GFP and GFP-tagged
KIF15. Scale bar = 20 μm. (B) Quantification of
rescue of integrin α2 trafficking inhibition.
Intracellular integrin α2 specific fluorescence is
normalized to over-expression of GFP in the
background of negative control transection Bars
represent means of 3 endopendent experiments
±.SEM. *, p≤0,05. 
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We found that, comparable to the the KIF15 downregulation in the course of 
validation experiments, only 49,2 ± 3,1 % of α2 integrin endocytosis could be detected 
when cytoplasmic GFP was expressed upon KIF15 knockdown, compared to negative 
control siRNA. GFP-mKIF15 overexpression in the background of negative control 
siRNA treatment, on the contrary, increased amount of internalized α2 integrin to 
139,3±3,1 %. Interestingly, internalized α2 integrin often tended to form accumulation in 
perinuclear area in the cells over-expressing GFP-mKIF15 (Figure R.10A). Over-
exression of GFP-mKIF15 in the human KIF15 knockdown background restored 
internalization of α2 integrin to 69,5±1,0 % of control with similar integrin perinuclear 
accumulation in the strongly overexpressing cells (Figure R.10A, B).  
To find out, which stage of α2 internalization was affected by KIF15 knock-down, 
we measured amount of internalized integrin at different timepoints upon KIF15 knock-
down. In negative control treated cells the internalized α2 integrin could be detected as 
early as upon 5 min of internalization, and then was gradually increasing till reaching 
maximum after 60 min of internalization. On the other hand, KIF15 knockdown resulted 
in alsmost complete absence of internalized α2 integrin at 5 min of internalization. At 15, 
30, and 45 min amount of internalized α2 integrin was at about 20% of coresponding 
time-point of the negative control (Figure R.11A, D). After 60 min, the amount of 
internlized integrin reached only 34% of control. In the cells internalizing α2 integrin 
upon KIF15 knock-down, the internalized integrin localized in similarly to the 
distribution in the negative control cells. Thus, lack of internalized α2 integrin in 
siKIF15-tranfected cells was due to block of early steps of integrin endocytosis.  
Next, we have tested effect of KIF15 knock-down on the trafficking of other 
endocytic cargoes, namely tranferrin and EGF. In agreement to (Collinet et al., 2010), 
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knock-down of KIF15 did not affect early steps (5 and 10 min) of internalization of either 
cargo. Yet, the later steps of tranferrin endocytic trafficking were clearly affected by 
KIF15 knock-down. In contrast to internalized EGF, which is destined for degradation 
(Carpenter and Cohen, 1976), transferrin is recycled (Dickson et al., 1983). Re-
appearance of fluorescently-bound transferrin on the plasma membrane of the control 
HeLa cells could be seen after 45 and 60 min of cells incubation with the ligand. KIF15 
knock-down prevented transferrin from recycling (Figure R.11B, E). On the contrary, it 
induced a prominent clustering of internalized cargo in perinuclear region, presumably in 
recycling endosome. This is reflected by mean intensity of internalized cargo that is 
significantly increased by 25% after 60 min of internalization in siKIF15 treated cells 
compared to control.  
For EGF, no difference could be observed also at all the measured time points  
(Figure R.11C, F).  
 
4.4.2. KIF15 knock-down affects distribution of endocytic adaptor Dab2  
The fact that KIF15 knock-down affects late steps of transferrin endocytic traffic, 
and the microtubule (+)-end directionality of the motor (Boleti et al., 1996), suggests, that 
KIF15 is involved in recycling of trafficking cargoes. Yet, its function is required for α2 
integrin endocytosis at the very early steps. We hypothesized that KIF15 is required for 
membrane localization of some integrin entry factor. Several endocytosis adaptors 
required for entry of integrin, but not transferrin, are known. Dab2, Arh, and Numb have 
been shown to mediate β1 integrin recruitment to clathrin-coated pits (Teckchandani et 
al., 2009). It was demonstrated that among the numerous integrin β1 heterodimers, Dab2 
regulates the endocytosis of integrins α2β1, α1β1, α3β1, but not α5 or αV (Teckchandani 
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et al., 2009, 2012). 
Interestingly, it has already been demonstrated, that Dab2 is required for recycling 
of transferrin and other cargoes (Fu et al., 2012; Penheiter et al., 2010), and knock-down 
of Dab2 results in the intracellular accumulation of transferrin, similar as observed for 
knock-down of KIF15 (Figure R.11B).  
In HeLa cells Dab2 localizes predominantly to the PM in punctate structures, but 
also to the cytoplasmic structures (Figure R12.A, D, negative control) . First, we have 
tested, whether KIF15 would affect the PM localization of Dab2. For this we performed 
the TIRF imaging of the cells surface-labeled on ice with the antibody against α2 integrin 
(as in our regular integrin internalization assay), then fixed without integrin 
internalization and co-stained for Dab2 and surface α2. The samples were imaged by total 
internal reflection fluorescence (TIRF) microscopy and epifluorescence mode to 
discriminate between Dab2 localized directly below the PM (TIRF mode) and all the 
Dab2 below the PM, including the particles localizing to deeper in the cytoplasm. Co-
localization of the imaged particles between TIRF and epifluorescence mode indicated 
that these particles localized to the PM. Alternatively, presence of the particle in the 
epifluorescence mode, but not in TIRF, would mean that the particle is located in the 
cytoplasm, but not at the PM. To ensure that the imaged cells were properly attached to 
the substrate, surface integrin α2 staining was also imaged in the TIRF mode and was 
used as a proof for the presence of PM in the focal plane. 
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Fiure R.11. KIF15 is specifically required for internalization of non-clustered integrin α2. (A) Knockdown 
of KIF15 inhibits integrin internalization, but not transferrin (B, E) and EGF (C, F) internalization. HeLa 
cells were transfected with corresponding siRNAs for 48h, then the endocytosis assays were performed to 
asses tranferrin, EGF, and integrin internalization. Representative phenotypes resulting from transfection 
with of KIF15 siRNA and control siRNA are given. Scale bar = 20 µm. (D-F) Quantification of KIF15 
knockdown effect on internalization of integrin, tranferrin, and EGF, correspondingly. Bars represent mean 
endocytosis rate (mean intensity of internalized ligand for transferrin and EGF) normalized to negative 
control siRNA at 60 min time-point (integrin) or 15 min time-point (transferrin and EGF) from three 
independent experiment ± SEM. 
 
We found that knock-down of KIF15 led to partial loss of Dab2 from the PM 
(Figure R.7, A-D). In the negative control treated cells majority of the Dab2-structures 
detected in the epifluorescence mode, had a corresponding particle when imaged with 
TIRF, indicating it is PM associated. Yet, upon knock-down of KIF15, number of Dab2 
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particles that were seen only in the epifluorescence mode, but not in the TIRF mode, 
appeared (Figure R.12, A, C arrows), although the cells were arrached properly (data not 
shown). In agreement to that, the mean fluorescence of Dab2 imaged in TIRF mode was 
only 60% of the control in siKIF15-treated cells, whereas total Dab2-specific 
fluorescence (imaged in epifluorescence mode) was not changed significantly (Figure R. 
12B). The latter was confirmed by the Western Blotting to detect total cellular Dab2 
(Figure R.8 E,F), which showed that levels of Dab2 are unchanged by knock-down of 
KIF15. Interestingly, Dab2 and integrin α2 showed nearly no co-localization with each 
other at the PM. 
Next, we asked ourselves, where the intracellular pool of Dab2 localized. As we 
assumed that Dab2 should be recycled in the KIF15-dependent manner, as tranferrin did, 
we expected to see it blocked in the perinuclear recycling compartment, as it was shown 
for transferrin after 60 min of internalization in KIF15 knockdown. In the negative 
control cells after 60 min of internalization transferrin was localized to the cytoplasm and 
the PM without any prominent accumulations. The same was true for Dab2 localization in 
the negative control. Interestingly, Dab2 and transferrin particles showed nearly no co-
localization, indicating that the trafficking of Dab2 and transferrin occurs in the different 
carrier vesicles. KIF15 knock-down blocked transferrin in the perinuclear area, 
presumably corresponding to the perinuclear recycling compartment. The similar 
perinuclear accumulation of Dab2 could be observed in KIF15-depleted cells (Figure 
R.12D). It has to be mentioned, that, although all the cells reproducibly exhibited loss of 
the PM-associated Dab2, only fraction demonstrated clear perinuclear accumulation of 
Dab2. Most likely it indicates the dynamic association of Dab2 with the membrane, 
which can be lost upon internalization or when recycling to the PM is delayed.  
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Figure R.12. Knock-down of KIF15 induces redistribution of Dab2. (A) Downregulation of KIF15 
displaces Dab2 associated with the PM (TIRF imaging mode) to the intracellular space (epifluorescence 
imaging mode, Epi). Epifluorescence and TIRF images are overlaid and the position that was used for 
fluorescence intensity profile plotting is indicated by dashed line. (B) Fluorescence intensity profile plot, 
demonstrating strong correlation of the peaks, corresponding to Dab2 particles in the TIRF and Epi modes 
in control. Upon KIF15 knock-down number of Dab2 particles are displaced from the PM, as visulized by 
fluorescence peaks present in Epi mode only, but not in TIRF mode (arrows). (C) Quantification of mean 
fluorescent intensities of Dab2 staining imaged in epifluorescence and TIRF mode. N = 15 cells; error bars 
indicate SEM; *, p≤0,05. (D) KIF15 Knock-down leads to perinuclear accumulation of Dab2 (arrows). 
Single confocal sections taken 0,75 µm above the PM focal plane are shown. Scale bar = 20 µm. 
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4.4. Integrin endocytosis on micropatterned substrates 
Integrin α2 internalization assay encounters of large cell-cell variability. To 
overcome this problem and improve the dynamic range of the assay, in each experiment 
we defined a population of strongly internalizing cells and disregard the others (see 
chapter Quantification of integrin internalization assay). This approach, although 
proved reliable, led to a gross loss of information, induced by omitting up to 70% of cells 
data. To improve the efficiency of the assay, we have attempted the biological 
normalization of cells by seeding them on micropatterns of certain shape and coating 
composition (Pitaval et al., 2011). The work on integrin internalization in the cells seeded 
on micropatterns was carried out in collaboration with Gintare Garbenciute (Vilnus 
University, Vilnus) and Philipp Albert (AG Schwarz, BioQuant, Heidelberg). 
Indeed, seeding the cells on the micropatterned chips resulted in lower variability 
between cells. For the α2 integrin endocytosis assay performed in the cell culture the ratio 
between brightest and dimmest 10% of the cell population reached 10. Yet, after 
performing the similar assay on the micropatterned chips , the difference between the 
brightest and the dimmest cell was on average 4, varying negligibly across different 
shapes and conditions.  
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Figure R.13. Integrin α2 endocytosis on CYTOOchips is inhibited upon down-regulation of Dnm2 
compared to control. HeLa cells were transfected 48h before the assay and seeded on micropatterned chip 
16h before the assay. The integrin α2 endocytosis assay was performed as described in (Methods). The 
corresponding micropatterned coating is fibronectin-Alexa550 (lower panel). Representative cells are show. 
Scale bar = 20µm. 
 
Next the effect of knock-down of DNM2 on integrin α2 internalization was tested 
in the cells seeded on the differently shaped and patterned fibronectin substrates. We 
could observe remarkable down-regulation of intracellular integrin α2 upon 1h of 
internalization, thereby reproducing the integrin internalization assay in the cell culture 
(Figure R.13). This method provides a possibility to address the intracellular distribution 
of internalized integrin in regard to cellular adhesion sites and elucidate the relation 
between the internalization of non-clustered integrin and cell motility (as the cells 
demonstrate different motility rates on the patterns of different sizes), however the 
methods for scoring of internalized integrin distribution and cell motility are yet to be 
developed.  
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5. Discussion 
In this study we for the first time systematically address the regulation of non-
clustered α2β1 integrin internalization. Although integrin α2β1 is a ubiquitously 
expressed receptor for collagen I, its intracellular traffic has barely been addressed. Here 
we describe the RNAi-based approach to identify novel regulators of integrin α2 
internaliyation and further characterization of the novel trafficking regulator KIF15 in the 
context of integrin endocytosis. 
 
5.1. Development of fluorescent-microscopy-based assay for analysis of 
non-clustered α2 integrin internalization 
There are number of ways to address internalization of cellular cargo, that could 
be classified in two main groups: population-based methods (i.e. biotinylation or 
antibody-based assays followed by protein analysis, scoring the plate fluorescence in the 
assays quantifying internalization of the fluorescent ligands, or FACS) (exemplified in 
(Roberts et al., 2001)) or cell-based methods (direct imaging of internalizing cells) (Erfle 
et al., 2011). The cell-based methods provide numerous advantages, such as possibility to 
estimate cellular phenotypes and intracellular distribution of internalized protein of 
interest, cell-to-cell variability, possibility for high-throughput and high-content studies, 
even though they can be technically demanding.  
In difference to the ligand-induced endocytosis, which is assayed in the 
transferrin, EGF or LDL internalization assays (Hanover et al., 1984; Dautry-Varsat, 
1986; Li et al., 2001), integrins undergo internalization both in ligand-bound and ligand-
free states. Several studies addressed the internalization of ligand-occupied integrins, and 
revealed that their trafficking follows the different pathways, predominantly degradative 
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(Lobert et al., 2010; Rintanen et al., 2011; Arjonen et al., 2012), compared to non-
occupied integrins (Teckchandani et al., 2009; Arjonen et al., 2012). Nevertheless, 
endocytic and recycling trafficking of non-occupied integrins seem to be highly 
physiologically relevant in processes related to cell migration (Huttenlocher and Horwitz, 
2011), and could even be a predominant mode of integrin trafficking, compared to 
integrin degradation (Lobert et al., 2010). It could be of particular importance for collagen 
I receptor integrin α2β1. Integrin α2β1 is ubiquitously expressed in different tissues. 
Although it is one of the most abundant integrins in keratinocytes (Watt, 2002), and is a 
prerequisite for keratinocytes binding to collagen I (Zhang et al., 2006), in the intact skin 
keratinocytes are never challenged with collagen I, which is a component of underlying 
dermal tissue, as they are separated from dermis by the basal membrane (Pilcher et al., 
1998). Thus, trafficking of α2β1 when it is non-clustered and non-engaged with collagen I 
can be of higher physiological relevance, at least for epithelial cells, from which HeLa 
derived.  
 Therefore, this study focused on the ligand-independent trafficking of α2β1 
integrin. The first step to address this was to establish appropriate quantitative cell-based 
integrin α2β1 internalization assay.  
As α2 chain forms a unique heterodimer with β1 (Hynes, 1992), labeling α2 chain 
with the antibody targeting α2 extracellular domain, was enough to follow the fate of 
α2β1 integrin. This antibody labeled surface α2 integrin and could be internalized 
together with it similarly to other integrin internalization assays (Powelka et al., 2004; 
Gao et al., 2000). Yet, large fraction of α2 integrin remained at the cell surface even after 
long incubation time from 1 to 6h (Figure R.1, R.2). To readily visualize the integrin that 
was internalized, a short stripping (30-40s) with acidic buffer was used before fixation of 
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the cells, to remove the surface-bound antibodies (Erfle et al., 2011). After that the cells 
were permeabilized and the internalized antibody bound to integrin visualized with 
appropriate fluorescently-labeled secondary antibodies. When acidic surface stripping 
was applied in integrin α2 internalization assay performed with the primary antibodies 
MAB1950, it could completely prevent appearance of the integrin-specific surface 
fluorescence (Figure R.2A, 0h) , indicating that the surface-bound anti-integrin α2 
antibody was properly removed. Yet, the acidic stripping, although used in several other 
published assays (Gao et al., 2000; Ma et al., 2012), was not a universal solution. Even at 
prolonged incubation time (up to 5 min on ice) it failed to completely remove the surface-
bound anti-β1 integrin and anti-α5 integrin antibodies in the similar internalization assays. 
The reason for that could be the properties of the particular antibodies, but also the high 
abundance of the plasma membrane integrins β1 and α 5. 
We demonstrate that trafficking of endogenous α2β1 in HeLa cells resembles the 
published data on the on α2β1 trafficking in Saos cells over-expressing α2, and 
endogenous β1 trafficking in various human cell lines. In Saos cells, over-expressing α2 
integrin chain, α2β1 integrin, depending on clustering, can pursue distinct trafficking 
pathways. α2β1, clustered by binding to EV1 virus, antibodies, or its natural ligand 
collagen I, is redistributed to caveolae, internalized via clathrin-independent pathway, 
follows non-recycling route to integrin-specific MVBs, and then is degraded by calpains. 
In contrast, non-clustered α2β1 integrin is recycled to the PM (Rintanen et al., 2012). In 
agreement to that, trafficking of β1 not bound to ligand is also following recycling 
pathway through Rab11-positive compartment in HeLa cells (Powelka et al., 2004).  
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5.2. Internalization of non-clustered α2β1 requires clathrin and caveolin  
The data on the entry routes of integrins in the endocytosis pathway are 
controversal. Number of studies have demonstrated that internalization of β1 integrins 
depends on clathrin and clathrin adaptors (Chao and Kunz, 2005; Teckchandani et al., 
2009, 2012). However, there is also evidence of caveolin involvement in internalization 
of ligand-bound β1 (Shi and Sottile, 2008; Bass et al., 2011), and clustered α2 integrin 
(Upla et al., 2004; Karjalainen et al., 2008; Rintanen et al., 2012). Interestingly, it was 
also reported, that in the interstinal epithelial cells internalization of β1 integrin occurs 
through lipid rafts in clarhin-independent manner, but can be upregulated upon knock-
down of caveolin1 or flotillins (Vassilieva et al., 2008). 
To the best of our knowledge, the information about entry determinants of the 
non-clustered α2 is limited to the study of integrin-specific clathrin adaptor Dab2, knock-
down of which resulted in entry block of β1 integrin and, consequently elevated surface 
level of β1 and several, but not all, corresponding a chains, α2 among them 
(Teckchandani et al., 2009). We tested the effect of knock-down of clathrin heavy chain 
(CLTC, the crucial component of clathrin-dependent endocytosis machinery), caveolin-1 
(player of caveolin-dependent pathway), and dynamin-2 which is required for abscission 
of the newly formed endocytic vesicles in both clathrin-dependent and clathrin-
independent pathways (Doherty and McMahon et al., 2009). To our surprise, both clathrin 
and caveolin were required for integrin endocytosis, as knock-down of either protein 
resulted in a strong inhibition (up to 75%) of integrin α2 internalization. Dynamin-2 
knock-down, presumably blocking both pathways, resulted in integrin endocytosis 
inhibition of similar strength with but minor additive effect (up to 80% inhibition) 
(Figure R.4).  
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It is not clear, whether the requirement of both clathrin and caveolin for integrin 
internalization indicate redundancy of these pathways for integrin α2 endocytosis. There 
are data, suggesting that some endocytic cargoes can be rather promiscuous in the entry 
pathway, as was shown for EGF receptor, internalized via both clathrin- and caveolin-
dependent pathways (Aguilar and Wendland, 2005; Schmidt-Glenewinkel et al., 2012). 
Yet, the nearly complete block of the integrin internalization upon either CLTC or 
caveolin-1 knock-down, suggests that the internplay of these pathways is more 
complicated and remains to be investigated. Although caveolin-1 have recently been 
identified as a transcriptional repressor of α5β1 integrin (Martin et al., 2009; Cosset et al., 
2012), in our experiments it did not induce any prominent effect on the α2 cellular levels 
(Appendix IV). However, it cannot be excluded, that caveolin-dependent integrin 
signaling (Grande-García et al., 2007; Radel et al., 2007; Horiguchi et al., 2011) takes 
part in promoting clathrin-dependent integrin endocytosis.  
 
5.3. Screening of cytoskeleton-associated proteins for involvement in 
integrin endocytosis 
To find specific regulators of integrin α2β1 endocytosis, we performed RNAi 
screening of 386 genes predicted to regulate intracellular traffic and cytoskeleton 
organization (Appendix I). Number of them have previously been associated with 
intracellular traffic, i.e. were found as hits in the screenings for intracellular traffic 
regulators (Collinet et al., 2010; Paul et al., 2011, Simpson et al., 2012) or annotated with 
relevant GO terms (GO:0046907 intracellular transport; GO:0032386  regulation of 
intracellular transport; GO:0030705 cytoskeleton-dependent intracellular transport; 
GO:0030050 vesicle transport along actin filament;  GO:0047496 vesicle transport along 
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microtubule; GO:0030139 endocytic vesicle; GO:0070382 exocytic vesicle). However, 
197 of them have never been studied in this context.  
By analyzing the amount of internalized integrin α2 in the cells, we identified 122 
primary hits that were considered potential regulators of integrin α2 endocytosis. We 
deliberately set the threshold discriminating primary hits from non-hits relatively low 
(z=±1), as our aim was to identify the networks of regulators of α2 internalization, and 
not only few strongest hits. Another reason for high incidence of hits among the screened 
genes was the composition of screened library, which contained number of regulators of 
intracellular trafficking or integrin function, if to compare the number of hits across this 
set of genes in the screening for of endocytic regulators (Collinet et al., 2010) or focal 
adhesion formation regulators (Winograd-Katz et al., 2009) (Figure R.6C). 
Comparing our hits with published  relevant datasets (Collinet et al., 2010; Paul et 
al., 2011) we found that 39 (32%) of our our hits were also identified as regulators of Tf 
and EGF endocytosis (Collinet et al., 2010). Considerably less was the overlap with the 
screenings targeting for regulators of anterograde trafficking: 21 primary hits (17%) of 
the screening for VSV-G secretion regulators (Simpson et al., 2012), out of them 5 
validated (4%),  were in common with  our primary screening,  and only 3 (2%) of our 
hits were found as regulators of the MHCII presentation  (Paul et al., 2011), This 
indicated that the trafficking regulators identified in our screening are specific for 
endocytic, but not secretory trafficking. Interestingly, the group of 83 hits that were 
identified as specific regulators of integrin α2 endocytosis, and did not affect transferrin 
or EGF endocytosis (according to Collinet et al., 2010) had no enrichment in the focal 
adhesion formation regulators (according to Winograd-Katz et al., 2009) and had 
impoverishment of the focal adhesion components compared to the whole screened 
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library (only 13% of α2 integrin-specific endocytic regulators were known as components 
of adhesome (Zaidel-Bar et al., 2007), while for the whole library the rate was 20%). This 
is well in agreement with the fact that our study addresses the endocytosis of integrin α2 
that is non-clustered and not engaged in the focal adhesions under the experimental 
conditions (Figure R.2). Yet, number of proteins involved in the dynamics of focal 
adhesions (i.e. clustered and ligand-bound integrins) were also idenfied in our screening, 
as revealed by comparison with the screening for focal adhesion regulators (Winograd-
Katz et al., 2009) (24 proteins in common) and epithelial cell migration regulators 
(Simpson et al., 2008) (9 proteins in common). This indicates a high level of cross-talk 
between regulation of clustered and non-clustered integrin.  
Similarly, we found a prominent overlap with the hits of recent studies of 
interactors of ligand-bound a4b1 and α5β1, and non-ligand bound integrin β1 (Humphries 
et al., 2009; Böttcher et al., 2012).  Nevertheless, mass-spectrometry of the proteins co-
precipitated with Flag-tagged α2 integrin chain over-expressed in HT1080 fibrosarcoma 
cells (Uematsu et al., 2011) showed only minor overlap of 2 hits with our screening hits 
(MYH9 and GAPDH). This might indicate, that the interactions, regulating integrin 
trafficking are mostly transient or indirect. On the other hand, the study of Uematsu and 
colleagues identified only 70 proteins (compared to more than 400 identified in 
(Humphries et al., 2009) only two of which were previously known as components of 
adhesome (Zaidel-Bar et al., 2007).  
In the screening we could identify not only individual hits, but the networks of 
proteins regulating integrin α2 endocytosis. For instance, NF2 was identified as a primary 
hit and validated as a strong inhibitors of integrin α2 internalization (Appendix II, Table 
R.1), and out of 7 proteins interacting with it, belonging to the screened library 
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(information from http://biomine.cigb.edu.cu/ sysbiomics/), 4 were found as hits in our 
screening. Out of them 3 were specific for integrin α2 endocytosis (ezrin, paxillin, and 
Ras GEF SOS1), and integrin β1 was also an effector of tranferrin and EGF endocytosis 
(Collinet et al., 2010). (Figure D.1) 
Figure D.1. Physical interactors of NF2 in the screened RNAi library. The proteins that were 
identified as integrin-specific regulators of integrin α2 endocytosis are highlighted in green; the regulators 
of both integrin α2, transferrin and EGF endocytosis in red; the proteins that did not regulate integrin α2 
endocytosis are highlighted in blue. The network was based on the interaction data from SysBiomics 
database (http://biomine.cigb.edu.cu/sysbiomics/) and created by Cytoskape 2.8.3.  
 
5.4. Validation of the primary screening results 
To test the specificity of the primary screening results, we reproduced the results 
of the primary screening in the modified experimental conditions for three groups of 
proteins. One group comprised 14 functionally heterogeneous hits that were targeted by 
multiple siRNAs in the primary screening, the second one encompassed the 12 kinesin 
hits of the primary screening, additionally, we analyzed 17 traffic-related kinesins, that 
were not hits in the primary screening, which allowed us to estimate occurrence of false-
negative results in the primary screening. 
Altogether, the validation experiments verified the reliability of the screening 
results obtained with these cirteria: among the tested primary hits the validation rate was 
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43%, comparable to other RNAi screenings, using more stringent hit-calling criteria (51% 
in (Winograd-Katz et al., 2009) , 46% in (Neumann et al., 2010). Among 17 tested non-
hits only one (KIF13A) had effect on integrin α2 endocytosis in the validation assays, and 
even this was with additional siRNAs, and not those used in the primary screening, and, 
most likely, this was due to down-regulation of total integrin α2 levels in the cell 
(Appendix IV). This indicates the reliability of the assignment of non-effector status as a 
screening result.  
From the group of 14 hits, targeted by multiple siRNAs we could reproduce 7 in 
the validation assays. Yet, the testing of integrin α2 expression levels revealed that 5 hits 
from the first group of proteins can affect it. Among the effectors α2 of integrin 
expression, integrin β1 is long known to transcriptionally regulate corresponding alpha 
chains (Heino et al., 1989). The 3 other hits are involved in the regulation of RhoA-
dependent actin organization and paxillin function: PTPN11 is required for paxillin 
dephosphorilation (Brown et al., 1998), kinase ABL2 is an upstream mediator of RhoA 
(Shimizu et al., 2008) and ARHGAP6 is a RhoA GAP (Prakash et al., 2000). The hits that 
affected integrin internalization but not expression were ARF1 (the regulator of COPI 
coat (Serafini et al., 1991), which was shown to mediate paxillin recruitment (Norman et 
al., 1998)  and the component of the adhesome, integrin β1 binding protein NF2, which, 
has previously been implicated in the clearance of Notch, Patched, Smoothened and EGF 
receptor from the PM (McCartney and Fehon, 1996; Obremski et al., 1998; Stamenkovic 
and Yu, 2010). On the contrary, none of the validated kinesins had prominent effect on the 
integrin expression levels, indicating that their knock-down affects integrin trafficking 
only.  
Next, we focused on kinesins because it is a prominent group of proteins which 
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contributes to specificity of intracellular trafficking, yet, the exhaustive analyzes of 
kinesins were mostly limited to their role in mitosis (Goshima and Vale, 2003, 2005; 
Tanenbaum et al., 2009; Zhu et al., 2005b; Neumann et al., 2010). On the contrary, there 
are only few datasets (coming from comprehensive genome-wide screenings) that could 
be used to analyze their traffic-related function(Collinet et al., 2010; (Paul et al., 2011; 
Simpson et al., 2012). So far only KIF1C is known to directly drive the integrin traffic 
(Theisen et al., 2012). Most of the tested hit kinesins (8 out of 12) in the primary 
screening were targeted by one out of two tested siRNAs, similar to most of our screening 
hits. Out of the 12 kinesin primary hits, that we took in the validation, for 9 we found 
evidence for expression in HeLa. From them, KIF15, KIF18A, and KIF23 had a profound 
inhibitory effect on integrin α2 internalization in the validation assays. The expression of 
integrin α2 remained unchanged in upon their knockdown.  
Analysis of the primary hits that were not validated could provide an additional 
insight in the performance of the screening and particular hits. Several kinesin primary 
hits that were not validated, were represented by two isoforms (KIF26A, KIF26B, KIF3B, 
KIF3C , KIF2A, KIF2C). Having analyzed only one isoform of two, we might have 
encountered redundancy in their functions. The combinatorial knock-down of the 
isoforms would be required to resolve such cases. Why the primary screening conditions 
turned to be more sensitive for detection of these molecules, remains a question. One 
possible factor that could play a role was the presence of ECM coating in the primary 
screening. In this context especially interesting is the case of CRK, the integrin-
interacting protein and component of integrin adhesome required for the formation of the 
focal adhesions (Wang et al., 1996; Winograd-Katz et al., 2009; Fathers et al., 2012), 
which was an α2 integrin internalization inhibitor under conditions of the primary 
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screening (Appendix II), but increased the integrin internalization in the validation 
assays (Appendix IV). Whether this was dependent on the availability of the ECM 
proteins is an open question. 
All the three validated kinesin hits have never previously been associated with 
intracellular trafficking except of the recent report on the traffic of VSV-G protein 
(Simpson et al., 2012), in which KIF15 and KIF23 were validated as inhibitors of VSV-G 
secretion. On the contrary their mitotic function was well characterized. KIF18 and 
KIF23 were found as hits in the RNAi screening for mitotic regulators (Neumann et al., 
2010). KIF18a is a crucial component in chromosome congression machinery (Mayr et 
al., 2007), and KIF23 is required for midbody formation and cytokinesis (Zhu et al., 
2005a; Liu and Erikson, 2007). KIF15 was shown to cooperate with KIF11 (Eg5) in 
organization of bipolar mitotic spindles, although its function is dispensable when 
functional KIF11 is present (Tanenbaum et al., 2009; Vanneste et al., 2009). Yet, recently 
accumulated data indicate, that mitotic kinesins can have additional functions during 
interphase, as was demonstrated for KIF11 (Blangy et al., 1995; Bartoli et al., 2011; 
Falnikar et al., 2011; Collinet et al., 2010). Both KIF15 and KIF23, in addition to their 
roles in mitosis , function in postmitotic neurons. KIF23 supports dendrite formation 
(Sharp et al., 1997). KIF15 associates with microtubules in growing neurons and can 
contribute to the microtubule stability and microtubules-actin interactions and promote 
axonal branching (Buster et al., 2003; Liu et al., 2010).  
KIF 15, KIF18a, and KIF23 all are microtubule (+)-end directed motors ((Nislow 
et al., 1992); Boleti et al., 1996; Mayr et al., 2007). The microtubular array in adherent 
non-polarized cells, including HeLa, is radial, with (-)-ends of the microtubules 
originating from cell center by centrosomes and (+)-ends growing towards cell periphery 
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( reviewed in Manneville and Manneville, 2006; Vinogradova et al., 2009). This suggests 
that (+)-end directed kinesins would be involved in the anterograde traffic and recycling 
of endocytic cargos towards PM, as was demonstrated for number of other kinesins i.e. 
for KIF16b or KIF5b (Hoepfner et al., 2005; Jaulin et al., 2007). Yet, for all the three 
validated hit kinesins we have observed strong inhibition of integrin endocytosis, which 
did not seem to result from the block in integrin recycling, but rather from perturbation of 
integrin internalization into the cell. 
 
5.5. KIF15 is a novel regulator of membrane trafficking 
To understand involvement of kinesins in integrin traffic, we have focused on 
KIF15, which was a strong inhibitor of integrin α2 endocytosis when downregulated, and, 
unlike KIF23, another strong inhibitor, did not affect cell proliferation. Human KIF15 
belongs KIF15-subfamily of kinesin-12 family protein family (Miki et al., 2005), which is 
barely characterized. Xenopus ortholog of KIF15, that also has a role in maintanance of 
bipolar spindle in mitosis, was shown to be functional homodimeric microtubule (+)-end 
directed motor (Boleti, Karsenti, & Vernos, 1996; Wittmann, Boleti, Antony, Karsenti, & 
Vernos, 1998).  
We confirmed the specificity of KIF15 effect on integrin α2 endocytosis by 
rescuing the knock-down phenotype with over-expression of siRNA-resistant murine 
KIF15 N-terminally fused to GFP, which was previously shown to completely rescue 
KIF15 mitotic phenotype (Tannenbaum et al., 2009). The over-expression of GFP-KIF15 
in the background of endogenous KIF15 knock-down significantly increased the amount 
internalized integrin α2 endocytosis, although the rescue not complete (70% of control), 
which might possibly indicate the hindering of N-terminal motor domain function by 
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GFP-fusion (in contrast, the association of KIF15 to mitotic spindle depends on C-
terminal leucine zipper (Tannenbaum et al., 2009).  
Time-resolved integrin α2 endocytosis assay revealed that KIF15 knock-down 
results in inhibition of the early steps of integrin internalization. In agreement to that, 
upon over-expression of GFP-KIF15 we observed increase in intracellular integrin α2 
after 5 min of internalizaition, and further accumulation of intracellular integrin after 60 
min of internalization, which indicates that balance of integrin endocytosis and recycling 
is shifted towards endocytosis. However, directionality of the motor implies that its 
requirement in the early steps of integrin endocytosis is mediated by some additional 
factor.  
KIF15 knock-down did not induce apparent alterations in either actin or 
microtubule cytoskeleton (our unpublished data), therefore it is unlikely that effect of 
KIF15 on integrin endocytosis is due to general cytoskeleton changes. Yet, testing of 
KIF15 impact on the other endocytic cargos, namely transferrin (recycled cargo (Dickson 
et al., 1983)) and EGF (degradable cargo (Carpenter and Cohen, 1976)), revealed that 
KIF15 is not for internalization of either transferrin or EGF, in agreement to the results of 
the screening of (Collinet et al., 2010), which measured intracellular EGF and transferrin 
after 10 min of internalization. 
The possible explanation of specific requirement for KIF15 in integrin 
internalization, would be that KIF15 is involved in delivery of some integrin 
internalization factor to the plasma membrane. The data on the entry routes of integrins in 
the endocytosis pathway are controversal. Number of studies have demonstrated that 
internalization of β1 integrins depends on clathrin and clathrin adaptors (Chao and Kunz, 
2005;  Nishimura and Kaibuchi, 2007; Ezratty et al., 2009; Teckchandani et al., 2009, 
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2012). However, there is also evidence of caveolin involvement in internalization of 
integrin β1 (Shi and Sottile, 2008; Bass et al., 2011), clustered α2 integrin (Upla et al., 
2004; Karjalainen et al., 2008; Rintanen et al., 2012), and α2 integrin internalized upon 
stimulation of the cells with EGF (Ning et al., 2007). Interestingly, it was also reported, 
that in the interstinal epithelial cells internalization of β1 integrin occurs through lipid 
rafts in clarhin-independent manner, but can be upregulated upon knock-down of 
caveolin1 or flotillins (Vassilieva et al., 2008).  
To the best of our knowledge, the information about entry determinants specific 
for non-clustered α2 is limited to the study of integrin-specific clathrin adaptor Dab2, 
knock-down of which resulted in entry block of β1 integrin and, consequently elevated 
surface level of β1 and several, but not all, corresponding a chains, α2 among them 
(Teckchandani et al., 2009).  Endocytic adaptors, such as AP2 or clathrin-associated 
sorting proteins (CLASPs) could be the factor affected by KIF15 knockdown. 
Insensitivity of early steps of transferrin and EGF endocytosis to KIF15 knock-down 
limits the range of suspects to the PTB-binding CLASPs Dab2, ARH, and Numb, which 
are known to regulate β1 integrin and LDLR, but not transferrin endocytosis (Keyel et al., 
2006)(Ezratty et al., 2005; Chao and Kunz, 2009; Teckchandani et al., 2009; Nishimura 
and Kaibuchi, 2007; Teckchandani et al., 2012). 
As shown by siRNA experiments, Dab2, ARH, and Numb are required for integrin 
β1 internalization in migrating cells (Nishimura and Kaibuchi, 2007; Ezratty et al., 2009) 
and disassembly of focal adhesions (Chao and Kunz, 2009), but only knock-down of 
Dab2 blocks bulk β1 internalization (Tackchandani et al., 2009, 2012). As neither KIF15 
knock-down or over-expression had no effect on the focal adhesion abundance (our 
unpublished data), we selected Dab2 for testing whether KIF15 knock-down affects 
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integrin endocytic adaptors.  
According to published studies, Dab2 in the interphase HeLa cells predominantly 
localizes to the PM, co-localizing with clathrin and AP2 adaptor (Keyel et al., 2006; 
Chetrit et al., 2011). Yet, for C. elegans orthologue (Ce-Dab-1) in addition to PM 
localization, partial localization to the perinuclear area was demonstrated. Perinuclear 
Dab2 co-localized with Golgi-markers, AP1 adaptor, and secretory cargos, but not with 
Rab11-positive perinuclear recycling compartment (Kamikura and Cooper, 2006).  
In agreement to published data, we detected Dab2 predominantly at the PM of 
HeLa cells, and, to the lesser extent, in the cytoplasm. According to our observations, 
KIF15 knock-down induced remarkable displacement of Dab2 from the PM (Figure 
R.12A-C) with its partial re-location to perinuclear compartment (Figure R.12D), 
distinct from transferrin-positive recycling compartment. This relocation is likely to be 
the cause of entry block of integrin in the cells. However, effect of KIF15 knock-down on 
the other integrin-specific adaptors is yet to be tested and further studies are required to 
elucidate, whether KIF15 directly transports Dab2 to the PM or their association is 
indirect. 
Moreover, interplay of KIF15 and Dab2 in the trafficking pathways can be more 
complicated. Dab2 is required for recycling of endocytic cargos, as was demonstrated for 
TGF-β, transferrin and cystic fibrosis transmembrane conductance receptor (Penheiter et 
al., 2010; Fu et al., 2012). Further experiments are required to clarify, whether recycling 
block of transferrin upon knock-down of KIF15 is a result of direct involvement of KIF15 
in transferrin anterograde transport, perturbation of Dab2-dependent steps along the 
endocytic recycling pathway, or combination of both. Also, potential involvement of 
KIF15 and Dab2 in integrin recycling is yet to be investigated.   
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According GENT database, KIF15 is upregulated in numerous cancers (Shin et 
al., 2011). Alterations in integrin trafficking is a prominent cancer hallmark, primarily 
associated with the motility of transformed cells (Mosesson et al., 2008; Shin et al., 
2012). Altogether our data demostrate that KIF15 over-expression can promote early 
steps of the integrin internalization, thus KIF15 can serve as a perspective therapeutic 
target in cancer treatment, and its implication in the the other steps of integrin trafficking, 
role in cell motility and cancer progression in vivo should be addressed. 
 
5.6. Integrin α2 internalization of micropatterned surfaces 
We have performed proof-of-principle experiments, demonstrating that non-
clustered integrin α2 in absence of its ligand is efficiently internalized when cells are 
seeded onto micropatterned substrate that restricts the cell shape and motility (Figure 
R.13). Lesser difference of the integrin α2 internalization and expression in the cells 
grown on micropatterns indicates, that certain biological pre-selection of cells occurs, 
possibly, at the point of cell attachment to micropatterns. This would allow us to reach 
higher dynamic range of the integrin internalization assay, without having to disregard the 
majority of the cell population, as done in the experiments performed in cell culture (see 
Quantification of microscopy-based integrin internalization assay). The use of both 
symmetric (Y- and H-shaped) and asymmetric (crossbow-shaped) patterns would allow us 
to directly compare the integrin internalization and intracellular distribution of 
internalized integrin in polarized and non-polarized cells, as the assymetric patterns were 
demonstrated to induce cell polarization (Thery et al., 2006) and focal adhesion re-
distribution in a manner, similar to migrating cells (Theisen et al., 2012).  
Yet, these experiments are still under development, and further optimization of 
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quantification of intracellular distribution of internalized integrin, as well as assessment 
of cell motility of the cells residing on micropatterns is needed.  
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6. Conclusions and outlook 
In this study we aimed to characterize the endocytic trafficking of non-clustered 
integrin α2β1 in HeLa cells and discover the novel regulators of it. For this, a quantitative 
method to measure internalization of endogenously expressed non-clustered integrin α2 in 
the adherent cells was developed and the scoring pipeline was optimized. For the first 
time we demonstrated, that internalization of non-clustered integrin α2 in HeLa cells 
requires both clathrin and caveolin1 and proceeds through Rab4- Rab5- and Rab11-
positive compartments.  
We carried out an RNAi screening of 386 cytoskeleton-associated genes, and 
identified 122 hits as potential regulators of α2 integrin internalization, 83 of which have 
not previously been associated with endocytic trafficking . The reliability of the primary 
screening results we have verified by reproducing the primary screening results for 10 
genes out of 26 taken into validation. Additionaly, we assessed effect of hits knock-down 
on the total integrin α2 expression and cell-counts, and identified 5 genes that affected α2 
integrin at the expression level.  
In our study we for the first time systematically addressed effect of kinesin 
molecular motors on integrin trafficking. Three kinesins (KIF15, KIF18a, and KIF23) 
were validated as inhibitors of integrin α2 internalization. We demonstrated that KIF15 is 
a novel trafficking regulator, that it is required at the early steps of α2 integrin 
endocytosis but not for endocytosis of transferrin or EGF. Strikingly, knock-down of 
KIF15 resulted in loss of integrin-specific clathrin adaptor Dab2 from the plasma 
membrane, which is likely to be the cause of integrin α2 internalization block. However, 
whether KIF15 directly transports Dab2 to the plasma membrane and whether its knock-
down affects other integrin-specific endocytic adaptors remains to be investigated. 
Another question is whether KIF15 is required for the other steps of integrin tranficking, 
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i.e. recycling similarly to its requirement for tranferrin recycling. 
Integrin trafficking is crucial for motility of cells, and deregulation of it, causing 
either to blockage or increase of integrin endocytic recycling, can lead to cancer 
development. Our results provide a link between integrin trafficking and KIF15, which is 
upregulated in numerous cancers, illuminating it as a potential therapeutic target. Further 
work is required to elucidate, whether KIF15  in vivo is involved in malignant 
transformation due to its interphase role in the integrin internalization. 
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Appendix 
Appendix I. List of genes tested in the primary screening for regulators of integrin α2 internalization 
Gene ID and gene information is given according to http://www.ncbi.nlm.nih.gov/gene/ 
Gene ontology annotations (GO) are given according to http://www.ebi.ac.uk/GOA/ 
Gene 
ID 
Gene symbol Gene description GO, Molecular Function 
25 ABL1 c-abl oncogene 1, receptor tyrosine kinase magnesium ion binding, protein kinase activity, adenyl ribonucleotide binding, 
transition metal ion binding 
27 ABL2 v-abl Abelson murine leukemia viral 
oncogene homolog 2 (arg, Abelson-related 
gene) 
magnesium ion binding, protein kinase activity, adenyl ribonucleotide binding, 
transition metal ion binding 
29 ABR active BCR-related gene Ras guanyl-nucleotide exchange factor activity 
60 ACTB actin, beta protein kinase binding, adenyl ribonucleotide binding 
87 ACTN1 actinin, alpha 1 calcium ion binding, actin filament binding 
81 ACTN4 actinin, alpha 4 calcium ion binding, actin filament binding 
11214 AKAP13 A kinase (PRKA) anchor protein 13 protein kinase activity, Ras guanyl-nucleotide exchange factor activity, transition 
metal ion binding 
57679 ALS2 amyotrophic lateral sclerosis 2 (juvenile) Ras guanyl-nucleotide exchange factor activity, Rab GTPase binding, small 
GTPase binding, protein serine/threonine kinase activator activity 
302 ANXA2 annexin A2 pseudogene 3; annexin A2; 
annexin A2 pseudogene 1 
 
162 AP1B1 adaptor-related protein complex 1, beta 1 
subunit 
 
324 APC adenomatous polyposis coli microtubule binding, protein kinase binding 
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Gene 
ID 
Gene symbol Gene description GO, Molecular Function 
10297 APC2 adenomatosis polyposis coli 2 microtubule binding 
116985 ARAP1 ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 1 
 
116984 ARAP2 ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 2 
 
64411 ARAP3 ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 3 
 
375 ARF1 ADP-ribosylation factor 1 pyrophosphatase activity, guanyl ribonucleotide binding 
392 ARHGAP1 Rho GTPase activating protein 1 Ras GTPase activator activity, Rho GTPase activator activity 
79658 ARHGAP10 Rho GTPase activating protein 10 Ras GTPase activator activity, Rho GTPase activator activity 
9824 ARHGAP11 Rho GTPase activating protein 11B; Rho 
GTPase activating protein 11A 
 
94134 ARHGAP12 Rho GTPase activating protein 12  
55843 ARHGAP15 Rho GTPase activating protein 15  
55114 ARHGAP17 Rho GTPase activating protein 17  
93663 ARHGAP18 Rho GTPase activating protein 18  
84986 ARHGAP19 Rho GTPase activating protein 19  
57569 ARHGAP20 Rho GTPase activating protein 20  
58504 ARHGAP22 Rho GTPase activating protein 22  
57636 ARHGAP23 Rho GTPase activating protein 23  
83478 ARHGAP24 Rho GTPase activating protein 24  
9938 ARHGAP25 Rho GTPase activating protein 25  
23092 ARHGAP26 Rho GTPase activating protein 26 Ras GTPase activator activity, Rho GTPase activator activity 
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Gene 
ID 
Gene symbol Gene description GO, Molecular Function 
201176 ARHGAP27 Rho GTPase activating protein 27 Ras GTPase activator activity, Rho GTPase activator activity 
79822 ARHGAP28 Rho GTPase activating protein 28  
9411 ARHGAP29 Rho GTPase activating protein 29 Ras GTPase activator activity, Rho GTPase activator activity, transition metal ion 
binding 
57514 ARHGAP31 Cdc42 GTPase-activating protein  
9743 ARHGAP32 Rho GTPase-activating protein  
115703 ARHGAP33 sorting nexin 26 Ras GTPase activator activity, Rho GTPase activator activity 
80728 ARHGAP39 Rho GTPase activating protein 39  
393 ARHGAP4 Rho GTPase activating protein 4 Ras GTPase activator activity, Rho GTPase activator activity 
394 ARHGAP5 Rho GTPase activating protein 5 Ras GTPase activator activity, Rho GTPase activator activity, pyrophosphatase 
activity, guanyl ribonucleotide binding 
395 ARHGAP6 Rho GTPase activating protein 6 Ras GTPase activator activity, Rho GTPase activator activity 
23779 ARHGAP8 Rho GTPase activating protein 8; proline rich 
5 (renal); PRR5-ARHGAP8 fusion 
 
64333 ARHGAP9 Rho GTPase activating protein 9  
396 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha GDP-dissociation inhibitor activity 
397 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta GDP-dissociation inhibitor activity 
398 ARHGDIG Rho GDP dissociation inhibitor (GDI) gamma GDP-dissociation inhibitor activity 
9138 ARHGEF1 Rho guanine nucleotide exchange factor 
(GEF) 1 
Ras guanyl-nucleotide exchange factor activity 
9639 ARHGEF10 Rho guanine nucleotide exchange factor 
(GEF) 10 
Ras guanyl-nucleotide exchange factor activity 
55160 ARHGEF10L Rho guanine nucleotide exchange factor 
(GEF) 10-like 
Ras guanyl-nucleotide exchange factor activity, Ras GTPase activator activity, Rho 
GTPase activator activity 
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Gene 
ID 
Gene symbol Gene description GO, Molecular Function 
9826 ARHGEF11 Rho guanine nucleotide exchange factor 
(GEF) 11 
Ras guanyl-nucleotide exchange factor activity 
23365 ARHGEF12 Rho guanine nucleotide exchange factor 
(GEF) 12 
Ras guanyl-nucleotide exchange factor activity 
22899 ARHGEF15 Rho guanine nucleotide exchange factor 
(GEF) 15 
Ras guanyl-nucleotide exchange factor activity 
27237 ARHGEF16 Rho guanine exchange factor (GEF) 16 Ras guanyl-nucleotide exchange factor activity 
9828 ARHGEF17 Rho guanine nucleotide exchange factor 
(GEF) 17 
Ras guanyl-nucleotide exchange factor activity 
23370 ARHGEF18 Rho/Rac guanine nucleotide exchange factor 
(GEF) 18 
Ras guanyl-nucleotide exchange factor activity 
9181 ARHGEF2 Rho/Rac guanine nucleotide exchange factor 
(GEF) 2 
Ras guanyl-nucleotide exchange factor activity, microtubule binding, small 
GTPase binding, transition metal ion binding 
115557 ARHGEF25 Rho guanine nucleotide exchange factor 
(GEF) 25 
Ras guanyl-nucleotide exchange factor activity 
50650 ARHGEF3 Rho guanine nucleotide exchange factor 
(GEF) 3 
Ras guanyl-nucleotide exchange factor activity 
50649 ARHGEF4 Rho guanine nucleotide exchange factor 
(GEF) 4 
Ras guanyl-nucleotide exchange factor activity 
7984 ARHGEF5 Rho guanine nucleotide exchange factor 
(GEF) 5 
Ras guanyl-nucleotide exchange factor activity, guanyl ribonucleotide binding 
9459 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange 
factor (GEF) 6 
Ras guanyl-nucleotide exchange factor activity 
8874 ARHGEF7 Rho guanine nucleotide exchange factor 
(GEF) 7 
Ras guanyl-nucleotide exchange factor activity 
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23229 ARHGEF9 Cdc42 guanine nucleotide exchange factor 
(GEF) 9; hypothetical protein LOC100134381
Ras guanyl-nucleotide exchange factor activity 
50807 ASAP1 ArfGAP with SH3 domain, ankyrin repeat and 
PH domain 1 
ARF GTPase activator activity, transition metal ion binding 
9564 BCAR1 similar to breast cancer anti-estrogen 
resistance 1; breast cancer anti-estrogen 
resistance 1 
protein kinase binding, protein phosphatase binding 
613 BCR breakpoint cluster region protein kinase activity, Ras guanyl-nucleotide exchange factor activity, adenyl 
ribonucleotide binding 
811 CALR calreticulin calcium ion binding, nuclear hormone receptor binding, transition metal ion 
binding 
821 CANX calnexin calcium ion binding 
823 CAPN1 calpain 1, (mu/I) large subunit endopeptidase activity, calcium ion binding, cysteine-type peptidase activity 
824 CAPN2 calpain 2, (m/II) large subunit endopeptidase activity, calcium ion binding, cysteine-type peptidase activity 
826 CAPNS1 calpain, small subunit 1 endopeptidase activity, calcium ion binding, cysteine-type peptidase activity 
857 CAV1 caveolin 1, caveolae protein, 22kDa cholesterol binding 
858 CAV2 caveolin 2 protein kinase activity, dopamine receptor binding 
867 CBL Cas-Br-M (murine) ecotropic retroviral 
transforming sequence 
calcium ion binding, small conjugating protein ligase activity, transition metal ion 
binding 
977 CD151 CD151 molecule (Raph blood group)  
975 CD81 CD81 molecule  
998 CDC42 cell division cycle 42 (GTP binding protein, 
25kDa); cell division cycle 42 pseudogene 2 
pyrophosphatase activity, guanyl ribonucleotide binding 
1062 CENPE centromere protein E, 312kDa pyrophosphatase activity, protein kinase binding, adenyl ribonucleotide binding 
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1072 CFL1 cofilin 1 (non-muscle)  
1123 CHN1 chimerin (chimaerin) 1 transition metal ion binding 
1124 CHN2 chimerin (chimaerin) 2 transition metal ion binding 
10519 CIB1 calcium and integrin binding 1 (calmyrin) calcium ion binding 
9793 CKAP5 cytoskeleton associated protein 5  
23332 CLASP1 cytoplasmic linker associated protein 1 microtubule binding 
23122 CLASP2 cytoplasmic linker associated protein 2 microtubule binding, fucosyltransferase activity 
6249 CLIP1 CAP-GLY domain containing linker protein 1 microtubule binding, transition metal ion binding 
7461 CLIP2 CAP-GLY domain containing linker protein 2 microtubule binding 
1213 CLTC clathrin, heavy chain (Hc)  
1398 CRK v-crk sarcoma virus CT10 oncogene homolog 
(avian) 
 
1399 CRKL v-crk sarcoma virus CT10 oncogene homolog 
(avian)-like 
protein kinase activity 
1445 CSK c-src tyrosine kinase protein kinase activity, adenyl ribonucleotide binding 
1465 CSRP1 cysteine and glycine-rich protein 1 transition metal ion binding 
1639 DCTN1 dynactin 1 (p150, glued homolog, Drosophila) pyrophosphatase activity 
1729 DIAPH1 diaphanous homolog 1 (Drosophila) small GTPase binding 
1730 DIAPH2 diaphanous homolog 2 (Drosophila) small GTPase binding 
81624 DIAPH3 diaphanous homolog 3 (Drosophila) small GTPase binding 
10395 DLC1 deleted in liver cancer 1 Ras GTPase activator activity, Rho GTPase activator activity 
1759 DNM1 dynamin 1 pyrophosphatase activity, guanyl ribonucleotide binding 
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1785 DNM2 dynamin 2 microtubule binding, pyrophosphatase activity, guanyl ribonucleotide binding 
23268 DNMBP dynamin binding protein Ras guanyl-nucleotide exchange factor activity 
1793 DOCK1 dedicator of cytokinesis 1  
55619 DOCK10 dedicator of cytokinesis 10 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, guanyl 
ribonucleotide binding 
139818 DOCK11 dedicator of cytokinesis 11 guanyl ribonucleotide binding 
1794 DOCK2 dedicator of cytokinesis 2 Ras guanyl-nucleotide exchange factor activity, Ras GTPase activator activity, Rho 
GTPase activator activity, transition metal ion binding 
1795 DOCK3 dedicator of cytokinesis 3 guanyl ribonucleotide binding 
9732 DOCK4 dedicator of cytokinesis 4 Ras GTPase activator activity, Rho GTPase activator activity, small GTPase 
binding 
80005 DOCK5 dedicator of cytokinesis 5  
57572 DOCK6 dedicator of cytokinesis 6 guanyl ribonucleotide binding 
85440 DOCK7 dedicator of cytokinesis 7 small GTPase binding, guanyl ribonucleotide binding 
81704 DOCK8 dedicator of cytokinesis 8 guanyl ribonucleotide binding 
23348 DOCK9 dedicator of cytokinesis 9 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, guanyl 
ribonucleotide binding 
1778 DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 pyrophosphatase activity, adenyl ribonucleotide binding 
1780 DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 microtubule binding, pyrophosphatase activity 
1781 DYNC1I2 similar to dynein cytoplasmic 1 intermediate 
chain 2; dynein, cytoplasmic 1, intermediate 
chain 2 
pyrophosphatase activity 
51143 DYNC1LI1 dynein, cytoplasmic 1, light intermediate 
chain 1 
pyrophosphatase activity, adenyl ribonucleotide binding 
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1783 DYNC1LI2 dynein, cytoplasmic 1, light intermediate 
chain 2 
pyrophosphatase activity, adenyl ribonucleotide binding 
79659 DYNC2H1 dynein, cytoplasmic 2, heavy chain 1 pyrophosphatase activity, adenyl ribonucleotide binding 
51626 DYNC2LI1 dynein, cytoplasmic 2, light intermediate 
chain 1 
pyrophosphatase activity 
8655 DYNLL1 dynein, light chain, LC8-type 1 pyrophosphatase activity 
140735 DYNLL2 dynein, light chain, LC8-type 2 pyrophosphatase activity 
83658 DYNLRB1 dynein, light chain, roadblock-type 1 pyrophosphatase activity 
83657 DYNLRB2 dynein, light chain, roadblock-type 2 pyrophosphatase activity 
6993 DYNLT1 dynein, light chain, Tctex-type 1 pyrophosphatase activity 
6990 DYNLT3 dynein, light chain, Tctex-type 3 pyrophosphatase activity 
1894 ECT2 epithelial cell transforming sequence 2 
oncogene 
Ras guanyl-nucleotide exchange factor activity, small GTPase binding 
55740 ENAH enabled homolog (Drosophila)  
51466 EVL Enah/Vasp-like  
7430 EZR hypothetical protein LOC100129652; ezrin actin filament binding 
51306 FAM13B family with sequence similarity 13, member B  
10160 FARP1 FERM, RhoGEF (ARHGEF) and pleckstrin 
domain protein 1 (chondrocyte-derived) 
Ras guanyl-nucleotide exchange factor activity 
9855 FARP2 FERM, RhoGEF and pleckstrin domain 
protein 2 
Ras guanyl-nucleotide exchange factor activity 
54751 FBLIM1 filamin binding LIM protein 1 transition metal ion binding 
10979 FERMT2 fermitin family homolog 2 (Drosophila)  
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2245 FGD1 FYVE, RhoGEF and PH domain containing 1 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, transition 
metal ion binding 
221472 FGD2 FYVE, RhoGEF and PH domain containing 2 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, transition 
metal ion binding 
89846 FGD3 FYVE, RhoGEF and PH domain containing 3 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, transition 
metal ion binding 
121512 FGD4 FYVE, RhoGEF and PH domain containing 4 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, transition 
metal ion binding, actin filament binding 
55785 FGD6 FYVE, RhoGEF and PH domain containing 6 Ras guanyl-nucleotide exchange factor activity, small GTPase binding, transition 
metal ion binding 
54848 FLJ20184 hypothetical protein FLJ20184 Ras guanyl-nucleotide exchange factor activity 
2316 FLNA filamin A, alpha (actin binding protein 280) protein kinase binding, small GTPase binding, Fc-gamma receptor I complex 
binding, actin filament binding 
2317 FLNB filamin B, beta (actin binding protein 278)  
2318 FLNC filamin C, gamma (actin binding protein 280)  
2534 FYN FYN oncogene related to SRC, FGR, YES protein kinase activity, adenyl ribonucleotide binding, transition metal ion binding 
2597 GAPDH glyceraldehyde-3-phosphate dehydrogenase-
like 6; hypothetical protein LOC100133042; 
glyceraldehyde-3-phosphate dehydrogenase 
glyceraldehyde-3-phosphate dehydrogenase activity 
28964 GIT1 G protein-coupled receptor kinase interacting 
ArfGAP 1 
ARF GTPase activator activity, transition metal ion binding 
9815 GIT2 G protein-coupled receptor kinase interacting 
ArfGAP 2 
ARF GTPase activator activity, transition metal ion binding 
51291 GMIP GEM interacting protein Ras GTPase activator activity, Rho GTPase activator activity, transition metal ion 
binding 
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10399 GNB2L1 guanine nucleotide binding protein (G 
protein), beta polypeptide 2-like 1 
protein phosphatase binding 
2885 GRB2 growth factor receptor-bound protein 2 phosphotyrosine binding 
2886 GRB7 growth factor receptor-bound protein 7  
2909 GRLF1 glucocorticoid receptor DNA binding factor 1 transcription corepressor activity, Ras GTPase activator activity, Rho GTPase 
activator activity 
2934 GSN gelsolin (amyloidosis, Finnish type) calcium ion binding 
23526 HMHA1 histocompatibility (minor) HA-1 transition metal ion binding 
3611 ILK integrin-linked kinase protein kinase activity, adenyl ribonucleotide binding 
3619 INCENP inner centromere protein antigens 135/155kDa  
8826 IQGAP1 IQ motif containing GTPase activating protein 
1 
Ras GTPase activator activity, protein phosphatase binding 
3688 ITGB1 integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
 
9270 ITGB1BP1 integrin beta 1 binding protein 1  
3690 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, 
antigen CD61) 
 
23421 ITGB3BP integrin beta 3 binding protein (beta3-
endonexin) 
 
3691 ITGB4 integrin, beta 4  
3693 ITGB5 integrin, beta 5  
3694 ITGB6 integrin, beta 6  
6453 ITSN1 intersectin 1 (SH3 domain protein) Ras guanyl-nucleotide exchange factor activity, calcium ion binding 
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50618 ITSN2 intersectin 2 Ras guanyl-nucleotide exchange factor activity, calcium ion binding 
8997 KALRN kalirin, RhoGEF kinase magnesium ion binding, protein kinase activity, Ras guanyl-nucleotide exchange 
factor activity, adenyl ribonucleotide binding 
3832 KIF11 kinesin family member 11 pyrophosphatase activity, adenyl ribonucleotide binding 
113220 KIF12 kinesin family member 12 pyrophosphatase activity, adenyl ribonucleotide binding 
63971 KIF13A kinesin family member 13A pyrophosphatase activity, adenyl ribonucleotide binding 
23303 KIF13B kinesin family member 13B pyrophosphatase activity, protein kinase binding, adenyl ribonucleotide binding 
9928 KIF14 kinesin family member 14 pyrophosphatase activity, adenyl ribonucleotide binding 
56992 KIF15 kinesin family member 15 pyrophosphatase activity, adenyl ribonucleotide binding 
55614 KIF16B kinesin family member 16B pyrophosphatase activity, adenyl ribonucleotide binding 
57576 KIF17 kinesin family member 17 pyrophosphatase activity, adenyl ribonucleotide binding 
81930 KIF18A kinesin family member 18A microtubule binding, pyrophosphatase activity, adenyl ribonucleotide binding 
146909 KIF18B kinesin family member 18B pyrophosphatase activity, adenyl ribonucleotide binding 
124602 KIF19 kinesin family member 19 pyrophosphatase activity, adenyl ribonucleotide binding 
547 KIF1A kinesin family member 1A pyrophosphatase activity, adenyl ribonucleotide binding 
23095 KIF1B kinesin family member 1B pyrophosphatase activity, adenyl ribonucleotide binding 
10749 KIF1C kinesin family member 1C pyrophosphatase activity, adenyl ribonucleotide binding 
10112 KIF20A kinesin family member 20A pyrophosphatase activity, adenyl ribonucleotide binding 
9585 KIF20B kinesin family member 20B pyrophosphatase activity, adenyl ribonucleotide binding 
55605 KIF21A kinesin family member 21A pyrophosphatase activity, adenyl ribonucleotide binding 
23046 KIF21B kinesin family member 21B pyrophosphatase activity, adenyl ribonucleotide binding 
3835 KIF22 kinesin family member 22 pyrophosphatase activity, adenyl ribonucleotide binding 
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9493 KIF23 kinesin family member 23 pyrophosphatase activity, adenyl ribonucleotide binding 
347240 KIF24 kinesin family member 24 pyrophosphatase activity, adenyl ribonucleotide binding 
3834 KIF25 kinesin family member 25 pyrophosphatase activity, adenyl ribonucleotide binding 
26153 KIF26A kinesin family member 26A pyrophosphatase activity, adenyl ribonucleotide binding 
55083 KIF26B kinesin family member 26B pyrophosphatase activity, adenyl ribonucleotide binding 
55582 KIF27 kinesin family member 27 pyrophosphatase activity, adenyl ribonucleotide binding 
3796 KIF2A kinesin heavy chain member 2A pyrophosphatase activity, adenyl ribonucleotide binding 
84643 KIF2B kinesin family member 2B pyrophosphatase activity, adenyl ribonucleotide binding 
11004 KIF2C kinesin family member 2C pyrophosphatase activity, centromeric DNA binding, adenyl ribonucleotide binding 
11127 KIF3A kinesin family member 3A pyrophosphatase activity, adenyl ribonucleotide binding 
9371 KIF3B kinesin family member 3B pyrophosphatase activity, adenyl ribonucleotide binding 
3797 KIF3C kinesin family member 3C pyrophosphatase activity, adenyl ribonucleotide binding 
24137 KIF4A kinesin family member 4B; kinesin family 
member 4A 
pyrophosphatase activity, adenyl ribonucleotide binding 
285643 KIF4B kinesin family member 4B pyrophosphatase activity, adenyl ribonucleotide binding 
3798 KIF5A kinesin family member 5A pyrophosphatase activity, adenyl ribonucleotide binding 
3799 KIF5B kinesin family member 5B microtubule binding, pyrophosphatase activity, adenyl ribonucleotide binding 
3800 KIF5C kinesin family member 5C pyrophosphatase activity, adenyl ribonucleotide binding 
221458 KIF6 kinesin family member 6 pyrophosphatase activity, adenyl ribonucleotide binding 
374654 KIF7 kinesin family member 7 pyrophosphatase activity, adenyl ribonucleotide binding 
64147 KIF9 kinesin family member 9 pyrophosphatase activity, adenyl ribonucleotide binding 
22920 KIFAP3 kinesin-associated protein 3  
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3833 KIFC1 kinesin family member C1 pyrophosphatase activity, adenyl ribonucleotide binding 
90990 KIFC2 kinesin family member C2 pyrophosphatase activity, adenyl ribonucleotide binding 
3801 KIFC3 kinesin family member C3 pyrophosphatase activity, adenyl ribonucleotide binding 
3927 LASP1 LIM and SH3 protein 1 transition metal ion binding, actin filament binding 
3984 LIMK1 LIM domain kinase 1 protein kinase activity, adenyl ribonucleotide binding, transition metal ion binding 
3985 LIMK2 LIM domain kinase 2 protein kinase activity, adenyl ribonucleotide binding, transition metal ion binding 
3987 LIMS1 LIM and senescent cell antigen-like domains 
1 
transition metal ion binding 
55679 LIMS2 LIM and senescent cell antigen-like domains 
2 
transition metal ion binding 
441930 LOC441930 similar to kinesin-like protein (103.5 kD) (klp-6) 
 
4035 LRP1 low density lipoprotein-related protein 1 
(alpha-2-macroglobulin receptor) 
calcium ion binding 
23499 MACF1 microtubule-actin crosslinking factor 1 calcium ion binding, microtubule binding, actin filament binding 
4214 MAP3K1 mitogen-activated protein kinase kinase 
kinase 1 
magnesium ion binding, protein kinase activity, MAP kinase kinase kinase activity, 
small conjugating protein ligase activity, protein kinase binding, adenyl 
ribonucleotide binding, transition metal ion binding 
5594 MAPK1 mitogen-activated protein kinase 1 phosphotyrosine binding, protein kinase activity, MAP kinase activity, protein 
kinase binding, adenyl ribonucleotide binding 
5595 MAPK3 hypothetical LOC100271831; mitogen-
activated protein kinase 3 
protein kinase activity, MAP kinase activity, adenyl ribonucleotide binding 
9479 MAPK8IP1 mitogen-activated protein kinase 8 interacting 
protein 1 
MAP-kinase scaffold activity, protein kinase binding 
23542 MAPK8IP2 mitogen-activated protein kinase 8 interacting MAP-kinase scaffold activity, protein kinase binding 
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protein 2 
23162 MAPK8IP3 mitogen-activated protein kinase 8 interacting 
protein 3 
MAP-kinase scaffold activity, protein kinase binding 
22919 MAPRE1 microtubule-associated protein, RP/EB family, 
member 1 
microtubule binding 
10982 MAPRE2 microtubule-associated protein, RP/EB family, 
member 2 
microtubule binding 
22924 MAPRE3 microtubule-associated protein, RP/EB family, 
member 3 
microtubule binding 
4168 MCF2 MCF.2 cell line derived transforming 
sequence 
Ras guanyl-nucleotide exchange factor activity 
23263 MCF2L MCF.2 cell line derived transforming 
sequence-like 
Ras guanyl-nucleotide exchange factor activity 
23101 MCF2L2 MCF.2 cell line derived transforming 
sequence-like 2 
Ras guanyl-nucleotide exchange factor activity 
79083 MLPH melanophilin microtubule binding, Rab GTPase binding, small GTPase binding, myosin V 
binding, transition metal ion binding 
4478 MSN moesin  
4619 MYH1 myosin, heavy chain 1, skeletal muscle, adult pyrophosphatase activity, adenyl ribonucleotide binding 
4628 MYH10 myosin, heavy chain 10, non-muscle pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
4629 MYH11 myosin, heavy chain 11, smooth muscle pyrophosphatase activity, adenyl ribonucleotide binding 
8735 MYH13 myosin, heavy chain 13, skeletal muscle pyrophosphatase activity, adenyl ribonucleotide binding 
22989 MYH15 myosin, heavy chain 15 pyrophosphatase activity, adenyl ribonucleotide binding 
4620 MYH2 myosin, heavy chain 2, skeletal muscle, adult pyrophosphatase activity, adenyl ribonucleotide binding 
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4621 MYH3 myosin, heavy chain 3, skeletal muscle, 
embryonic 
pyrophosphatase activity, adenyl ribonucleotide binding 
4622 MYH4 myosin, heavy chain 4, skeletal muscle pyrophosphatase activity, adenyl ribonucleotide binding 
4624 MYH6 myosin, heavy chain 6, cardiac muscle, alpha pyrophosphatase activity, adenyl ribonucleotide binding 
4625 MYH7 myosin, heavy chain 7, cardiac muscle, beta pyrophosphatase activity, adenyl ribonucleotide binding 
57644 MYH7B myosin, heavy chain 7B, cardiac muscle, beta pyrophosphatase activity, adenyl ribonucleotide binding 
4626 MYH8 myosin, heavy chain 8, skeletal muscle, 
perinatal 
pyrophosphatase activity, adenyl ribonucleotide binding 
4627 MYH9 myosin, heavy chain 9, non-muscle pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
29116 MYLIP myosin regulatory light chain interacting 
protein 
small conjugating protein ligase activity, transition metal ion binding 
4638 MYLK myosin light chain kinase magnesium ion binding, protein kinase activity, calcium ion binding, adenyl 
ribonucleotide binding 
4651 MYO10 myosin X pyrophosphatase activity, adenyl ribonucleotide binding 
51168 MYO15A myosin XVA pyrophosphatase activity, adenyl ribonucleotide binding 
80022 MYO15B myosin XVB pseudogene  
23026 MYO16 myosin XVI pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
399687 MYO18A myosin XVIIIA pyrophosphatase activity, adenyl ribonucleotide binding 
84700 MYO18B myosin XVIIIB pyrophosphatase activity, adenyl ribonucleotide binding 
4640 MYO1A myosin IA pyrophosphatase activity, adenyl ribonucleotide binding 
4430 MYO1B myosin IB pyrophosphatase activity, adenyl ribonucleotide binding 
4641 MYO1C myosin IC pyrophosphatase activity, adenyl ribonucleotide binding 
4642 MYO1D myosin ID pyrophosphatase activity, adenyl ribonucleotide binding 
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4643 MYO1E myosin IE pyrophosphatase activity, adenyl ribonucleotide binding 
4542 MYO1F myosin IF pyrophosphatase activity, adenyl ribonucleotide binding 
64005 MYO1G myosin IG pyrophosphatase activity, adenyl ribonucleotide binding 
53904 MYO3A myosin IIIA protein kinase activity, pyrophosphatase activity, adenyl ribonucleotide binding 
140469 MYO3B myosin IIIB protein kinase activity, pyrophosphatase activity, adenyl ribonucleotide binding 
4644 MYO5A myosin VA (heavy chain 12, myoxin) pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
4645 MYO5B similar to acetyl-Coenzyme A acyltransferase 
2 (mitochondrial 3-oxoacyl-Coenzyme A 
thiolase); similar to KIAA1119 protein; 
myosin VB 
pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
55930 MYO5C myosin VC pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
4646 MYO6 myosin VI pyrophosphatase activity, adenyl ribonucleotide binding, actin filament binding 
4647 MYO7A myosin VIIA pyrophosphatase activity, adenyl ribonucleotide binding 
4648 MYO7B myosin VIIB pyrophosphatase activity, adenyl ribonucleotide binding 
4649 MYO9A myosin IXA pyrophosphatase activity, adenyl ribonucleotide binding, transition metal ion 
binding 
4650 MYO9B myosin IXB Ras GTPase activator activity, Rho GTPase activator activity, pyrophosphatase 
activity, small GTPase binding, adenyl ribonucleotide binding, transition metal ion 
binding, actin filament binding 
4690 NCK1 NCK adaptor protein 1  
8440 NCK2 NCK adaptor protein 2  
10276 NET1 neuroepithelial cell transforming 1 Ras guanyl-nucleotide exchange factor activity 
91624 NEXN nexilin (F actin binding protein) actin filament binding 
4771 NF2 neurofibromin 2 (merlin)  
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25791 NGEF neuronal guanine nucleotide exchange factor Ras guanyl-nucleotide exchange factor activity 
84309 NUDT16L1 nudix (nucleoside diphosphate linked moiety 
X)-type motif 16-like 1 
 
84033 OBSCN obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF 
magnesium ion binding, protein kinase activity, Ras guanyl-nucleotide exchange 
factor activity, adenyl ribonucleotide binding 
4952 OCRL oculocerebrorenal syndrome of Lowe phosphatase activity 
4983 OPHN1 oligophrenin 1 Ras GTPase activator activity, Rho GTPase activator activity 
5048 PAFAH1B1 platelet-activating factor acetylhydrolase, 
isoform Ib, subunit 1 (45kDa) 
microtubule binding, heparin binding 
5058 PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 protein kinase activity, small GTPase binding, adenyl ribonucleotide binding 
5062 PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 protein kinase activity, adenyl ribonucleotide binding 
10298 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 protein kinase activity, adenyl ribonucleotide binding 
23022 PALLD palladin, cytoskeletal associated protein alpha-actinin binding 
55742 PARVA parvin, alpha  
29780 PARVB parvin, beta  
5216 PFN1 profilin 1 small GTPase binding 
5217 PFN2 profilin 2  
5290 PIK3CA phosphoinositide-3-kinase, catalytic, alpha 
polypeptide 
lipid kinase activity, inositol or phosphatidylinositol kinase activity, adenyl 
ribonucleotide binding, phosphoinositide 3-kinase activity 
5291 PIK3CB phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
lipid kinase activity, inositol or phosphatidylinositol kinase activity, adenyl 
ribonucleotide binding, phosphoinositide 3-kinase activity 
5294 PIK3CG phosphoinositide-3-kinase, catalytic, gamma 
polypeptide 
lipid kinase activity, inositol or phosphatidylinositol kinase activity, adenyl 
ribonucleotide binding, phosphoinositide 3-kinase activity 
5295 PIK3R1 phosphoinositide-3-kinase, regulatory subunit phosphatidylinositol binding, protein phosphatase binding 
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1 (alpha) 
5296 PIK3R2 phosphoinositide-3-kinase, regulatory subunit 
2 (beta) 
lipid kinase activity, inositol or phosphatidylinositol kinase activity, 
phosphoinositide 3-kinase activity 
23396 PIP5K1C phosphatidylinositol-4-phosphate 5-kinase, 
type I, gamma 
lipid kinase activity, inositol or phosphatidylinositol kinase activity, 
phosphatidylinositol phosphate kinase activity, adenyl ribonucleotide binding 
64857 PLEKHG2 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 2 
Ras guanyl-nucleotide exchange factor activity 
25894 PLEKHG4 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 4 
Ras guanyl-nucleotide exchange factor activity 
57449 PLEKHG5 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 5 
Ras guanyl-nucleotide exchange factor activity 
55200 PLEKHG6 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 6 
Ras guanyl-nucleotide exchange factor activity 
8500 PPFIA1 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein 
(liprin), alpha 1 
 
5478 PPIA similar to TRIMCyp; peptidylprolyl isomerase 
A (cyclophilin A); peptidylprolyl isomerase A 
(cyclophilin A)-like 3 
 
57580 PREX1 phosphatidylinositol-3,4,5-trisphosphate-
dependent Rac exchange factor 1 
Ras guanyl-nucleotide exchange factor activity, Ras GTPase activator activity, Rho 
GTPase activator activity 
5578 PRKCA protein kinase C, alpha protein kinase activity, calcium ion binding, adenyl ribonucleotide binding, 
transition metal ion binding 
5581 PRKCE protein kinase C, epsilon protein kinase activity, adenyl ribonucleotide binding, transition metal ion binding 
5587 PRKD1 protein kinase D1 protein kinase activity, adenyl ribonucleotide binding, transition metal ion binding 
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5728 PTEN phosphatase and tensin homolog; phosphatase 
and tensin homolog pseudogene 1 
magnesium ion binding, phosphatase activity 
5747 PTK2 PTK2 protein tyrosine kinase 2 protein kinase activity, adenyl ribonucleotide binding 
5770 PTPN1 protein tyrosine phosphatase, non-receptor 
type 1 
phosphatase activity, transition metal ion binding 
5781 PTPN11 protein tyrosine phosphatase, non-receptor 
type 11; similar to protein tyrosine 
phosphatase, non-receptor type 11 
phosphatase activity, peptide hormone receptor binding 
5782 PTPN12 protein tyrosine phosphatase, non-receptor 
type 12 
phosphatase activity 
5786 PTPRA protein tyrosine phosphatase, receptor type, A phosphatase activity, transmembrane receptor protein phosphatase activity 
5792 PTPRF protein tyrosine phosphatase, receptor type, F phosphatase activity, transmembrane receptor protein phosphatase activity 
5829 PXN paxillin transition metal ion binding 
5879 RAC1 ras-related C3 botulinum toxin substrate 1 
(rho family, small GTP binding protein Rac1) 
pyrophosphatase activity, guanyl ribonucleotide binding 
5880 RAC2 ras-related C3 botulinum toxin substrate 2 
(rho family, small GTP binding protein Rac2) 
pyrophosphatase activity, guanyl ribonucleotide binding 
5881 RAC3 ras-related C3 botulinum toxin substrate 3 
(rho family, small GTP binding protein Rac3) 
pyrophosphatase activity, guanyl ribonucleotide binding 
29127 RACGAP1 Rac GTPase activating protein 1 pseudogene; 
Rac GTPase activating protein 1 
alpha-tubulin binding, gamma-tubulin binding, transition metal ion binding, beta-
tubulin binding 
10928 RALBP1 hypothetical LOC100129773; ralA binding 
protein 1 
Ras GTPase activator activity, Rho GTPase activator activity, pyrophosphatase 
activity, small GTPase binding 
5923 RASGRF1 Ras protein-specific guanine nucleotide-
releasing factor 1 
Ras guanyl-nucleotide exchange factor activity 
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5924 RASGRF2 Ras protein-specific guanine nucleotide-
releasing factor 2 
Ras guanyl-nucleotide exchange factor activity, calcium ion binding 
5962 RDX radixin  
64283 RGNEF Rho-guanine nucleotide exchange factor Ras guanyl-nucleotide exchange factor activity, transition metal ion binding 
387 RHOA ras homolog gene family, member A magnesium ion binding, pyrophosphatase activity, guanyl ribonucleotide binding 
388 RHOB ras homolog gene family, member B pyrophosphatase activity, guanyl ribonucleotide binding 
9886 RHOBTB1 Rho-related BTB domain containing 1 guanyl ribonucleotide binding 
23221 RHOBTB2 Rho-related BTB domain containing 2 guanyl ribonucleotide binding 
389 RHOC ras homolog gene family, member C pyrophosphatase activity, guanyl ribonucleotide binding 
29984 RHOD ras homolog gene family, member D pyrophosphatase activity, guanyl ribonucleotide binding 
54509 RHOF ras homolog gene family, member F (in 
filopodia) 
pyrophosphatase activity, guanyl ribonucleotide binding 
391 RHOG ras homolog gene family, member G (rho G) pyrophosphatase activity, guanyl ribonucleotide binding 
399 RHOH ras homolog gene family, member H small GTPase binding, guanyl ribonucleotide binding 
57381 RHOJ ras homolog gene family, member J pyrophosphatase activity, guanyl ribonucleotide binding 
23433 RHOQ ras homolog gene family, member Q; similar 
to small GTP binding protein TC10 
pyrophosphatase activity, guanyl ribonucleotide binding 
58480 RHOU ras homolog gene family, member U magnesium ion binding, pyrophosphatase activity, guanyl ribonucleotide binding 
171177 RHOV ras homolog gene family, member V magnesium ion binding, guanyl ribonucleotide binding 
9912 RICH2 Rho-type GTPase-activating protein RICH2  
27289 RND1 Rho family GTPase 1 pyrophosphatase activity, guanyl ribonucleotide binding 
8153 RND2 Rho family GTPase 2 pyrophosphatase activity, guanyl ribonucleotide binding 
390 RND3 Rho family GTPase 3 pyrophosphatase activity, guanyl ribonucleotide binding 
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6048 RNF5 ring finger protein 5; ring finger protein 5 
pseudogene 1 
transition metal ion binding 
6093 ROCK1 similar to Rho-associated, coiled-coil 
containing protein kinase 1; Rho-associated, 
coiled-coil containing protein kinase 1 
protein kinase activity, small GTPase binding, adenyl ribonucleotide binding, 
transition metal ion binding 
9475 ROCK2 Rho-associated, coiled-coil containing protein 
kinase 2 
protein kinase activity, adenyl ribonucleotide binding, transition metal ion binding 
6385 SDC4 syndecan 4 alpha-actinin binding 
6386 SDCBP syndecan binding protein (syntenin) interleukin-5 receptor binding 
26084 SGEF Src homology 3 domain-containing guanine 
nucleotide exchange factor 
Ras guanyl-nucleotide exchange factor activity 
23616 SH3BP1 SH3-domain binding protein 1  
140885 SIRPA signal-regulatory protein alpha  
65012 SLC26A10 RhoA/RAC/CDC42 exchange factor; solute 
carrier family 26, member 10 
Ras guanyl-nucleotide exchange factor activity, antiporter activity 
10580 SORBS1 sorbin and SH3 domain containing 1 protein kinase binding 
10174 SORBS3 sorbin and SH3 domain containing 3  
6654 SOS1 son of sevenless homolog 1 (Drosophila) Ras guanyl-nucleotide exchange factor activity, Ras GTPase activator activity, Rho 
GTPase activator activity 
6655 SOS2 son of sevenless homolog 2 (Drosophila) Ras guanyl-nucleotide exchange factor activity 
221178 SPATA13 spermatogenesis associated 13 Ras guanyl-nucleotide exchange factor activity 
6714 SRC v-src sarcoma (Schmidt-Ruppin A-2) viral 
oncogene homolog (avian) 
protein kinase activity, adenyl ribonucleotide binding 
57522 SRGAP1 SLIT-ROBO Rho GTPase activating protein 1  
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23380 SRGAP2 SLIT-ROBO Rho GTPase activating protein 2  
9901 SRGAP3 SLIT-ROBO Rho GTPase activating protein 3  
90627 STARD13 StAR-related lipid transfer (START) domain 
containing 13 
 
9754 STARD8 StAR-related lipid transfer (START) domain 
containing 8 
 
57519 STARD9 StAR-related lipid transfer (START) domain 
containing 9 
pyrophosphatase activity, adenyl ribonucleotide binding 
85360 SYDE1 synapse defective 1, Rho GTPase, homolog 1 
(C. elegans) 
Ras GTPase activator activity, Rho GTPase activator activity 
23371 TENC1 tensin like C1 domain containing phosphatase 
(tensin 2) 
phosphatase activity, transition metal ion binding 
26136 TES testis derived transcript (3 LIM domains) transition metal ion binding 
7041 TGFB1I1 transforming growth factor beta 1 induced 
transcript 1 
transcription coactivator activity, nuclear hormone receptor binding, transition 
metal ion binding 
7074 TIAM1 T-cell lymphoma invasion and metastasis 1 Ras guanyl-nucleotide exchange factor activity 
26230 TIAM2 T-cell lymphoma invasion and metastasis 2 Ras guanyl-nucleotide exchange factor activity 
7094 TLN1 talin 1  
83660 TLN2 talin 2  
7145 TNS1 tensin 1  
7168 TPM1 tropomyosin 1 (alpha)  
7169 TPM2 tropomyosin 2 (beta)  
7170 TPM3 tropomyosin 3  
7171 TPM4 tropomyosin 4 calcium ion binding 
154 
 
Gene 
ID 
Gene symbol Gene description GO, Molecular Function 
7204 TRIO triple functional domain (PTPRF interacting) protein kinase activity, Ras guanyl-nucleotide exchange factor activity, adenyl 
ribonucleotide binding 
7205 TRIP6 thyroid hormone receptor interactor 6 interleukin-1 receptor binding, nuclear hormone receptor binding, transition metal 
ion binding 
54822 TRPM7 transient receptor potential cation channel, 
subfamily M, member 7 
protein kinase activity, ion channel activity, calcium ion binding, cation 
transmembrane transporter activity, substrate specific channel activity, adenyl 
ribonucleotide binding, transition metal ion binding 
7106 TSPAN4 tetraspanin 4  
7105 TSPAN6 tetraspanin 6  
10376 TUBA1B hypothetical gene supported by AF081484; 
NM_006082; tubulin, alpha 1b 
pyrophosphatase activity, guanyl ribonucleotide binding 
203068 TUBB tubulin, beta; similar to tubulin, beta 5; 
tubulin, beta pseudogene 2; tubulin, beta 
pseudogene 1 
pyrophosphatase activity, guanyl ribonucleotide binding, MHC class I protein 
binding 
7408 VASP vasodilator-stimulated phosphoprotein  
7409 VAV1 vav 1 guanine nucleotide exchange factor Ras guanyl-nucleotide exchange factor activity, transition metal ion binding 
7410 VAV2 vav 2 guanine nucleotide exchange factor Ras guanyl-nucleotide exchange factor activity, transition metal ion binding 
10451 VAV3 vav 3 guanine nucleotide exchange factor Ras guanyl-nucleotide exchange factor activity, transition metal ion binding 
7414 VCL vinculin  
7431 VIM vimentin protein kinase binding 
7525 YES1 v-yes-1 Yamaguchi sarcoma viral oncogene 
homolog 1 
protein kinase activity, adenyl ribonucleotide binding 
7791 ZYX zyxin transition metal ion binding
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Appendix II. Results of the primary screening for regulators of integrin α2 internalization for individual tested 
siRNAs 
1 Gene name and Gene ID according to  http://www.ncbi.nlm.nih.gov/gene/  
2 Target mRNA accession number according to  http://www.ncbi.nlm.nih.gov/nuccore/ 
3  SiRNA target sequence and siRNA ID according to manufacturer's information 
4 Gene summary according to performance of all tested siRNAs 
5 Performance of individual siRNAs in the screening (see Methods for explanation of Z-scores and p-values calculation) 
 
Gene Symbol 
1 
Gene ID1 RefSeq  
Accession 
Number2 
siRNA ID3 Antisense (target) siRNA Sequence3 Hit gene4 Z-score 5 P-value 5 
Scramble   251283 ACGUGACACGUUCGGAGAAtt Negative control 0 0,913 
CLTC 1213 NM_004859 SI00299880 *TAATCCAATTCGAAGACCAAT Positive control -1,54 7,45E-29 
DNM2 1785 
NM_001005360 
NM_001005361 
NM_001005362 
NM_004945 SI02654687 *CTGCAGCTCATCTTCTCAAAA Positive control -1,49 2,24E-13 
        
ABL1 25 NM_007313 1241 UAUCUCAGCGAGAUGGACCtc Non-hit -0,874 0,066 
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ABL1 25 NM_007313 147447 AUAGCCUAAGACCCGGAGCtt Non-hit -0,843 0,056 
ABL2 27 NM_007314 1478 GAUAGCCUCAUUUAGUGCCtg Mild hit -1,043 0,016 
ABL2 27 NM_005158 103346 GUAGUGAUACACACGUCCCtc Mild hit -1,452 0,088 
ABL2 27 NM_007314 103430 CUCAGCAGUCACAUACACCtt Mild hit -0,350 0,826 
ABL2 27 NM_007314 147450 GUAACCAAGGACUCGUAGCtt Mild hit -1,292 0,000 
ABR 29 NM_021962 29582 GUGGAUCUCAUAGAUGUCCtg Mild hit -1,235 0,143 
ABR 29 NM_021962 29678 CAGGUUGUCAUAGAACUCCtt Mild hit -0,442 0,553 
ABR 29 NM_021962 29772 AUUGUUGUCCUUGUUGACCtt Mild hit -1,392 0,013 
ABR 29 NM_021962 147813 UUAAUGUAGAUCUCUUCGCtg Mild hit -1,112 0,003 
ABR 29 NM_021962 147814 ACAGUCAUACUGCUGGUGCtt Mild hit -0,570 0,092 
ABR 29 NM_021962 147815 GUGCAUCAUGCAGUUUUCCtt Mild hit -0,171 0,870 
ABR 29 NM_001092 288548 UUCUUAGCCUGACUCCUGCtg Mild hit -0,774 0,028 
ABR 29 NM_021962 288549 GCAUCAAACAGACCACUGCtg Mild hit -0,620 0,243 
ACTB 60 NM_001101 9415 GUCGCCCACAUAGGAAUCCtt Mild hit -1,106 0,153 
ACTB 60 NM_001101 9511 CGUUCCAGUUUUUAAAUCCtg Mild hit -0,546 0,334 
ACTN1 87 NM_001102 9416 UGUGCACUCUCAUCUUGCCtc Strong hit -1,529 0,168 
ACTN1 87 NM_001102 9512 GGCUAUGAAAUCCAGGGCCtt Strong hit 0,241 0,421 
ACTN4 81 NM_004924 15476 AUUGAAGGCAAGACCAUCCtt Non-hit -0,915 0,040 
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ACTN4 81 NM_004924 15570 UUGGUUGACAGCCAGCACCtt Non-hit -0,967 0,671 
AKAP13 11214 NM_006738 1475 AGAAUCUUUCUCCUUCUCCtt Non-hit 0,417 0,643 
AKAP13 11214 NM_007200 1569 GUCUUUAGAAUCUUUCUCCtt Non-hit -1,263 0,028 
AKAP13 11214 NM_007200 103341 CUAGACUUUCUCGGCAGCCtt Non-hit -0,391 0,432 
AKAP13 11214 NM_144767 103506 UUUUCAUUAAAGGUCCUCCtt Non-hit -0,746 0,015 
AKAP13 11214 NM_144767 136052 GUAUAGGCAUCUUUGUUGGtg Non-hit -0,444 0,466 
AKAP13 11214 NM_144767 136053 UCCGACUCCAAGACUCUGCtt Non-hit -0,359 0,346 
ALS2 57679 NM_020919 28809 UAUGGGAAAGGAUCCUGCCtg Mild hit -1,300 0,045 
ALS2 57679 NM_020919 133298 CAUUGUACAAGGGCUAAGCtg Mild hit -0,509 0,643 
ANXA2 302 NM_004039 147285 GUAGGCGAAGGCAAUAUCCtg Non-hit -0,003 0,334 
ANXA2 302 NM_004039 147286 AUAAGGCUGACUUCAGUGCtg Non-hit 0,049 0,824 
ANXA2 302 NM_004039 147287 UGUGUCCGAAAUAAUGUCCtt Non-hit -0,404 0,829 
ANXA2 302 NM_004039 288566 ACUGUUAUUCGCAAGCUGGtt Non-hit -0,239 0,842 
ANXA2 302 NM_001002858 288567 AUGAGAGAGUCCUCGUCGGtt Non-hit -1,050 0,067 
ANXA2 302 NM_001002858 288568 AAUGUUCAAAGCAUCCCGCtc Non-hit 0,279 0,246 
AP1B1 162 NM_145730 9431 UGCCUCCUUCUUCUUCUCCtt Mild hit -1,382 0,149 
AP1B1 162 NM_145730 9527 CACAUAUGGAUCCUCGUCCtt Mild hit -0,510 0,011 
APC 324 NM_000038 42812 CUUCAUCUUCAAUACUUCCtt Non-hit -0,769 0,719 
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APC 324 NM_000038 44755 UGGAAUUAUCUUCUAGCUCtt Non-hit -0,951 0,092 
APC2 10297 NM_005883 16896 UAGGUGCUUCAGGACCUCCtt Mild hit 0,055 0,318 
APC2 10297 NM_005883 16991 GAUGUCCAUCUGUAGGGCCtt Mild hit -1,230 0,035 
ARAP1 116985 NM_139181 22844 GCAUUUCAUUUUCACUACCtc Non-hit -0,916 0,221 
ARAP1 116985 NM_139181 128706 ACGCUCAUGUCGAUGAAGGtg Non-hit -0,282 0,912 
ARAP1 116985 NM_139181 128707 CAGGACAACUGAGUAGUGCtt Non-hit 0,128 0,625 
ARAP1 116985 NM_139181 128708 GAACUUCAUCAUGCCAUGCtt Non-hit -1,359 0,002 
ARAP2 116984 NM_015230 22649 CUCUUGACUUAAUACACCCtc Non-hit -0,709 0,757 
ARAP2 116984 NM_139182 22745 AGUAACUCAAGAAGCCUCCtt Non-hit -0,654 0,223 
ARAP2 116984 NM_139182 22840 UUUAAAGCUUCUUGCAUCCtt Non-hit -0,823 0,130 
ARAP2 116984 NM_139182 128701 UGUCCAUAGCAAACCAGCCtt Non-hit 0,185 0,753 
ARAP3 64411 NM_022481 29944 CUGGAAGACAUAGUUUCCCtg Non-hit -0,006 0,546 
ARAP3 64411 NM_022481 30036 CCAAAGUACAUCAGACUCCtc Non-hit -0,128 0,825 
ARF1 375 NM_001024227 10237 GCCUGAAUGUACCAGUUCCtg Strong hit -0,673 0,481 
ARF1 375 NM_001024228 10333 AGGAGUACCAGAAACUGCCtc Strong hit 0,554 0,081 
ARF1 375 NM_001658 10426 UCGAUGGCAAAUCGGACCCtt Strong hit 0,385 0,184 
ARF1 375 NM_001658 147188 GUACUCCACGGUUUCCACGtt Strong hit -1,420 0,196 
ARF1 375 NM_001658 147189 ACACGCUCUCUGUCAUUGCtg Strong hit 0,431 0,903 
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ARF1 375 NM_001024228 214733 AACAGUUGAUUACUAAUCGtg Strong hit -0,562 0,171 
ARF1 375 NM_001658 288550 UAAAUUUAACAGCUCCAGCtt Strong hit -1,623 0,001 
ARF1 375 NM_001024227 288551 AAAUAGACCAGUUCUGAGGtt Strong hit -1,252 0,261 
ARHGAP1 392 NM_004308 14383 GCCCAUACUUGUCAUCUCCtg Non-hit -0,828 0,658 
ARHGAP1 392 NM_004308 14477 AUGCACGAUGUACAAGGCCtt Non-hit 0,053 0,995 
ARHGAP10 79658 NM_024605 31229 UGCGAGUAGUACAGUUCCCtt Non-hit -0,903 0,540 
ARHGAP10 79658 NM_024605 127413 UCUCCAUGUAACUCAUAGGtc Non-hit -0,288 0,649 
ARHGAP11
A 9824 NM_199357 21847 GCUGCUGUUUCAUGUCUCCtg Non-hit -1,444 0,023 
ARHGAP11
A 9824 NM_199357 21943 CUGAUUUCCGAAAAAGCCCtt Non-hit -0,552 0,012 
ARHGAP11
A 9824 NM_199357 140197 UUAGGCGAAUCACAGAUCCtg Non-hit 0,211 0,399 
ARHGAP11
A 9824 NM_199357 140198 GUGCAGAAGAUAGGCAACCtt Non-hit 1,210 0,333 
ARHGAP12 94134 NM_018287 26692 UUUUUCACCAAGAUGUACCtc Non-hit -0,771 0,047 
ARHGAP12 94134 NM_018287 128737 UAACAGGUGGCAUGAGAGCtt Non-hit -0,359 0,770 
ARHGAP15 55843 NM_018460 26915 UUCUCAUUUGCACAGCUCCtg Non-hit -0,328 0,847 
ARHGAP15 55843 NM_018460 132552 UUCUGUGUCUGGAUAUAGGtt Non-hit -0,228 0,719 
ARHGAP17 55114 NM_018054 26031 GGCAGUUUUUUGUGUCUCCtc Non-hit 0,104 0,795 
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ARHGAP17 55114 NM_018054 132261 CUUCCAGCUGAGUCGAUGCtt Non-hit -0,208 0,759 
ARHGAP17 55114 NM_001006634 132262 UAAAGUUGUACAUGUCUGCtg Non-hit 0,082 0,539 
ARHGAP17 55114 NM_018054 132263 AAUAGGAUUUUAAAGCACCtg Non-hit -1,306 0,018 
ARHGAP18 93663 NM_033515 35378 UAGUUCAUCCAAAGAAUCCtg Mild hit -1,326 0,606 
ARHGAP18 93663 NM_033515 128827 UGAUCGAUCAAAUGGAGGCtt Mild hit -1,054 0,125 
ARHGAP19 84986 NM_032900 34874 GUAUAUUGGUCUUGUUUCCtt Non-hit -0,603 0,159 
ARHGAP19 84986 NM_032900 35051 UAACUUUGUGAUAUUCUCCtg Non-hit 0,009 0,757 
ARHGAP20 57569 NM_020809 148781 UAGGAAAAGAUGCCGCUCCtg Mild hit -0,803 0,032 
ARHGAP20 57569 NM_020809 148782 AAUGCUCUUCGGGUAGUCCtt Mild hit -1,224 0,029 
ARHGAP22 58504 NM_021226 29210 UUCUCAGGUCAGCACUCCCtt Non-hit -0,204 0,546 
ARHGAP22 58504 NM_021226 147798 GAGCAGGUUGUAAUUUGCCtg Non-hit -0,265 0,605 
ARHGAP23 57636 XM_290799 272050 UAGGUCUUCCCAAUGACGCtt Non-hit -0,101 0,395 
ARHGAP23 57636 XM_290799 272051 CUUGGGCAUGAUAGACAGCtc Non-hit -0,433 0,713 
ARHGAP24 83478 NM_031305 33188 GUUUCUGUCCAAAAAUGCCtt Non-hit -0,238 0,637 
ARHGAP24 83478 NM_031305 33369 AUCAUUGUGAACUUUUUCCtc Non-hit 0,322 0,360 
ARHGAP24 83478 NM_031305 148939 CUCCUUAACAAGAUUAGCCtg Non-hit -0,019 0,678 
ARHGAP24 83478 NM_031305 148941 GCAAAUAUACUUGAGGAGGtt Non-hit 0,176 0,511 
ARHGAP25 9938 NM_014882 22105 CAGUUCUUCACGAUGGACCtc Non-hit -0,335 0,458 
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ARHGAP25 9938 NM_014882 22201 CUUCGUGUCCUCUUCAUCCtt Non-hit -0,230 0,526 
ARHGAP25 9938 NM_001007231 22297 AAGGUUUUUAAUCUGUUCCtc Non-hit 0,143 0,401 
ARHGAP25 9938 NM_014882 288610 UGAAUACAGCGAUGGAUGGtc Non-hit -0,530 0,315 
ARHGAP26 23092 NM_015071 22398 UAUGAGUGACUUCCCGUCCtt Non-hit -0,707 0,534 
ARHGAP26 23092 NM_015071 22590 AUUCUUAAUUCUCAUUCCCtg Non-hit -0,130 0,891 
ARHGAP27 201176 NM_199282 142018 GUCCACCUUAUAGCGUAGCtt Non-hit -0,181 0,681 
ARHGAP27 201176 NM_199282 142019 AAGCCCUCCAUCAAACUCCtc Non-hit 0,527 0,154 
ARHGAP28 79822 NM_030672 32666 ACUUUCUCUGUUUUGUUCCtt Non-hit 0,134 0,308 
ARHGAP28 79822 NM_030672 32759 AAAUCCCAUUGUCUCGUCCtt Non-hit 0,057 0,229 
ARHGAP28 79822 NM_001010000 32847 CUGAAAGUCGAAAAAUUCCtt Non-hit -0,736 0,050 
ARHGAP28 79822 NM_030672 288619 GUUCCACAGACUCAUUCGGtt Non-hit 0,320 0,960 
ARHGAP29 9411 NM_004815 122573 UAAAACACGGAGCAGUUCCtc Mild hit -1,148 0,079 
ARHGAP29 9411 NM_004815 122574 AUUUGUUAGCCUGGAGAGCtg Mild hit -0,691 0,093 
ARHGAP31 57514 NM_020754 219541 GUAUGUUUGAGGUGACUCCtg Non-hit 0,068 0,313 
ARHGAP31 57514 NM_020754 219542 UUCUUUAGACCUGAGGAGGtt Non-hit -0,285 0,617 
ARHGAP32 9743 NM_014715 21792 UGUGCAGCUUUGAAGAACCtg Non-hit -0,076 0,501 
ARHGAP32 9743 NM_014715 21983 UCGUGGAUUUUUAUCAGCCtt Non-hit -0,562 NA 
ARHGAP33 115703 NM_052948 35730 CAUUUCUGUACAAGGACCCtc Non-hit -0,260 0,088 
163 
 
Gene Symbol 
1 
Gene ID1 RefSeq  
Accession 
Number2 
siRNA ID3 Antisense (target) siRNA Sequence3 Hit gene4 Z-score 5 P-value 5 
ARHGAP33 115703 NM_052948 35819 AGUUACAAAGUUAGAAACCtg Non-hit 0,573 0,840 
ARHGAP39 80728 NM_025251 261264 CAGUACUUGGCAUACGUGCtt Strong hit 0,586 0,443 
ARHGAP39 80728 NM_025251 288618 GGUAGAGCUUGGUUUUUGGtc Strong hit -1,740 0,028 
ARHGAP4 393 NM_001666 10244 GCUCUCCAUGUGAUAUGCCtg Non-hit 0,220 0,802 
ARHGAP4 393 NM_001666 10340 AGCAUGCACCUCGAGAACCtt Non-hit -0,572 0,774 
ARHGAP44 9912 NM_014859 22182 AAUAUUUGGGAUUUCCACCtc Non-hit -0,201 0,879 
ARHGAP44 9912 NM_014859 22278 UCAUCUCUGUAAUGUUCCCtt Non-hit 0,016 0,381 
ARHGAP5 394 NM_001173 9456 UUCCAACUCCACAGUUACCtt Non-hit -0,460 0,051 
ARHGAP5 394 NM_001030055 9551 CAUUGUUUACUACUCGUCCtc Non-hit 0,199 0,589 
ARHGAP5 394 NM_001030055 147081 GCUAAGCACAGAAGUAUGCtc Non-hit 0,427 0,151 
ARHGAP5 394 NM_001173 147082 GUCUUGUUCUAAGCCUAGCtg Non-hit -0,137 0,792 
ARHGAP6 395 NM_006125 20636 UUCCUUUUUACUUUGAGCCtc Strong hit -1,067 0,336 
ARHGAP6 395 NM_013427 121662 AGAUGCAUCUUUCUGCUCGtc Strong hit -0,395 0,595 
ARHGAP6 395 NM_013423 288604 UGAUUGUCAUCAAGAUCGGtg Strong hit -1,505 0,016 
ARHGAP6 395 NM_013423 288605 AAUCCCACGGUCAAAUUCCtc Strong hit -0,787 0,009 
ARHGAP6 395 NM_013423 288606 AGGUUGGGUCCAAAUAUGGtg Strong hit -0,754 0,005 
ARHGAP6 395 NM_013427 288607 CAGGCUGAUCAGCACUUCGtt Strong hit 0,082 0,827 
ARHGAP6 395 NM_001174 20459 UAAGGGCAUUCCAAAUGCCtg Strong hit -0,067 0,628 
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ARHGAP6 395 NM_001174 20550 UGCUUGAGUUUAUAGGCCCtg Strong hit -2,109 0,001 
ARHGAP6 395 NM_001174 121663 CUGAGAGAUGAGUUACUGCtt Strong hit -0,659 0,013 
ARHGAP6 395 NM_001174 121664 UCAUUCGGUGUUUCUGAGGtt Strong hit 0,813 0,222 
ARHGAP9 64333 NM_032496 34278 UUCUGACGGCAAGUCUUCCtg Non-hit 0,386 0,665 
ARHGAP9 64333 NM_032496 34374 UGCAGGACAUCAUUGUUCCtc Non-hit -0,675 0,772 
ARHGDIA 396 NM_004309 14384 UUGGUCCCUUGUUUGUUCCtg Non-hit -0,238 0,258 
ARHGDIA 396 NM_004309 119907 CUUCAGCACAAACGACUGCtt Non-hit -0,079 0,569 
ARHGDIB 397 NM_001175 9457 AUCAUCUUUGUCCAUUUCCtg Non-hit 0,293 0,283 
ARHGDIB 397 NM_001175 9552 CUUUAACACAAUGGUUUCCtt Non-hit 0,221 0,626 
ARHGDIG 398 NM_001176 9458 AUCUCCAAGAGGCUCUUCCtc Non-hit -0,637 0,944 
ARHGDIG 398 NM_001176 9553 CAGGACAAACACCUGGUCCtt Non-hit -0,381 0,527 
ARHGEF1 9138 NM_004706 5309 GUUCUCAAAAUCCUCAUCCtc Mild hit -0,558 0,105 
ARHGEF1 9138 NM_199002 5491 UUUUUCCGGAAGAAGUUCCtc Mild hit -1,387 0,047 
ARHGEF1 9138 NM_199002 119420 UUCUUGUCUCCACUCUUGGtc Mild hit 0,580 0,206 
ARHGEF1 9138 NM_199002 119421 AGCACACCAGUUUUUCCGCtc Mild hit 0,155 0,943 
ARHGEF1 9138 NM_199002 119422 UAGAAGGCUUUGUGAUCGGtg Mild hit 0,395 0,900 
ARHGEF1 9138 NM_004706 214561 UAAAAAGGACGUAGAAGGCtt Mild hit -1,299 0,070 
ARHGEF10 9639 NM_014629 21727 AAAUAAGCCUUUGUAAACCtg Non-hit -0,477 0,247 
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ARHGEF10 9639 NM_014629 138290 UAGGUCAUGAGAAAGUUGCtt Non-hit -0,349 0,594 
ARHGEF10L 55160 NM_001011722 26281 CUGGAUGAGCACAUUGUCCtt Non-hit -0,346 0,126 
ARHGEF10L 55160 NM_018125 26377 GUACACCUUAUUCUGAGCCtg Non-hit -0,244 0,902 
ARHGEF10L 55160 NM_018125 123057 CAAACAAGUGAUACUGGGCtt Non-hit -0,713 0,251 
ARHGEF10L 55160 NM_018125 123058 GGCACAGACAAGCAUGUCGtt Non-hit -0,102 0,914 
ARHGEF11 9826 NM_198236 21848 UUUUUGAACUUCGGGAUCCtg Non-hit -0,962 0,542 
ARHGEF11 9826 NM_198236 119417 AGAUGCCCAUGGAUGAAGGtg Non-hit -0,501 0,127 
ARHGEF11 9826 NM_198236 119418 UGGGCUUUGAUCUACACCCtg Non-hit -0,271 0,585 
ARHGEF11 9826 NM_014784 214646 GUUGUUGAAAUAACCCGGGtc Non-hit -1,221 0,052 
ARHGEF12 23365 NM_015313 22673 UAUCUCGGAUCUACUCUCCtc Mild hit -0,590 0,424 
ARHGEF12 23365 NM_015313 119311 AUCUGUUGGUGACUCUCGGtt Mild hit -1,066 0,939 
ARHGEF15 22899 NM_173728 122079 CAUUCACAUCUGCUCUCGCtt Non-hit -0,017 0,185 
ARHGEF15 22899 NM_173728 122080 AGACAGGACCAGUCAUUGCtg Non-hit -0,674 0,874 
ARHGEF16 27237 NM_014448 42188 UCCUCGAAGAACCUCUGACtg Non-hit -0,680 0,644 
ARHGEF16 27237 NM_014448 42260 GCUCUCCUCGCUCUUCUUCtt Non-hit -0,139 0,591 
ARHGEF17 9828 NM_014786 21850 GUACGAGGGAAAGCUCACCtt Non-hit -0,515 0,019 
ARHGEF17 9828 NM_014786 21946 AGACCAUAGGUCGUCGUCCtt Non-hit 0,292 0,776 
ARHGEF18 23370 NM_015318 43400 AAUCGGCUUCAUCCAUCUCtc Non-hit -0,095 0,997 
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ARHGEF18 23370 NM_015318 43583 ACUUGUAAUGACUAACAGCtt Non-hit -0,276 0,884 
ARHGEF2 9181 NM_004723 15160 CAUAGCACAUGGUCAUGCCtg Mild hit -1,081 0,294 
ARHGEF2 9181 NM_004723 15256 CUGUUGCUUCUGCUUGACCtt Mild hit -0,178 0,606 
ARHGEF25 115557 NM_182947 36435 CUUCUUCUUCUGUUCCUCCtc Non-hit -1,305 0,009 
ARHGEF25 115557 NM_182947 141956 GUUCUCAUAUGGUCCUGCCtg Non-hit -0,411 0,443 
ARHGEF26 26084 NM_015595 22998 AGUCAACCCAGUAAGGUCCtc Non-hit -0,627 0,065 
ARHGEF26 26084 NM_015595 121751 AUCCGUAAUUAGUAACCCGtt Non-hit -0,248 0,691 
ARHGEF3 50650 NM_019555 27760 CCGUUUAUUACUAGGCUCCtc Non-hit -0,761 0,065 
ARHGEF3 50650 NM_019555 135243 GACCCGUUUAUUACUAGGCtc Non-hit 0,744 0,202 
ARHGEF38 54848 NM_017700 25195 AGCAUAUAGAGUCUAGACCtc Strong hit -0,024 0,984 
ARHGEF38 54848 NM_017700 25387 AUAGGAUUUAUGUGAGACCtt Strong hit 1,702 0,005 
ARHGEF4 50649 NM_015320 22774 CAGGUCAUCAUACAGGUCCtc Non-hit -0,380 0,390 
ARHGEF4 50649 NM_032995 22869 UCAACAUCCUUGAAGUCCCtg Non-hit -1,161 0,211 
ARHGEF4 50649 NM_032995 119317 AGUAGAUCUGGAAGUCGGCtt Non-hit -0,527 0,807 
ARHGEF4 50649 NM_032995 119318 CAAGGCGGCUUCAACAUCCtt Non-hit 0,373 0,065 
ARHGEF5 7984 NM_005435 2841 AAUCAGCUCAAAUUUGACCtc Non-hit -0,184 0,658 
ARHGEF5 7984 NM_005435 3027 UUCUAGGUUAGAAGAUACCtt Non-hit -0,389 0,510 
ARHGEF5 7984 NM_005435 121538 ACGAGAGAAGAGCCAUUGGtg Non-hit -1,434 0,164 
167 
 
Gene Symbol 
1 
Gene ID1 RefSeq  
Accession 
Number2 
siRNA ID3 Antisense (target) siRNA Sequence3 Hit gene4 Z-score 5 P-value 5 
ARHGEF5 7984 NM_005435 288577 CUGGAUUUUGUCCUUGAGCtt Non-hit 0,112 0,240 
ARHGEF6 9459 NM_004840 5326 CGAGGACUUUAAAAACUCCtc Non-hit -0,692 0,393 
ARHGEF6 9459 NM_004840 119232 UUUCAAAUCCUUUGACGGCtt Non-hit -0,309 0,665 
ARHGEF7 8874 NM_145735 38124 UGAGAAGGAAAGCUCGUCCtc Non-hit -0,588 0,156 
ARHGEF7 8874 NM_145735 38215 UGGCAGUCGUAUCAAAUCCtt Non-hit -0,962 0,032 
ARHGEF7 8874 NM_145735 38295 UCUAUCUGUAUGAUAAUCCtc Non-hit -0,483 0,899 
ARHGEF7 8874 NM_145735 119396 UGCAAUGGCCGUAGGUACGtt Non-hit -0,014 0,865 
ARHGEF9 23229 NM_015185 22731 UCGUCACUGAACAUGUCCCtt Non-hit 0,263 0,818 
ARHGEF9 23229 NM_015185 22826 AAUGUUCCCAAAGAUUACCtt Non-hit -0,765 0,616 
ASAP1 50807 NM_018482 42901 AACUGUGUGAAGGGUUGACtt Strong hit 0,369 0,494 
ASAP1 50807 NM_018482 43082 AGCAUGGGAAAAGAAACACtt Strong hit 2,265 0,111 
BCAR1 9564 NM_014567 21515 CACCGUCAUGAUGUCACCCtt Non-hit -0,147 0,343 
BCAR1 9564 NM_014567 21608 UGGCACCUGGUAAAUAUCCtg Non-hit 0,066 0,578 
BCR 613 NM_004327 1237 GUCAUAGCUCUUCUUUUCCtt Non-hit 0,576 0,851 
BCR 613 NM_021574 1332 CACCUCUUUGUCGUUGACCtt Non-hit -0,423 0,661 
BCR 613 NM_004327 1427 UUUUCAUAGCACAGUAUCCtc Non-hit -0,871 0,183 
BCR 613 NM_021574 110844 GUUCUUGGUCGUUGGAUCCtt Non-hit -0,960 0,048 
BCR 613 NM_021574 147329 GUCCGACACCUCUUUGUCGtt Non-hit -0,146 0,734 
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BCR 613 NM_021574 147330 UCCAGAGAGUUCUUGGUCGtt Non-hit -0,412 0,673 
BCR 613 NM_021574 147331 UCAGAGGAGAUCAGGAACGtg Non-hit -0,514 0,259 
BCR 613 NM_021574 214833 UGGGACCUUUAGACUUCGGtg Non-hit 1,061 0,075 
CALR 811 NM_004343 14400 UCCGUCCAGAAACUGCUCCtt Mild hit -1,024 0,280 
CALR 811 NM_004343 14494 CAAACCUUUAUCUUUCUCCtc Mild hit -0,521 0,676 
CANX 821 NM_001746 10290 GACAUCGUCAAGGUCAUCCtc Non-hit -1,489 0,002 
CANX 821 NM_001746 10385 UGGUUUUGAGUCUUCUACCtc Non-hit -0,168 0,963 
CANX 821 NM_001024649 10472 UCCAUUUUGGAAAUUAACCtc Non-hit -0,966 0,061 
CANX 821 NM_001746 145945 CUAGUGUUCAACUGGAGCCtg Non-hit -0,045 0,069 
CAPN1 823 NM_005186 15805 AUUUACCUUGGCAUAGGCCtt Strong hit -1,754 0,169 
CAPN1 823 NM_005186 15898 GAAGUUCUCGUCAAUCUCCtc Strong hit -0,759 0,037 
CAPN2 824 NM_001748 10292 UUGAGGUACUUGAUGGCCCtc Non-hit 0,215 0,266 
CAPN2 824 NM_001748 10387 GAUCCCUGCAUAGUUUUCCtg Non-hit 0,455 0,429 
CAPNS1 826 NM_001003962 10293 AGGGUGUCGUGUCACAACCtt Non-hit -1,128 0,010 
CAPNS1 826 NM_001749 10388 CCACAAGUACUUGAAUUCCtc Non-hit -0,323 0,119 
CAPNS1 826 NM_001003962 10475 GAACUGUUUGUAUAUGGCCtg Non-hit 1,245 0,097 
CAPNS1 826 NM_001003962 105571 UGAUCGGUCAGUGUCGAACtg Non-hit -0,121 0,539 
CAV1 857 NM_001753 10297 GUUGACCAGGUCGAUCUCCtt Mild hit -0,976 0,133 
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CAV1 857 NM_001753 145951 CGGUAAAACCAGUAUUUCGtc Mild hit -1,140 0,010 
CAV2 858 NM_198212 9481 GGGUCCAAGUAUUCAAUCCtg Non-hit -0,147 0,354 
CAV2 858 NM_001233 9575 GUAUCCCAAUCUCCAGACCtg Non-hit -0,757 0,540 
CAV2 858 NM_198212 145680 CCAAGUAUUCAAUCCUGGCtc Non-hit 0,850 0,002 
CAV2 858 NM_198212 145681 UACUAUAAUCGUUGUGUGCtt Non-hit -0,712 0,635 
CBL 867 NM_005188 2827 CAUUCUUUCUUUUCCCUCCtt Non-hit -0,478 0,277 
CBL 867 NM_005188 2921 AUACAUUCUUUCUUUUCCCtc Non-hit 0,248 0,913 
CD151 977 NM_139030 43352 CAGGCUGAUGUAGUCACUCtt Non-hit -0,166 0,778 
CD151 977 NM_004357 43447 AGCAGGCUGAUGUAGUCACtc Non-hit 0,204 0,774 
CD151 977 NM_139030 43538 CUGGAUGAAGGUCUCCAACtt Non-hit -0,265 0,795 
CD151 977 NM_139030 288629 GGUCAUGGUGUCCUUCAGGtt Non-hit -0,874 0,243 
CD81 975 NM_004356 14407 AUCCUUGGCGAUCUGGUCCtt Non-hit 0,016 0,340 
CD81 975 NM_004356 14501 AUAGAACUGCUUCACAUCCtt Non-hit -0,990 0,072 
CDC42 998 NM_001791 10324 UGUCAUAAUCCUCUUGCCCtg Non-hit -0,392 0,778 
CDC42 998 NM_044472 10418 UCGUAAUCUGUCAUAAUCCtc Non-hit -0,580 0,601 
CDC42 998 NM_001791 242554 ACAUCUGUUUGUGGAUAACtc Non-hit -1,089 0,010 
CDC42 998 NM_044472 242555 AGGAGUCUUUGGACAGUGGtg Non-hit -0,704 0,824 
CENPE 1062 NM_001813 10520 AUAUAGUACCAUUGUAGCCtt Mild hit -1,011 0,212 
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CENPE 1062 NM_001813 121337 UGGCAGAAUCGAUGAUUGGtg Mild hit 0,251 0,942 
CFL1 1072 NM_005507 5366 GAUGAUGUUCUUCUUGUCCtc Non-hit -0,640 0,794 
CFL1 1072 NM_005507 5455 AUCCUCCUUCUUGCUCUCCtt Non-hit -0,133 0,507 
CHN1 1123 NM_001025201 10528 AAGCCAAAGUGUAGGUCCCtg Strong hit -0,147 0,655 
CHN1 1123 NM_001025201 10622 UUGCCAUCGUAGUAGAGCCtg Strong hit 2,737 0,000 
CHN1 1123 NM_001025201 146034 AGCCACAAUCAAGAGCUGGtc Strong hit 0,165 0,756 
CHN1 1123 NM_001025201 146035 GGUUGUGUAUCCUACGUGCtc Strong hit 1,323 0,098 
CHN2 1124 NM_004067 14167 AAGGUCUGGUUUCCAAACCtg Mild hit 0,828 0,411 
CHN2 1124 NM_004067 146298 CACAAAGUGUUUCCCGUCGtg Mild hit -1,194 0,006 
CIB1 10519 NM_006384 17715 CCUGUCAAUGUCAGACUCCtc Mild hit -1,100 0,008 
CIB1 10519 NM_006384 17808 AGGUUGAUGGUUCCAUCCCtg Mild hit -0,506 0,977 
CKAP5  9793 NM_001008938 21827 UCUUCAUACCCACUUAACCtt Non-hit -0,177 0,958 
CKAP5  9793 NM_001008938 21923 CAAGUGCAGCUUCUAAUCCtt Non-hit -1,102 0,093 
CKAP5  9793 NM_001008938 22017 UAUGUGAACAGCUAUUUCCtt Non-hit -0,162 0,707 
CKAP5  9793 NM_014756 122703 CAUACCCACUUAACCUUGCtt Non-hit 0,143 0,817 
CLASP1 23332 NM_015282 136866 ACAAGUUUAUCUAACAUGGtc Non-hit 0,024 0,391 
CLASP1 23332 NM_015282 136867 UUAGUGUUAAAGUCUGUGCtc Non-hit -0,348 0,828 
CLASP2 23122 NM_015097 261144 UAGUUUCAACCAAGACGGCtg Non-hit -0,394 0,174 
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CLASP2 23122 NM_015097 261145 UGGUAAUUUUUGAGUCGGCtg Non-hit -0,202 0,226 
CLIP1 6249 NM_002956 12224 GUCAUCCACAAAUUCCUCCtg Mild hit -0,082 0,767 
CLIP1 6249 NM_198240 12317 AAAGUCAUCCACAAAUUCCtc Mild hit -0,450 0,567 
CLIP1 6249 NM_198240 142516 UCCAUUCACCCAAACUCGCtc Mild hit -1,218 0,132 
CLIP1 6249 NM_002956 142517 ACUGGAAAUACCGAACUCCtg Mild hit -1,049 0,184 
CLIP2 7461 NM_032421 43346 CGAAUGCAAUGACAGGUUCtg Non-hit -0,317 0,745 
CLIP2 7461 NM_032421 43442 GGAAGCCGAUACGGAUCACtt Non-hit 0,163 0,476 
CLIP2 7461 NM_003388 43533 CUCGUAGUCCAACAUCUUCtt Non-hit -0,735 0,120 
CLIP2 7461 NM_032421 139011 UCGCCUGACUUACACUUGCtc Non-hit 0,833 0,121 
COPB1 1315 NA   AUUAGGAUGUUGAAGAUCCtt Non-hit -0,660 0,027 
CRK 1398 NM_005206 6472 GAGAAUCACUCCACUACCCtg Mild hit -0,631 0,232 
CRK 1398 NM_016823 146743 GAGGCAAGAUACCUAUCCCtt Mild hit -1,137 0,146 
CRK 1398 NM_016823 146744 AGUUAGGACUCUAGUUAGCtg Mild hit -0,053 0,964 
CRK 1398 NM_005206 146745 UCGCCAUUUGAUAGUAUGGtt Mild hit -1,433 0,042 
CRKL 1399 NM_005207 2828 CGGCAAAUGGUCAAAUUCCtg Non-hit 0,195 0,648 
CRKL 1399 NM_005207 2922 AUUGGUGGGCUUGGAUACCtg Non-hit -0,934 0,116 
CSK 1445 NM_004383 146413 GGCCCACCUUGUUUUUGGCtt Mild hit -1,344 0,036 
CSK 1445 NM_004383 146414 GUACAUGAUGCGGUAGUGCtc Mild hit 0,299 0,965 
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CSRP1 1465 NM_004078 14079 AUUUAUGGAAGCUGUUGCCtt Mild hit -1,322 0,275 
CSRP1 1465 NM_004078 14172 CUUCCCAGCACCAAUCACCtt Mild hit -0,023 0,971 
DCTN1 1639 NM_023019 14081 CAGGGUCUCUAGUUUCUCCtc Non-hit -0,826 0,118 
DCTN1 1639 NM_023019 146317 CAGCUGCAUAGUACAGUCCtc Non-hit 0,654 0,796 
DCTN1 1639 NM_023019 146318 UAGGAGCGUGUCAGAUACCtg Non-hit -1,007 0,077 
DCTN1 1639 NM_023019 242560 AUCAAUGGUGCUCUCUGCCtg Non-hit -0,346 0,169 
DIAPH1 1729 NM_005219 15997 AUUUCUUUUCUUCUCCACCtt Mild hit -1,239 0,632 
DIAPH1 1729 NM_005219 242566 AUAGUACUGAGGUCUGGCCtc Mild hit -0,733 0,747 
DIAPH2 1730 NM_007309 18467 GGGUUUGUUUUUCGUUUCCtc Non-hit 0,123 0,802 
DIAPH2 1730 NM_006729 18657 CUUCCUGAUUUUCUAAACCtt Non-hit 0,033 0,667 
DIAPH2 1730 NM_007309 146689 UCGUUCAUCAUAUAAUGGCtg Non-hit 0,890 0,019 
DIAPH2 1730 NM_007309 146690 UUCGUUAAGGUUCAUGUCCtc Non-hit -0,942 0,019 
DIAPH3 81624 NM_030932 32930 UCAUUUCUGAUGUGAAGCCtg Non-hit -0,896 0,196 
DIAPH3 81624 NM_030932 33026 AAGCUCAUUAAUCUUUGCCtc Non-hit 0,141 0,532 
DLC1 10395 NM_182643 17367 CGAAAGAGUCGUCAUUGCCtg Mild hit 0,705 0,085 
DLC1 10395 NM_024767 31555 GUUGGAAAAAUUGGAUCCCtt Mild hit 0,104 0,415 
DLC1 10395 NM_024767 31650 CCAGCAACAUGGAAAAGCCtc Mild hit 0,773 0,105 
DLC1 10395 NM_024767 46352 CAUCCACUUCCAACUUUACtg Mild hit -0,152 0,499 
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DLC1 10395 NM_182643 202494 CUAGUCCAUGAUGACAUGCtg Mild hit 1,415 0,272 
DLC1 10395 NM_182643 213191 GUCAGGUUUCCUUCGUUGCtg Mild hit 1,053 0,036 
DNM1 1759 NM_001005336 14616 GUCGGUGAAUUUCUUUCCCtt Non-hit 0,958 0,412 
DNM1 1759 NM_001005336 14711 CAGGAUGAGGCAGUUCUCCtt Non-hit -0,904 0,027 
DNM1 1759 NM_004408 14804 UAAUCCUUGUAGACAUUCCtc Non-hit 0,535 0,085 
DNM1 1759 NM_004408 146449 AGGUGUCGAUCUGAUCUCCtg Non-hit -0,594 0,020 
DNMBP 23268 NM_015221 136834 AAAAAUGCCUCUUCGGCCCtc Non-hit -0,033 0,212 
DNMBP 23268 NM_015221 136835 ACUGUAGAAUAAUACUGGCtt Non-hit 0,371 0,273 
DOCK1 1793 NM_001380 145822 UUAGACUUUUUUCGUAACGtg Mild hit -1,110 0,002 
DOCK1 1793 NM_001380 145823 ACACUUCGAAACAUCUCCCtg Mild hit 0,577 0,411 
DOCK10  55619 NM_014689 258559 CUUGAGUCGAUUCUGAAGGtg Non-hit 0,498 0,343 
DOCK10  55619 NM_014689 258560 UCCAUUGUGACAAGAGACCtg Non-hit -0,868 0,031 
DOCK11 139818 NM_144658 37496 UGAAAUUUGACUUUAGCCCtt Mild hit -1,257 0,351 
DOCK11 139818 NM_144658 129250 UAGACUGCACCGUUCUGCGtt Mild hit -0,763 0,606 
DOCK2 1794 NM_004946 146561 CUAUACCAGUCUCCACACGtc Non-hit -0,937 0,092 
DOCK2 1794 NM_004946 146562 UCUGACAAUCAAAUCAAGCtc Non-hit -0,644 0,374 
DOCK3 1795 NM_004947 146564 UGACCAGACAGUAGCUGCCtt Non-hit -0,488 0,396 
DOCK3 1795 NM_004947 146565 UGGGCGCAUUGUAUCUACCtg Non-hit -0,869 0,523 
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DOCK4 9732 NM_014705 21785 GCGUAUAUACAUCUCCUCCtt Non-hit -0,978 0,017 
DOCK4 9732 NM_014705 21881 GUAGCGUAUAUACAUCUCCtc Non-hit -0,357 0,538 
DOCK5 80005 NM_024940 31982 ACUGAGGUGAUGGACAACCtc Strong hit -0,928 0,052 
DOCK5 80005 NM_024940 130801 CUUGUUGUUCACGUAGAGCtt Strong hit -2,022 0,243 
DOCK6 57572 NM_020812 133244 AGACACUUGACCAAGAUCCtt Non-hit -0,330 0,782 
DOCK6 57572 NM_020812 133245 GGGCUUGAUAUGAAGCAGCtc Non-hit 0,629 0,328 
DOCK7 85440 NM_033407 147974 AUACUACGGCUGUAUAGGCtt Non-hit -0,761 0,716 
DOCK7 85440 NM_033407 147975 AGUUAAAGUAGCAGGAAGCtt Non-hit -0,837 0,359 
DOCK8 81704 NM_203447 149461 GUCCUACAUUCCUUUGGCGtg Non-hit -0,646 0,545 
DOCK8 81704 NM_203447 149462 CAGGAGGUUUUCUAGCCGCtt Non-hit 0,240 0,527 
DOCK9 23348 NM_015296 22669 UGAGCAUAUGUAUCGACCCtg Non-hit -0,147 0,918 
DOCK9 23348 NM_015296 22765 AAACAAGCUCUGUGCUUCCtc Non-hit -0,087 0,222 
DYNC1H1  1778 NM_001376 118309 CAUCAAUCACGGGAGUACGtt Mild hit -1,241 0,064 
DYNC1H1  1778 NM_001376 118310 CGGAAUUUCAAUAUUUUGCtg Mild hit -0,064 0,658 
DYNC1I1 1780 NM_004411 14617 CUUUUUCCUCUCCUCUUCCtt Non-hit -0,103 0,833 
DYNC1I1 1780 NM_004411 14712 UCAGCCUCUUUCUUUUUCCtc Non-hit -0,280 0,616 
DYNC1I2 1781 NM_001378 9741 CACAGGAGCAACAGCUUCCtt Non-hit -0,183 0,278 
DYNC1I2 1781 NM_001378 9836 UUCCAAGUUUAAUAGGUCCtc Non-hit -0,745 0,144 
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DYNC1LI1 51143 NM_016141 23822 CUUAUACUCCUCUAUUCCCtg Non-hit 0,466 0,546 
DYNC1LI1 51143 NM_016141 24008 AAUAUUCCAAUCCUCUUCCtt Non-hit 0,261 0,580 
DYNC1LI2 1783 NM_006141 17395 UUUUGCCAUGCUCAGCUCCtt Non-hit 1,178 0,084 
DYNC1LI2 1783 NM_006141 118326 UCCAUCCAGAAUCCACACGtt Non-hit -1,480 0,240 
DYNC2H1  79659 HSU53531 288695 UGGCAAUCAUCAACCAGCUtt Non-hit -0,366 0,123 
DYNC2H1  79659 HSU53531 288696 AAAUUAGGCUCUUCCAGUCta Non-hit 0,084 0,566 
DYNC2LI1 51626 NM_016008 124933 AGUGAGCGAUAUCUUUUGGtg Non-hit -0,941 0,185 
DYNC2LI1 51626 NM_001012665 215817 AAGCUAAGGUUGGUUUUGGtg Non-hit -0,623 0,274 
DYNLL1 8655 NM_001037495 13539 GUACUUCUUGUCAAAUUCCtt Non-hit -0,331 0,486 
DYNLL1 8655 NM_003746 118315 UGGUAUUUGGAAUUUAGGCtg Non-hit -0,905 0,150 
DYNLL2  140735 NM_080677 35969 AUUGUACUUCUCCAUGGCCtg Non-hit -0,099 0,426 
DYNLL2  140735 NM_080677 118341 GAUGAAGUGCUUUGUCUCGtg Non-hit -0,156 0,930 
DYNLRB1 83658 NM_014183 279206 AAGCUCUUGCUCCAAAACCtg Non-hit -0,133 0,952 
DYNLRB1 83658 NM_014183 279207 CGACAAAGUGAACUGAAGGtc Non-hit -0,304 0,506 
DYNLRB2 83657 NM_130897 36233 UUGUUCGGAUGGGAAUACCtt Mild hit -0,360 0,139 
DYNLRB2 83657 NM_130897 118342 CAGUGUCGCUUAAACAGCCtt Mild hit -1,031 0,495 
DYNLT1 6993 NM_006519 17983 AAUUGCGCUUUCUAUAGCCtc Non-hit 0,022 0,384 
DYNLT1 6993 NM_006519 139625 UUCUGCAUAAUUACACAGGtc Non-hit -0,504 0,289 
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DYNLT3  6990 NM_006520 17984 UACCAGAUUUAAUUUACCCtc Non-hit -0,616 0,166 
DYNLT3  6990 NM_006520 18077 GAUUCACUUUUUUCCUCCCtt Non-hit -0,522 0,609 
ECT2 1894 NM_018098 26070 AAAGCCCACUUUAAUGUCCtt Non-hit -0,052 0,587 
ECT2 1894 NM_018098 146755 AGUUAAUGCUAGACUCUGGtg Non-hit 0,459 0,297 
ENAH 55740 NM_018212 26351 ACUUGGGAAAGAGGUAUCCtc Non-hit -0,349 0,513 
ENAH 55740 NM_018212 26445 UCACACCAAUAGCAUUCCCtc Non-hit -0,026 0,746 
ENAH 55740 NM_018212 132358 GUUUAUCACGACCUGAUGGtc Non-hit -0,019 0,404 
ENAH 55740 NM_018212 132359 GGUGGAAGGUCUGUGUAGCtt Non-hit -1,186 0,050 
EVL 51466 NM_016337 24121 GAUCACAACCUGCUGAUCCtg Non-hit 0,013 0,708 
EVL 51466 NM_016337 24216 UGAAUAAUUGAUCACAACCtg Non-hit -0,282 0,731 
EZR 7430 NM_003379 13018 GCCGAUAGUCUUUACCACCtg Strong hit -1,513 0,141 
EZR 7430 NM_003379 13110 UCAGCCAGGUAGGAAAUCCtt Strong hit -0,387 0,382 
FAM13B  51306 NM_016603 135118 AUCUAAGAAGGCUAAUAGCtg Non-hit -0,587 0,887 
FAM13B  51306 NM_016603 135119 GAAUACUGACACACGCUGCtt Non-hit 0,721 0,097 
FARP1 10160 NM_005766 16818 UGAUGGACACGAGUUUUCCtg Non-hit -0,201 0,945 
FARP1 10160 NM_005766 16914 UGGAACUUCAAAUGCCUCCtg Non-hit -0,930 0,212 
FARP1 10160 NM_005766 138078 ACAACAACGUGCUUUGGCCtt Non-hit -0,357 0,655 
FARP1 10160 NM_001001715 215120 UGUCCACGUUCCAAGGUACtg Non-hit 0,352 0,485 
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FARP2 9855 NM_014808 22052 CACUUGUGUCAGUAAUACCtg Mild hit -1,016 0,004 
FARP2 9855 NM_014808 22148 AGCACCACAUUCUUUGGCCtt Mild hit -0,003 0,260 
FBLIM1  54751 NM_001024216 108962 AGGCACUUUUUAAGGGACCtt Non-hit -0,184 0,184 
FBLIM1  54751 NM_001024216 279293 CAUUGAAGAGCUGCAUAGGtg Non-hit 0,020 0,647 
FBLIM1  54751 NM_017556 279294 CCAUCCUUCUGGUAGAAGCtc Non-hit -0,165 0,775 
FBLIM1  54751 NM_001024216 288613 CCACCCUCUUCUCAGGCUUtg Non-hit 0,103 0,396 
FBLIM1  54751 NM_017556 288614 UUCCUCCGCCACGGCCACAtc Non-hit -0,869 0,264 
FBLIM1  54751 NM_017556 288615 GCCUCACAAACUGCCUGCCtc Non-hit -0,750 0,228 
FERMT2 10979 NM_006832 136119 AUACCAUACUUAUCUAAGGtc Mild hit -0,031 0,167 
FERMT2 10979 NM_006832 136120 GAUAGAUUAAUAGUCGUGCtt Mild hit -1,076 0,297 
FGD1 2245 NM_004463 14738 UUCUCUGUCCUUCUCUUCCtc Mild hit -1,355 0,022 
FGD1 2245 NM_004463 14826 CAGCUUUAACAGAUAGUCCtt Mild hit -0,747 0,192 
FGD2 221472 NM_173558 40846 UUCAGGGAGUUCAGGUACCtc Non-hit 0,248 0,412 
FGD2 221472 NM_173558 41034 CAUCCAGGAAAUCAUUUCCtc Non-hit -0,018 0,817 
FGD3 89846 NM_033086 131558 CUUUAAGCUACCACUCAGCtc Non-hit 0,398 0,168 
FGD3 89846 NM_033086 131559 GACACACCCACAUCUAUCCtg Non-hit 0,028 0,976 
FGD4 121512 NM_139241 129200 GGUUCUAGGAGCAUUUAGGtt Non-hit -0,070 0,947 
FGD4 121512 NM_139241 129201 GUGGUUGUCAAUCCAUGCCtt Non-hit 0,100 0,431 
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FGD6 55785 NM_018351 26648 UAAUCUGUCAGCAACAGCCtg Non-hit 0,137 0,781 
FGD6 55785 NM_018351 26743 GUUUCUGAAAGUUGUCUCCtt Non-hit 0,052 0,988 
ARHGEF25 115557 AK057416 288683 CAGGACAAUUAGGUUUGGUtc Non-hit -0,854 0,011 
ARHGEF25 115557 AK057416 288684 GUGGGUGGGUUGCAGAACUta Non-hit 0,460 0,261 
FLNA 2316 NM_001456 9963 GCUUCUUCACCAUGUUGCCtg Non-hit -0,360 0,643 
FLNA 2316 NM_001456 144674 AUUGUCCAAGCACUCGAGCtg Non-hit 0,044 0,466 
FLNB 2317 NM_001457 9964 UUCUUCAGGAGUGAUGACCtg Mild hit 0,449 0,903 
FLNB 2317 NM_001457 10059 CAAACACCAUCACGUCUCCtt Mild hit -1,495 0,022 
FLNC 2318 NM_001458 9965 ACCAGGUUUGAGCUUGGCCtt Mild hit 0,015 0,759 
FLNC 2318 NM_001458 10060 GUCAUUGUUGGGAACCACCtt Mild hit -1,165 0,024 
FYN 2534 NM_153048 1442 CUCCAAAGACGGUGAGUCCtt Mild hit -0,393 0,188 
FYN 2534 NM_153047 1537 GAGACGAAGAGUUCACACCtc Mild hit -0,339 0,169 
FYN 2534 NM_002037 1627 AGAAAUCCAGUAAACUUCCtt Mild hit 0,711 0,586 
FYN 2534 NM_153048 144827 CCACAAAGAGUGUCACUCCtg Mild hit -0,131 0,208 
FYN 2534 NM_153048 144828 AAAGGACAAUAGCUGUCGCtc Mild hit -0,482 0,815 
FYN 2534 NM_153047 144829 CGCGGAUAAGAAAGGUACCtc Mild hit -0,268 0,508 
GAPD 2597 NM_002046 42838 AAAGUUGUCAUGGAUGACCtt Mild hit -1,245 0,463 
GAPD 2597 NM_002046 44902 AAGCUUCCCGUUCUCAGCCtt Mild hit -0,589 0,712 
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ARHGEF25 115557 NM_133483 36531 AGCCUUCUUCUUCUGUUCCtc Non-hit -0,699 0,029 
ARHGEF25 115557 NM_133483 36623 AUAUUCCCAAACACAAUCCtg Non-hit -0,123 0,719 
GIT1 28964 NM_014030 20497 UAUUGGCACUCAACCAGCCtt Non-hit 0,224 0,457 
GIT1 28964 NM_014030 20586 AUUUUCUCUUCGAUCCACCtc Non-hit -0,907 0,820 
GIT2 9815 NM_057170 35700 GGUGUGUGUUUCAGAUGCCtc Non-hit -0,046 0,858 
GIT2 9815 NM_057169 35791 AUUGGGAUGUACUUUAUCCtg Non-hit -0,136 0,735 
GIT2 9815 NM_057169 35874 UUUUUGUGAUCUGGUUUCCtg Non-hit -1,019 0,096 
GIT2 9815 NM_057170 138618 GCACCGUUAUUAUACAAGGtc Non-hit -0,902 0,055 
GIT2 9815 NM_057170 138619 CCAUAUAGAGUUAGCACCGtt Non-hit -0,704 0,407 
GIT2 9815 NM_057170 138620 ACUCAUAAUAGACGCAGGGtc Non-hit -0,254 0,721 
GIT2 9815 NM_057170 288632 GAUGGUUUUCAGUAUGAGCtc Non-hit -0,521 0,979 
GIT2 9815 NM_057170 288631 CACUCAUCACAUAAAAACGtt Non-hit -0,779 0,223 
GMIP 51291 NM_016573 24794 UUUUUCCUUAUAGGAACCCtc Non-hit -0,274 0,024 
GMIP 51291 NM_016573 108901 CCCAAAAGGGUUUUAGGCCtc Non-hit 0,611 0,375 
GNB2L1 10399 NM_006098 3664 CCAUAGUUGGUCUCAUCCCtg Non-hit -0,567 0,795 
GNB2L1 10399 NM_006098 3757 GUUAGCCAGGUUCCAUACCtt Non-hit -0,544 0,991 
GRB2 2885 NM_203506 4196 ACAUUCUUCGUUCAAAACCtt Non-hit -0,814 0,099 
GRB2 2885 NM_002086 4292 UUUUCCAUUAAGCUCUGCCtt Non-hit -0,753 0,183 
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GRB2 2885 NM_203506 106680 GCUAGGACUAUACGUGGCCtt Non-hit -0,383 0,992 
GRB2 2885 NM_203506 144866 CGUCAGCUAGGACUAUACGtg Non-hit -1,080 0,238 
GRB7 2886 NM_005310 2834 UCCUCCUCUCGAAGUUUCCtg Non-hit 0,638 0,282 
GRB7 2886 NM_001030002 2928 CCCAUCCUCACUGUACACCtt Non-hit -0,515 0,056 
GRB7 2886 NM_001030002 3020 CACUUCUCCCAUAAUUCCCtg Non-hit -0,316 0,926 
GRB7 2886 NM_005310 288576 CACGUACACGUUGGACUCGtt Non-hit -0,386 0,135 
GRLF1 2909 AF159851 288677 GGAGACAAACUUGAGCUGGtc Non-hit -0,815 0,052 
GRLF1 2909 AF159851 288678 CUUUUUUGUUUUUGCAAGCtg Non-hit -0,126 0,620 
GSN 2934 NM_000177 8031 AUCCUGAUGCCACACCUCCtt Non-hit -0,749 0,171 
GSN 2934 NM_000177 8127 UGAAUCCUGAUGCCACACCtc Non-hit 0,019 0,574 
GSN 2934 NM_000177 8218 UUCUUCUUCUUGAGAAUCCtt Non-hit 0,028 0,871 
GSN 2934 NM_198252 242584 UUGAAGUAGCCUAGGAAGGtg Non-hit -0,150 0,651 
HMHA1 23526 NM_012292 147474 AUCUGGUAGUAGGAGAUCGtg Mild hit -1,280 0,232 
HMHA1 23526 NM_012292 147475 GAAAGAACCACACGGUGGCtt Mild hit -0,662 0,410 
ILK 3611 NM_001014794 1461 CACGACAAUGUCAUUGCCCtg Non-hit -0,375 0,978 
ILK 3611 NM_001014795 1556 CAAAGCAAACUUCACAGCCtg Non-hit -1,308 0,034 
ILK 3611 NM_004517 145116 GGUUCAUUACAUUGAUCCGtg Non-hit 2,838 0,016 
ILK 3611 NM_001014795 145117 AGAGUGAUUCUCGUUGAGCtt Non-hit 0,926 0,246 
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ILK 3611 NM_001014795 145118 CUUCUGUACAAUAUCACGGtg Non-hit -1,160 0,000 
ILK 3611 NM_001014795 288570 GCACUGAGUGAAAAUGUCGtc Non-hit 0,205 0,523 
INCENP 3619 NM_020238 28431 AAUCUGCUUCUUCUUCUCCTC Non-hit -0,041 0,742 
IQGAP1 8826 NM_003870 13799 UCUCCUUUCAUCCAUCUCCtc Non-hit -0,130 0,610 
IQGAP1 8826 NM_003870 13894 UUCUUCUGUGAAGUCAACCtt Non-hit -0,372 0,944 
ITGB1 3688 NM_133376 35488 GUGCAGAAGUAGGCAUUCCtt Mild hit -0,509 0,242 
ITGB1 3688 NM_133376 109877 UUGGAUCUGAGUAAUAUCCtc Mild hit 0,136 0,627 
ITGB1 3688 NM_033668 109878 UCACUUGUGCAAGGGUUCCtg Mild hit -0,992 0,018 
ITGB1 3688 NM_133376 109879 GUUAAAAUAGGAACAUUCCtg Mild hit -1,312 0,006 
ITGB1 3688 NM_033668 112291 ACCCACAAUUUGGCCCUGCtt Mild hit -0,208 0,678 
ITGB1 3688 NM_002211 112292 UUGGAUCUGAGUAAUAUCCtc Mild hit -1,032 0,284 
ITGB1 3688 NM_133376 112293 GUACAUAUUAUUUUCCAGGtg Mild hit -0,676 0,104 
ITGB1 3688 NM_133376 288621 CAAAUUUCCAGAUAUGCGCtg Mild hit -1,328 0,102 
ITGB1 3688 NM_133376 288622 CAGAUAAUGUUCCUACUGCtg Mild hit -1,133 0,013 
ITGB1 3688 NM_033668 288625 UUUAAAGCUGUCAGAAUCCtt Mild hit 0,033 0,929 
ITGB1 3688 NM_033669 35396 AGAAGUAGGCAUUCCUUCCtg Mild hit -0,539 0,532 
ITGB1 3688 NM_033666 35575 GCUAAUUUCAAAUUGAACCtc Mild hit -0,269 0,118 
ITGB1BP1 9270 NM_022334 44218 AGGCAACUUUCCAUCUUGCtg Non-hit -1,412 0,029 
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ITGB1BP1 9270 NM_022334 44998 CAUCUCGUCUUCGUGACACtt Non-hit 0,579 0,339 
ITGB1BP1 9270 NM_004763 137692 CGUCUUCGUGACACUUAGGtt Non-hit -0,685 0,656 
ITGB1BP1 9270 NM_004763 137693 GAGCGGUAAUCUUUUAAGGtt Non-hit -0,810 0,024 
ITGB3 3690 NM_000212 8055 AUCCUUCAGCAGAUUCUCCtt Non-hit -0,139 0,723 
ITGB3 3690 NM_000212 106001 CUAAUAGUUCAGCUCUCCCtg Non-hit -0,593 0,406 
ITGB3BP 23421 NM_014288 21001 UUCAAGCUCUCUACUGCCCtc Strong hit -2,114 0,021 
ITGB3BP 23421 NM_014288 21093 AUGCUUUGUGAGGAAGUCCtg Strong hit 0,205 0,488 
ITGB4 3691 NM_001005731 2793 GAACAUCUUGGAGGUGACCtc Non-hit -0,602 0,959 
ITGB4 3691 NM_001005619 2888 AUGUGAAAGGACCCAGUCCtc Non-hit -1,882 0,040 
ITGB4 3691 NM_001005731 2981 UUUCAGAUGGAUGUUGCCCtt Non-hit -1,026 0,148 
ITGB4 3691 NM_001005731 288542 AAUAGGUCGGUUGUCAUCGtt Non-hit 0,217 0,919 
ITGB4 3691 NM_001005731 288543 UCGCUGUACAUAAGGAAGCtg Non-hit 0,877 0,213 
ITGB4 3691 NM_001005731 288544 CAGUUGAAAUGGAUCUUCCtg Non-hit 0,999 0,415 
ITGB5 3693 NM_002213 11108 UAGUGCAUAUGUUGAGACCtg Non-hit 0,537 0,305 
ITGB5 3693 NM_002213 11289 AAAGAAGAGAUUAAGAUCCtc Non-hit 0,376 0,636 
ITGB6 3694 NM_000888 8947 CUUCACAGGUUUCUGCACCtc Non-hit 0,061 0,205 
ITGB6 3694 NM_000888 9041 UGGAUGAGUAAAAUUCUCCtg Non-hit -0,415 0,690 
ITSN1 6453 NM_001001132 12452 CAGAGGGUAGCUGAUAUCCtt Non-hit -0,808 0,347 
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ITSN1 6453 NM_003024 12546 UAGUGUUUAGUUGUGACCCtg Non-hit -0,786 0,011 
ITSN1 6453 NM_001001132 12635 UGACUAUUGAAUAAUUGCCtg Non-hit -0,965 0,110 
ITSN1 6453 NM_003024 142608 GUGGAUGUAUCCUUGUCGCtt Non-hit -0,846 0,151 
ITSN2 50618 NM_019595 17648 UUGAGGUUAUCAAACUGCCtg Non-hit 1,234 0,017 
ITSN2 50618 NM_147152 17743 CACCUGUUAUGUAACCUCCtg Non-hit -0,721 0,984 
ITSN2 50618 NM_019595 133782 GCCUGUCAUGCUUAGUACGtt Non-hit -0,493 0,021 
ITSN2 50618 NM_147152 133783 GAUCACCUGUUAUGUAACCtc Non-hit -0,985 0,009 
ITSN2 50618 NM_019595 133784 AAGUAUCCUUAUCCUUACGtt Non-hit -0,523 0,506 
KALRN 8997 NM_001024660 845 AGAGGAGGACAUUUCAUCCtg Non-hit -0,315 0,992 
KALRN 8997 NM_003947 13846 CAUCAUUCCGAAAAGACCCtc Non-hit 0,477 0,311 
KALRN 8997 NM_001024660 13939 CACGAAGGCCACCUUUUCCtt Non-hit 0,695 0,347 
KALRN 8997 NM_001024660 14029 AGUUGAUAUUUGGUGAUCCtt Non-hit 0,103 0,690 
KALRN 8997 NM_001024660 124683 CACUUCUUAAGAGUGUUGGtg Non-hit -0,437 0,959 
KALRN 8997 NM_001024660 137405 UCCACAGAUACCAUGCUCGtc Non-hit 0,890 0,123 
KIF11 3832 NM_004523 14672 AGCUCUUGUCAGCCAAUCCtc Non-hit 0,442 0,423 
KIF11 3832 NM_004523 14765 CAUUAGGUGACCUUUCACCtt Non-hit -0,022 0,583 
KIF12 113220 NM_138424 36707 CAAAAGUUCCAUCAGGGCCtc Non-hit -0,847 0,384 
KIF12 113220 NM_138424 118498 UGACGGCUGAUGUAAAGGGtg Non-hit 0,746 0,307 
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KIF13A 63971 NM_022113 29651 GCAGGACCGUUUGAUUCCCtt Non-hit -0,523 0,403 
KIF13A 63971 NM_022113 29745 AAUACCUUGGGAGGUUUCCtt Non-hit -0,193 0,701 
KIF13B 23303 NM_015254 22657 UGAAAACAAUAUCUUGACCtg Non-hit -0,525 0,051 
KIF13B 23303 NM_015254 22848 GUACUUUUCAAUAUAAGCCtc Non-hit -0,129 0,770 
KIF14 9928 NM_014875 22099 UUAUGUCUCUGACUUUACCtg Non-hit -0,435 0,253 
KIF14 9928 NM_014875 22195 UUGUUCCUUGUAGUUCUCCtc Non-hit 0,980 0,276 
KIF15 56992 NM_020242 28246 AAACUUUGAUGGCAUCACCtt Mild hit -1,265 0,106 
KIF15 56992 NM_020242 118474 AGUUCUGCUCUCCAUCAGCtg Mild hit 0,258 0,456 
KIF16B 55614 BX647572 288693 UGUGAAACGUAAUCUGGGCtt Strong hit -1,637 0,008 
KIF16B 55614 BX647572 288694 UGUUGAUGAUGUUUUUGGCtc Strong hit -0,727 0,044 
KIF17 57576 NM_020816 118477 UCGUUGUAGAUCUGCUCGGtg Non-hit -0,685 0,196 
KIF17 57576 NM_020816 118478 GAUCUCGUUGUAGAUCUGCtc Non-hit -0,096 0,647 
KIF18A 81930 NM_031217 32973 UCAGUGGGAUGUUGUGUCCtg Strong hit -1,762 0,026 
KIF18A 81930 NM_031217 118492 CUUUAUGAAAUCCAGCUGCtt Strong hit -0,925 0,116 
KIF18B 146909 XM_085634 251223 GGCUUUUGAUGACUGUGGCtg Non-hit -0,533 0,467 
KIF18B 146909 XM_085634 251224 UAUGUACAUGCCAAGAAGCtg Non-hit -0,471 0,197 
KIF19 124602 NM_153209 39789 AGACAGUGGCAUUGUAGCCtg Mild hit -1,131 0,027 
KIF19 124602 NM_153209 39883 UGUAGGUUUUCCCACAGCCtg Mild hit -1,192 0,042 
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KIF1A 547 NM_004321 14392 GAUGCACACGUUGUAUCCCtc Non-hit 0,373 0,767 
KIF1A 547 NM_004321 147322 GUAUCCCUCAAAGGCAUGCtg Non-hit -0,475 0,195 
KIF1B 23095 NM_183416 22400 AAUGAUGCAUUUGGAUUCCtt Strong hit -0,980 0,262 
KIF1B 23095 NM_183416 118460 GAAGGACUUUGGAGCUUCCtt Strong hit -1,987 0,017 
KIF1C 10749 NM_006612 18210 AGAUGCACACGUUGUAGCCtt Non-hit 0,588 0,755 
KIF1C 10749 NM_006612 18304 GAUCUCCAUAUAGCUCACCtc Non-hit -0,249 0,151 
KIF2A 3796 NM_004520 14669 CCAGGUCAAUCUCUUUGCCtt Mild hit -1,286 0,037 
KIF2A 3796 NM_004520 14762 GUCUAUAAUCCAAACUUCCtc Mild hit -0,480 0,297 
KIF20A 10112 NM_005733 16618 ACUGUCCUCAGAUGGAACCtg Non-hit -0,458 0,245 
KIF20A 10112 NM_005733 288582 AGGCUUGACGAAGUUUUCCtg Non-hit -0,076 0,579 
KIF20B 9585 NM_016195 24036 AGAUUCGAAACUGUUUGCCtc Non-hit -0,389 0,298 
KIF20B 9585 NM_016195 118465 UUCAUGAGACAGAUCAAGCtt Non-hit -0,936 0,099 
KIF21A 55605 NM_017641 118471 AUGUACAAAUAUGGCAUCCtt Non-hit -0,307 0,576 
KIF21A 55605 NM_017641 118472 AUCUUUCCCUAGGAAGACCtg Non-hit -0,758 0,229 
KIF21B 23046 BC078676 288691 AGAGCUGAGGGAAAGAACAta Non-hit -0,233 0,676 
KIF21B 23046 BC078676 288692 CCGUCAGGUCACUGGAGGCtg Non-hit -0,977 0,097 
KIF22 3835 NM_007317 19353 CUGGUAUUUGAGAGUCUCCtg Mild hit -1,014 0,323 
KIF22 3835 NM_007317 118450 CGAGUAGCUCCAAUCUUGCtt Mild hit -1,330 0,194 
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KIF23 9493 NM_138555 36749 AAAUGAAUACUGAGUCUCCtt Mild hit -1,261 0,077 
KIF23 9493 NM_138555 118501 CUUAUAGUCUCCAUUUCGGtt Mild hit -1,279 0,108 
KIF24 55265 NM_018278 26683 CUGUGGCAUUCAGAAUUCCtg Mild hit -0,884 0,065 
KIF24 55265 NM_018278 26777 AAAUAACUUAUUGUCACCCtg Mild hit -1,285 0,015 
KIF25 3834 NM_030615 32833 GUAUUUUCCAAAAUGAGCCtg Non-hit -0,082 0,666 
KIF25 3834 NM_030615 118490 AUGGUAUAGCUCUUUCCGCtg Non-hit 0,675 0,894 
KIF26A 26153 XM_050278 263710 CCUAUGCUAUGCACGAUCCtc Mild hit -0,893 0,611 
KIF26A 26153 XM_050278 263711 AGAAAAGUCCAAAUCAAGGtc Mild hit -1,023 0,121 
KIF26B 55083 BC035896 288689 GUCUUCUUUUUCUUCAUCCtc Mild hit -1,207 0,193 
KIF26B 55083 BC035896 288690 CAUGGAUUUUUUCAAAACCtg Mild hit -1,026 0,418 
KIF27 55582 NM_017576 118468 UUCUCGGAUGUGAAGAUCCtt Non-hit -0,652 0,155 
KIF27 55582 NM_017576 118469 CAACAAUCACUGUGUUUCCtt Non-hit -0,129 0,556 
KIF2B 84643 NM_032559 34309 CCAGGUCAAUCUUCUUGCCtt Non-hit -0,538 0,101 
KIF2B 84643 NM_032559 118495 UUUUCUCUGUUGAUCUCCGtg Non-hit -0,429 0,278 
KIF2C 11004 NM_006845 18553 UUCUCCAAGUUCACAGUCCtt Mild hit -0,381 0,432 
KIF2C 11004 NM_006845 18738 CUUCAUUUUUUCCACUUCCtt Mild hit -1,016 0,224 
KIF3A 11127 NM_007054 19038 AAAUAGUCCCAUUGUAGCCtt Non-hit 0,739 0,642 
KIF3A 11127 NM_007054 118447 AAGUAAAUGUCUUUGGAGGtt Non-hit -0,301 0,177 
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KIF3B 9371 NM_004798 15207 AUACGAAGCAGCCUUUUCCtt Mild hit 0,414 0,621 
KIF3B 9371 NM_004798 118432 UCAUAGACGGCAUCAAAGGtg Mild hit -1,366 0,063 
KIF3C 3797 NM_002254 11118 CAGGUCUCGAAUCUCUUCCtg Mild hit -0,507 0,479 
KIF3C 3797 NM_002254 118421 GAUGUGGGUGAAGAUGUGCtc Mild hit -1,144 0,021 
KIF4A 24137 AF071592 288675 UGUUCUUGAUUUUUCUUGCtc Non-hit 0,774 0,177 
KIF4A 24137 AF071592 288676 UUAGAUGAUUAAGUUCAGCtg Non-hit -0,160 0,941 
KIF4B 285643 AF241316 288679 UGUAUUACCCUAGGAAUAAtg Non-hit -0,009 0,801 
KIF4B 285643 AF241316 288680 CUCUUUUGAUCAAUUUCUUtg Non-hit -0,914 0,088 
KIF5A 3798 NM_004984 15501 CCAUGGUAUGUGUUUUCCCtg Non-hit -0,151 0,805 
KIF5A 3798 NM_004984 118435 ACGGUCAAAAACAUAUGGCtt Non-hit -0,013 0,381 
KIF5B 3799 NM_004521 14670 AGAUGCCAAAAGCUCCUCCtg Non-hit -0,105 0,438 
KIF5B 3799 NM_004521 14763 GGUAGAUGCCAAAAGCUCCtc Non-hit -0,213 0,481 
KIF5C 3800 NM_004522 14764 CGCACAUGCAUUGUAAACCtg Non-hit -0,412 0,210 
KIF5C 3800 NM_004522 14850 GAUCUCAAAAUAGGAAACCtt Non-hit 0,702 0,535 
KIF6 221458 NM_145027 37797 UAUACUUUCUCCCAGGGCCtt Mild hit -1,016 0,106 
KIF6 221458 NM_145027 37893 CCGCUGGGUGAUUUCUUCCtt Mild hit -0,928 0,084 
KIF7 374654 NM_198525 118513 UUUCUGCGCAGGUGUAAGGtc Non-hit -0,460 0,553 
KIF7 374654 NM_198525 118514 CAACUCCUCAAGGCAAAGCtc Non-hit -0,291 0,459 
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KIF9 64147 NM_022342 30070 UUGCUCAUUCUUAAACUCCtc Non-hit -0,080 0,989 
KIF9 64147 NM_182903 118509 UUCGAUCAUCCUAAAAACCtg Non-hit -0,150 0,516 
KIFAP3 22920 NM_014970 22364 CAUUCUUCAACCACCUUCCtt Non-hit 0,392 0,583 
KIFAP3 22920 NM_014970 118456 CAUAGUGAACAAUGAGUGCtt Non-hit -0,596 0,163 
KIFC1 3833 NM_002263 43827 UCCUCUUGAGUCUGCUUCCtg Non-hit -0,261 0,521 
KIFC1 3833 NM_002263 43923 UGUCCGUUUCUUCUCAGGCtc Non-hit 0,244 0,832 
KIFC2 90990 NM_145754 38128 AGAGUCAGAUGCUGAACCCtt Non-hit -0,389 0,701 
KIFC2 90990 NM_145754 118504 ACCCUUUUCUCUGAGUCCGtc Non-hit -0,667 0,062 
KIFC3 3801 NM_005550 16324 UCAGCUCUGACAGCAUGCCtt Non-hit -0,508 0,871 
KIFC3 3801 NM_005550 118438 UCUGACAGCAUGCCUUUGCtt Non-hit -0,868 0,175 
LASP1 3927 NM_006148 17398 CUUGUUCUUCUCAAACUCCtc Mild hit -0,285 0,493 
LASP1 3927 NM_006148 17494 UACGCUGAAACCUUUGCCCtt Mild hit -1,138 0,075 
LIMK1 3984 NM_002314 1413 GAAGUUGAGCCUCUUGUCCtt Non-hit -1,073 0,184 
LIMK1 3984 NM_016735 1318 UGUCUCACGGUGUGUCACCtt Non-hit -0,748 0,026 
LIMK1 3984 NM_016735 143455 UGUAUCGUGAGGGUCAUGCtc Non-hit 0,608 0,760 
LIMK1 3984 NM_016735 143456 UUAUUGUUCUGCGUCUGGGtt Non-hit -0,959 0,003 
LIMK2 3985 NM_016733 1469 GCAGUAGAGCUUCCCAUCCtt Mild hit 0,003 0,342 
LIMK2 3985 NM_001031801 1563 CCCAUCCUCAAUGAUCACCtt Mild hit -1,374 0,082 
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LIMK2 3985 NM_016733 1653 CAGGUUCAGCUUCUUAUCCtt Mild hit -0,312 0,550 
LIMK2 3985 NM_016733 144048 GAGAUACUGUUACUGCGCCtt Mild hit -0,988 0,365 
LIMK2 3985 NM_005569 144049 UUCGAGAAUGCUGGUCUGCtc Mild hit -0,771 0,008 
LIMK2 3985 NM_005569 144050 UAAGUUUGAAAACAUGAGGtg Mild hit -1,183 0,260 
LIMS1 3987 NM_004987 15503 CAAACUCAUAGAAGAGUCCtt Strong hit -1,540 0,240 
LIMS1 3987 NM_004987 15596 GUUCACAGUACUUUCUUCCtt Strong hit 0,211 0,820 
LIMS2 55679 NM_017980 25885 AGAGUUGAGGUCUGUGGCCtt Mild hit 0,348 0,251 
LIMS2 55679 NM_017980 132221 AGCCUUCAUUGUGCAAGCGtg Mild hit -1,439 0,157 
LRP1 4035 NM_002332 11342 CCACAAAGUAGAAGUUGCCtg Non-hit -0,341 0,865 
LRP1 4035 NM_002332 111141 ACCCAGGCAGUUAUGCUCGtt Non-hit -0,473 0,154 
MACF1 23499 NM_033044 258846 AUCCUUCAAGUCACUUUGGtt Non-hit 0,480 0,865 
MACF1 23499 NM_033044 258847 UGUUUAUCAUCCAACCAGGtc Non-hit -0,321 0,209 
MACF1 23499 NM_033044 258848 UUCUAUCCAUGGCACAAGGtc Non-hit 0,585 0,474 
MACF1 23499 NM_033044 288620 CUCUAAAGUUCUGAGGGCCtt Non-hit -1,233 0,257 
MAP3K1 4214 XM_042066 263692 CCAAAUUGACAUGCAGUGGtg Non-hit -0,615 0,161 
MAP3K1 4214 XM_042066 263693 UCACAUACUUAGGUAAGGGtt Non-hit -0,252 0,629 
MAPK1 5594 NM_002745 1449 AUCUGUUUCCAUGAGGUCCtg Non-hit -0,529 0,150 
MAPK1 5594 NM_138957 1544 CAUAUUCUGUCAGGAACCCtg Non-hit -0,417 0,485 
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MAPK1 5594 NM_138957 1634 UAGUUCUUUGAGCUUUUCCtt Non-hit -1,304 0,036 
MAPK1 5594 NM_138957 142301 UUUGCUCGAUGGUUGGUGCtc Non-hit -0,446 0,449 
MAPK3 5595 NM_002746 142304 GUUAAAGGUUAACAUCCGGtc Mild hit 0,019 0,911 
MAPK3 5595 NM_002746 214749 GUUGAUGAUACAAUUCAGGtc Mild hit -1,428 0,002 
MAPK8IP1 9479 NM_005456 16261 GUCUUCAUCCUCAAACUCCtc Non-hit -0,561 0,262 
MAPK8IP1 9479 NM_005456 16356 AUUAUUAUUCAGUGUGUCCtg Non-hit 0,214 0,687 
MAPK8IP2 23542 NM_012324 19889 AAACUCCUGGAAGUCAUCCtg Non-hit -0,368 0,980 
MAPK8IP2 23542 NM_016431 20076 UCAAGGAUGGGAUGAUCCCtt Non-hit -0,248 0,721 
MAPK8IP3 23162 NM_033392 22516 AUCGGCAUAGUUCUUGGCCtt Non-hit -0,081 0,407 
MAPK8IP3 23162 NM_033392 136770 CUUGGACCUCUCAAUGUGCtc Non-hit -0,690 0,116 
MAPRE1 22919 NM_012325 3708 CACCCAUUCUCUUAAAACCtg Non-hit -0,013 0,592 
MAPRE1 22919 NM_012325 3891 AACGAAUUCAAAAUUGUCCtg Non-hit -0,318 0,671 
MAPRE2 10982 NM_014268 20987 CUUCUCCACUGGAAUUACCtt Mild hit -1,250 0,109 
MAPRE2 10982 NM_014268 136574 UUCCGGAAAGGAAUGAUGGtc Mild hit -0,622 0,276 
MAPRE3 22924 NM_012326 19890 GCCUGGAACUUCACUUUCCtc Non-hit -0,257 0,943 
MAPRE3 22924 NM_012326 136502 CAGCAGAGGGUUGUAAUCCtt Non-hit 0,207 0,502 
MCF2 4168 NM_005369 2835 UUUAGGCAUAAAAUCCUCCtg Non-hit 0,169 0,135 
MCF2 4168 NM_005369 144005 AGCAAAUCACUAACUGAGCtc Non-hit 0,031 0,731 
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MCF2L 23263 NM_024979 32098 CAUGACAUUCUGGAACUCCtt Non-hit -0,173 0,569 
MCF2L 23263 NM_024979 137007 GUCCUUUGGAAAAAACCCGtc Non-hit -0,438 0,647 
MCF2L2  23101 NM_015078 22402 UAUUCGUGUCAAGGAUGCCtt Strong hit 1,534 0,022 
MCF2L2  23101 NM_015078 119310 UCCAGUUGAACUAAUAACCtt Strong hit -0,237 0,912 
MLPH 79083 NM_024101 42410 UCUCUGAGCAGGACUCAUCtg Non-hit -0,549 0,153 
MLPH 79083 NM_024101 42493 UGUCUGGAAGGUGAGAUGCtg Non-hit 0,328 0,608 
MSN 4478 NM_002444 11593 GCCAAUAGUUUUCACCACCtg Non-hit -0,320 0,889 
MSN 4478 NM_002444 143572 UCAAAUAGCUGCUUCCCGGtg Non-hit -0,463 0,045 
MYH1 4619 NM_005963 17114 UGGGCUUCAAUUCGCUCCCtt Mild hit -1,081 0,055 
MYH1 4619 NM_005963 17208 UGCUUUCACAAAGGACUCCtt Mild hit -0,733 0,528 
MYH10 4628 NM_005964 147398 UCCACACUAGCUUUUUAGCtg Mild hit -1,397 0,162 
MYH10 4628 NM_005964 147399 GUUCUUCUUUGAUACUAGCtg Mild hit -1,071 0,299 
MYH11 4629 NM_022844 43338 UCUCCUCCUUAAUGCUGGCtg Non-hit -0,993 0,508 
MYH11 4629 NM_002474 118370 AUCUUUCCCAACCGUGACCtt Non-hit -0,293 0,722 
MYH13 8735 NM_003802 13581 UUGAGCCUCGAUUCUCUCCtt Non-hit -0,824 0,323 
MYH13 8735 NM_003802 13674 GCCUUUCACAUACAUUUCCtt Non-hit -0,731 0,278 
MYH15 22989 AB023217 288671 UUGGAAAUCUCUCCUCUGCtt Non-hit -0,952 0,078 
MYH15 22989 AB023217 288672 AUAGUAGGCUUUGAUUUGCtc Non-hit -0,796 0,207 
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MYH2 4620 NM_017534 24900 UCACCGUCACUUUUCCUCCtt Non-hit -0,539 0,566 
MYH2 4620 NM_017534 118403 GGGUAAUCAUAUGGGUUCGtg Non-hit 0,088 0,748 
MYH3 4621 NM_002470 11602 CUCAGUUUCCACAGUGACCtt Mild hit -0,370 0,385 
MYH3 4621 NM_002470 11788 UCCAAUUUCCUUUUGUUCCtt Mild hit -1,176 0,150 
MYH4 4622 NM_017533 24899 CUGAGCUUCAAUUCGCUCCtt Non-hit -0,138 0,552 
MYH4 4622 NM_017533 24994 UGCUUUCACGUAGGACUCCtt Non-hit -0,744 0,247 
MYH6 4624 NM_002471 11603 GGCUUUGACAAACUCUUCCtt Non-hit -0,550 0,309 
MYH6 4624 NM_002471 11699 UUUCAGCAAUGACCUUGCCtc Non-hit -0,326 0,159 
MYH7 4625 NM_000257 8079 UUCUUGAGGUCAAAAGGCCtg Non-hit -0,392 0,140 
MYH7 4625 NM_000257 8172 AUCAGGCACGAAGACAUCCtt Non-hit -0,087 0,455 
MYH7B 57644 AB040945 288673 GGUCAUCAGCUUGUUGAGGtt Mild hit -1,121 0,376 
MYH7B 57644 AB040945 288674 CUUCAUCUUGAAAAAGAGCtt Mild hit -1,332 0,169 
MYH8 4626 NM_002472 11604 AAACGGCUUGUUUUGGGCCtc Non-hit -0,719 0,071 
MYH8 4626 NM_002472 11700 GCUCUUCACAUAGGAUUCCtt Non-hit -0,757 0,098 
MYH9 4627 NM_002473 11605 AUCCUUGUUCACCUUCACCtt Mild hit -0,102 0,795 
MYH9 4627 NM_002473 11701 GAUGUCAUCCUUGUUCACCtt Mild hit -1,355 0,120 
MYLIP 29116 NM_013262 20179 UCUAUGAUUCCCAGUCGCCtg Non-hit -0,421 0,997 
MYLIP 29116 NM_013262 118397 GAUAUGCCUAGUCUGCUCCtg Non-hit 0,203 0,550 
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MYLK 4638 NM_053032 1510 GACCCUGUUGAGGAUUUCCtg Non-hit 0,522 0,118 
MYLK 4638 NM_053027 1692 UUUUACAUGAGGCUUUUCCtc Non-hit -0,389 0,936 
MYLK 4638 NM_053026 103376 UAAAGAGCAGUUCCCGUCCtc Non-hit -1,240 0,095 
MYLK 4638 NM_053031 144402 CAUCGUUUCCACAAUGAGCtc Non-hit 0,806 0,531 
MYLK 4638 NM_053031 288626 GUUGAAAUCUGUUUCAUCGtg Non-hit 0,480 0,620 
MYLK 4638 NM_053031 288627 GCUGCUAGGUAUCAACUGCtg Non-hit -0,461 0,859 
MYLK 4638 NM_053031 288628 GGAACUCUUAAAAAGUCCCtt Non-hit 0,378 0,906 
MYLK 4638 NM_005965 103460 UCCAAGACUGUUGACAGCCtt Non-hit 0,115 0,291 
MYLK 4638 NM_053030 144401 UUUUCUGCAUUGAGCGGGCtg Non-hit -1,237 0,309 
MYLK 4638 NM_053030 144403 AGCAUAAUGUCCUUAAUGCtt Non-hit -0,877 0,277 
MYO10 4651 NM_012334 19898 UAGUGCUUUCGGUUUUACCtg Non-hit -0,669 0,299 
MYO10 4651 NM_012334 19992 AACACAGGAUGUCUUCUCCtt Non-hit -0,421 0,742 
MYO15A 51168 NM_016239 24065 AUAAUACUCGCCCAGGUCCtg Non-hit -0,360 0,950 
MYO15A 51168 NM_016239 118400 UGCGUCAUGAGCUUUGACGtg Non-hit -0,474 0,474 
MYO15B 80022 BC027875 251256 AAGCCUUCAUUUCACCCGGtg Non-hit -0,160 0,441 
MYO15B 80022 BC027875 251257 UCUAUCAGGAAGACAGUGGtg Non-hit -0,159 0,529 
MYO16 23026 AB020672 288669 UCCUCUCACAGAACUGAAGtt Mild hit -0,614 0,457 
MYO16 23026 AB020672 288670 UUAACUAAAGGGUGCACAAtc Mild hit -1,052 0,181 
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MYO18A 399687 NM_078471 147986 GAGGAUGAUUGACUGAUCCtg Strong hit -1,545 0,353 
MYO18A 399687 NM_203318 147987 CUUGUAUCUUUCCAACUCCtg Strong hit -0,980 0,116 
MYO18B 84700 NM_032608 34346 CUUCCUCUGUCUCGCUUCCtt Mild hit -1,371 0,371 
MYO18B 84700 NM_032608 118407 CUUGUCUUCUCCAUCUGGGtc Mild hit -0,503 0,231 
MYO1A 4640 NM_005379 16050 AAACGGCUUGUUUUGGGCCtc Strong hit -1,484 0,084 
MYO1A 4640 NM_005379 144012 GCGAUAAUUCUUUCGGGCCtt Strong hit -1,594 0,102 
MYO1B 4430 NM_012223 148408 GGGUAAAGACCGGUAUGGGtt Non-hit 0,482 0,248 
MYO1B 4430 NM_012223 148409 CGGGUUGGACUGUAAAAGCtg Non-hit -0,687 0,133 
MYO1C 4641 NM_033375 35347 UCCAUGUACUUCCCGAACCtg Non-hit -0,641 0,170 
MYO1C 4641 NM_033375 118410 GAACCUGCUGGAGUUAUCGtt Non-hit 0,063 0,385 
MYO1D 4642 NM_015194 222682 CUGUAAUGCUCAGUUUGCCtt Strong hit -0,401 0,783 
MYO1D 4642 NM_015194 251683 UCGAUUUACCUUACGGACGtg Strong hit -1,699 0,076 
MYO1E 4643 NM_004998 15509 UUUCAUACUGUGCCGCUCCtt Non-hit -0,182 0,362 
MYO1E 4643 NM_004998 15693 GAGAAUAAAAAUGUCAUCCtg Non-hit -0,028 0,987 
MYO1F 4542 NM_012335 19899 AUCUUUGACGUGCUGGACCtt Non-hit -0,945 0,055 
MYO1F 4542 NM_012335 118394 AUAGAGGUCGAUCUCACGGtc Non-hit -0,333 0,673 
MYO1G 64005 NM_033054 221471 ACUGUUGACGGGAAACACCtc Mild hit -1,215 0,094 
MYO1G 64005 NM_033054 221472 GUUUGCCAUACUCAGGGCCtt Mild hit 0,340 0,787 
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MYO3A 53904 NM_017433 1486 UAGCAUCACAUCUUUGCCCtc Mild hit -0,078 0,315 
MYO3A 53904 NM_017433 131930 AAUCUCUUCGUCAAUAUCGtg Mild hit -1,097 0,183 
MYO3B 140469 NM_138995 1137 AUCUCUCUUGUUAGUUACCtt Non-hit -0,782 0,635 
MYO3B 140469 NM_138995 1138 CAAUUGAAGGUAACAUUCCtg Non-hit -0,670 0,299 
MYO5A 4644 NM_000259 8081 GCAGGAGGACUUUAUCUCCtg Strong hit 0,072 0,406 
MYO5A 4644 NM_000259 8174 UUCCAAAUCCUUUCCUUCCtc Strong hit -1,522 0,030 
MYO5B 4645 AY274809 288685 CUUCUUUGUAGUCCUUGGUta Mild hit -1,012 0,126 
MYO5B 4645 AY274809 288686 AUAGAUUGGCAACUGUUCAta Mild hit -0,814 0,100 
MYO5C 55930 NM_018728 27397 GUCACCAACUCUGUAGUCCtt Mild hit 0,314 0,456 
MYO5C 55930 NM_018728 118404 CACGGCAAAUAUGUGUGGGtc Mild hit -1,252 0,548 
MYO6 4646 NM_004999 15510 GAGCCAAAAAUGUCUUGCCtt Non-hit -0,407 0,806 
MYO6 4646 NM_004999 15603 CACAUCUUUUUUACUGUCCtc Non-hit -0,875 0,505 
MYO7A 4647 NM_000260 8082 GUCUUCAUCAUCCACCACCtg Non-hit -0,754 0,165 
MYO7A 4647 NM_000260 8175 UAGAACACGUGGUAGUUCCtt Non-hit -0,521 0,635 
MYO7B 4648 XM_291001 263743 GGCGAAAAUGGACCUCUCCtt Mild hit -1,134 0,117 
MYO7B 4648 XM_291001 263744 CACAUAUGAGGUCAGCAGGtc Mild hit -0,307 0,308 
MYO9A 4649 NM_006901 18770 UCGGACAGUAGAUUGUCCCtt Non-hit 0,136 0,808 
MYO9A 4649 NM_006901 18866 UAUAAGAGACUCAAUCACCtc Non-hit 0,444 0,704 
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MYO9A 4649 NM_006901 18960 AUUUUUUUCCCGGAAAUCCtt Non-hit -0,910 0,355 
MYO9A 4649 NM_006901 144275 UCCACCAAAUUCCUUUACCtc Non-hit -0,241 0,616 
MYO9B 4650 NM_004145 14116 GAAGUAGUAGCCAUCCUCCtg Non-hit -0,302 0,883 
MYO9B 4650 NM_004145 14207 CAGGAAGUAGUAGCCAUCCtc Non-hit 0,219 0,655 
MYO9B 4650 NM_004145 14293 CUUGAUCUGAUAUUUCACCtt Non-hit -1,306 0,019 
MYO9B 4650 NM_004145 143862 AUUUCUCGACGACAGCUCCtc Non-hit -0,698 0,337 
NCK1 4690 NM_006153 17402 AGUUAGAAGGCACAAAACCtg Non-hit -0,677 0,891 
NCK1 4690 NM_006153 17498 UUCCGAGCACUGUUUUUCCtt Non-hit -0,563 0,269 
NCK2 8440 NM_003581 13296 CUUCUCGAAGUUGAGCUCCtc Non-hit -0,630 0,030 
NCK2 8440 NM_003581 13379 UGAAGUGUUUGUUCUUCCCtg Non-hit -1,567 0,013 
NCK2 8440 NM_003581 13457 AUUGUCCACGAGCUGCACCtt Non-hit -1,044 0,228 
NCK2 8440 NM_003581 215169 UGUCUUUCUGAGUCACCGGtt Non-hit -0,954 0,220 
NCK2 8440 NM_001004722 288563 UAAAGUGUUGGUAGCUCCCtt Non-hit -0,874 0,694 
NCK2 8440 NM_003581 288564 CAAAGAUCAGCUGUUUUCCtt Non-hit 1,404 0,006 
NET1 10276 NM_005863 16886 UCUUUUAUUGCUUGGCUCCtc Non-hit -0,195 0,025 
NET1 10276 NM_005863 16981 CAUUUCAUAUAUUGCCUCCtg Non-hit -0,517 0,287 
NEXN 91624 NM_144573 37246 CCUCUUUUCUAACAUAUCCtg Non-hit -0,053 0,805 
NEXN 91624 NM_144573 37341 UAAGUAGUGAAUCAUCUCCtt Non-hit 0,174 0,659 
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NF2 4771 NM_181833 8090 AAUCAAAGAGGUCCUUCCCtt Mild hit -1,147 0,019 
NF2 4771 NM_016418 8183 CACCAAAUCAAAGAGGUCCtt Mild hit -0,217 0,693 
NF2 4771 NM_181832 8273 UAAAAUCUGCUUCUUUACCtg Mild hit -0,195 0,918 
NF2 4771 NM_181825 202366 GGCAGUAGAUCUUUUCAUCta Mild hit -1,139 0,110 
NF2 4771 NM_181832 202367 AGGAGGGCAGUAGAUCUUUtc Mild hit -0,786 0,562 
NF2 4771 NM_181828 202368 UCAGGAGGGCAGUAGAUCUtt Mild hit 0,841 0,063 
NF2 4771 NM_181834 288641 CUCUUGAGAGAGCUGAAGCtc Mild hit -1,174 0,009 
NF2 4771 NM_181834 288642 GCGUCCAUGGUGACGAUCCtc Mild hit -0,061 0,914 
NGEF 25791 NM_019850 135246 ACUCAGGUUUCACCUUGGCtg Non-hit -0,638 0,004 
NGEF 25791 NM_019850 135247 CGGAGCUGAGUCAAAUACCtg Non-hit -0,472 0,904 
ITSN2 50618 NM_006277 17834 CUUUCUAUGUCUUUUCUCCtt Non-hit 0,281 0,443 
NUDT16L1 84309 NM_032349 34040 GGGCAUCAUGUUGAGCACCtt Strong hit -0,228 0,923 
NUDT16L1 84309 NM_032349 34136 AGAAUAAACAAGAGCAUCCtg Strong hit 1,726 0,026 
OBSCN 84033 NM_052843 131675 GCUUUCGGAGGAGGUUUCCtt Mild hit -0,830 0,226 
OBSCN 84033 NM_052843 251364 AUUAUGCACUGACUGCUCCtt Mild hit -1,171 0,275 
OCRL 4952 NM_000276 8189 AUCUUGAACAUGCUGUUCCtt Non-hit -0,174 0,574 
OCRL 4952 NM_000276 104448 GUACCAGCUAGAUGAGUCCtt Non-hit -0,864 0,637 
OCRL 4952 NM_001587 114042 GCUAGAUGAGUCCUUUUGCtc Non-hit -0,468 0,484 
198 
 
Gene Symbol 
1 
Gene ID1 RefSeq  
Accession 
Number2 
siRNA ID3 Antisense (target) siRNA Sequence3 Hit gene4 Z-score 5 P-value 5 
OCRL 4952 NM_001587 104450 GAUAUGUUUGAUGAGACCCtc Non-hit 0,449 0,813 
OPHN1 4983 NM_002547 11646 GAGCAAUUCAGCAAAUUCCtt Mild hit -0,825 0,129 
OPHN1 4983 NM_002547 143673 GACUCGAAAAAAUUGUGCCtc Mild hit -1,111 0,089 
PAFAH1B1 5048 NM_000430 8383 CACAUCUAAUUCAGCUUCCtt Mild hit -1,241 0,026 
PAFAH1B1 5048 NM_000430 8478 CACCUUAAUUGUAGCAUCCtc Mild hit -0,702 0,173 
PAK1 5058 NM_002576 249 GUCCUUCUUUUUCUUCUCCtc Non-hit -0,806 0,273 
PAK1 5058 NM_002576 143703 AAUGGAUCGGUAAAAUCGGtc Non-hit -0,526 0,372 
PAK2 5062 NM_002577 110776 CAGUGAGCUUAACAGAUCCtt Non-hit -0,208 0,389 
PAK2 5062 NM_002577 110779 UCUAAUUUUAGCUACUACCtg Non-hit 0,442 0,309 
PAK4 10298 NM_001014831 732 UUCUCGUGCUGGUAGUCCCtc Non-hit 0,231 0,215 
PAK4 10298 NM_001014831 733 ACACUCAUACAUGUUCACCtc Non-hit -0,326 0,810 
PAK4 10298 NM_001014834 288584 CUGGAGUUCAGUAGUAGGGtc Non-hit -0,737 0,678 
PAK4 10298 NM_001014835 288585 CUGGUUCUUCAGGCAGUGGtt Non-hit -0,381 0,827 
PAK4 10298 NM_001014834 288586 AAGUCUGACAGCUUCACCCtg Non-hit 0,379 0,893 
PAK4 10298 NM_001014835 288587 GUUCAGUAGUAGGGUCUCAtc Non-hit -0,786 0,003 
PAK4 10298 NM_001014835 288588 CUUGAUGAAGUUGUCCAGGta Non-hit 0,465 0,338 
PAK4 10298 NM_005884 288589 GUUCUUCAGGCAGUGGUUCtg Non-hit 0,976 0,087 
PAK4 10298 NM_001014834 288590 UUCACCUCUUAGUGUUCUCtc Non-hit -0,696 0,005 
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PAK4 10298 NM_001014835 288591 AAGGCCACUCUUCGGACAUtc Non-hit -0,509 0,626 
PAK4 10298 NM_005884 288592 UGUCCAGGUGCAGUAGUCAtt Non-hit -0,463 0,475 
PAK4 10298 NM_001014834 288593 AAAGUCACGAGAUCAAAACtg Non-hit -0,309 0,906 
PALLD  23022 NM_016081 23784 ACUCUUGUUUAUCUCUUCCtg Mild hit -1,384 0,050 
PALLD  23022 NM_016081 23879 UUCACCCAAUUUGGUCUCCtt Mild hit 0,216 0,824 
PARVA 55742 NM_018222 26357 ACCUCCUUGGCUUUCUUCCtc Non-hit -0,373 0,229 
PARVA 55742 NM_018222 26545 GUUUAAAUGAAUGCAUUCCtc Non-hit -0,170 0,536 
PARVB 29780 NM_001003828 20220 AGUUGAUGGCAUUCUUGCCtt Non-hit -0,943 0,211 
PARVB 29780 NM_013327 20312 GAGGACCUUGACCAGUUCCtt Non-hit -0,855 0,739 
PARVB 29780 NM_001003828 134049 AAUCAUCGUGCGCUCCUCGtt Non-hit -0,912 0,066 
PARVB 29780 NM_001003828 134050 GCACGAGUGUUUAGAAUCCtg Non-hit -1,176 0,032 
PFN1 5216 NM_005022 15713 UCAAACCACCGUGGACACCtt Non-hit -0,377 0,701 
PFN1 5216 NM_005022 45010 CGUAAAAACUUGACCGGUCtt Non-hit 0,358 0,484 
PFN2 5217 NM_053024 11684 AACCGUUGGUAAAGAAACCtt Non-hit -0,309 0,726 
PFN2 5217 NM_002628 11776 CUUUCUUGUUAAGUGUGCCtc Non-hit -1,381 0,005 
PFN2 5217 NM_053024 11862 UGAUGCAUGCACUUUUUCCtc Non-hit -0,606 0,051 
PFN2 5217 NM_053024 143784 AUUUCUAUUGGCGUAAUGCtc Non-hit -0,744 0,638 
PIK3CA 5290 NM_006218 2960 AAUAUUUCUUCGGAAGUCCtg Strong hit -1,637 0,038 
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PIK3CA 5290 NM_006218 144250 CUUCACGGUUGCCUACUGGtt Strong hit -0,764 0,163 
PIK3CB 5291 NM_006219 17439 UGUUUCAUCUUCAAGCUCCtc Non-hit -0,490 0,589 
PIK3CB 5291 NM_006219 144253 ACCUCUGAGCUUACGAUGGtt Non-hit 0,389 0,096 
PIK3CG 5294 NM_002649 11879 GAACACACUCUCGUGGUCCtt Mild hit -1,076 0,313 
PIK3CG 5294 NM_002649 11974 AUGCCUCUGAUCUUGACCCtg Mild hit -0,084 0,464 
PIK3R1 5295 NM_181524 203811 GUAUUAGAGAUACAGUAGGtt Non-hit -1,486 0,031 
PIK3R1 5295 NM_181524 118085 UGUUGGCUACAGUAGUAGGtt Non-hit -0,658 0,374 
PIK3R1 5295 NM_181524 118086 GUAUUCUUUGCUGUACCGCtc Non-hit 0,210 0,686 
PIK3R1 5295 NM_181524 118087 GUUUAAUGCUGUUCAUACGtt Non-hit 0,576 0,838 
PIK3R1 5295 NM_181524 288635 AUCUAUUCAUAUUCAGCCGtt Non-hit 0,254 0,433 
PIK3R1 5295 NM_181523 288636 AGAUUCAUUCCGGUAGUGGtt Non-hit -0,758 0,323 
PIK3R1 5295 NM_181523 288637 AUCAUAUAUCAGGAGUGCCtc Non-hit -0,013 0,689 
PIK3R1 5295 NM_181524 288638 CAACCACAUCAAGUAUUGGtc Non-hit -0,647 0,315 
PIK3R1 5295 NM_181523 288639 UUUAGGAUGCUACACUGGGtg Non-hit -0,423 0,411 
PIK3R1 5295 NM_181523 288640 UCAUCAUACAGCCUUAGGCtg Non-hit -0,794 0,080 
PIK3R2 5296 NM_005027 15718 CUGCUCUUCCAAGUGUUCCtg Mild hit 1,109 0,050 
PIK3R2 5296 NM_005027 15906 GAUAGUCUCAUUGAAGGCCtc Mild hit -0,098 0,434 
PIP5K1C 23396 NM_012398 136520 UAAAACGGCACACACGUGCtt Non-hit 1,599 0,224 
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PIP5K1C 23396 NM_012398 136521 GAGGUUUGCACAUUUCUCCtg Non-hit -1,112 0,019 
PLEKHG2  64857 NM_022835 148850 AUGGUACUUGAGAAUGCGCtg Non-hit -0,747 0,734 
PLEKHG2  64857 NM_022835 148851 AGCGUGCUUGAAUCCAGGCtt Non-hit -0,178 0,718 
PLEKHG4  25894 AK024475 288681 UGAUAUUUCUGAUAAAGGGtc Non-hit 0,357 0,803 
PLEKHG4  25894 AK024475 288682 AGGCAAUGUUCCUUGGAGCtg Non-hit 0,590 0,482 
PLEKHG5  57449 NM_020631 123225 AGAGUGAAGCAUUCCUUGCtt Non-hit -0,142 0,401 
PLEKHG5  57449 NM_020631 217272 ACAAAGUCUUGUAAGGAGGtt Non-hit 0,938 0,264 
PLEKHG5  57449 NM_198681 217273 UUUCAGAGUGAAGCAUUCCtt Non-hit -0,673 0,438 
PLEKHG5  57449 NM_198681 288617 AAAUACAGGCAGCAGCACCtc Non-hit -1,218 0,620 
PLEKHG6  55200 NM_018173 26321 AUGGGCCUUGGUGAGUUCCtt Strong hit -1,552 0,337 
PLEKHG6  55200 NM_018173 140527 CUUUCUCACGUAGAUCAGCtc Strong hit -0,443 0,543 
PPFIA1 8500 NM_177423 13311 GUAUCAAGAAGGCGGUCCCtt Non-hit -0,268 0,913 
PPFIA1 8500 NM_177423 13394 AUCUCUUUCAUGACCAACCtc Non-hit 0,078 0,831 
PPFIA1 8500 NM_177423 13472 CUCAUUAAGAGUUUGUACCtt Non-hit 1,059 0,143 
PPFIA1 8500 NM_177423 107195 CUUUCAAGGAGCUGUUCCCtg Non-hit 0,251 0,026 
PPIA 5478 NM_203430 7523 UUCUGCUGUCUUUGGGACCtt Non-hit -0,449 0,147 
PPIA 5478 NM_203431 103856 ACCCUUAUAACCAAAUCCUtt Non-hit -0,096 0,587 
PPIA 5478 NM_021130 112126 ACCUCUUAAUUCUGGCUCCtt Non-hit -0,711 0,194 
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PPIA 5478 NM_203431 122514 UGACCCAACCUCUUAAUUCtg Non-hit -0,192 0,707 
PPIA 5478 NM_203431 122515 UGCAGACUGACCCAACCUCtt Non-hit 0,075 0,347 
PPIA 5478 NM_203430 288645 AUAAUAGCUCACUCUAGGCtc Non-hit 1,233 0,251 
PREX1 57580 NM_020820 28779 GAUGUUCGAGAACAGGACCtt Non-hit 0,080 0,963 
PREX1 57580 NM_020820 121870 AACAUUCCCAAGUUCAUGCtg Non-hit -0,415 0,468 
PRKCA 5578 NM_002737 300 AAACUUGGCACUGGAAGCCtt Strong hit -1,644 0,030 
PRKCA 5578 NM_002737 42854 UUGAACUUGUGCUUGCUCCtg Strong hit -1,258 0,069 
PRKCE 5581 NM_005400 679 CUCCAGAUCAAUCCAGUCCtc Non-hit -0,911 0,617 
PRKCE 5581 NM_005400 677 GACUUGACACUGGUAUCCCtg Non-hit 0,218 0,494 
PRKD1 5587 NM_002742 103310 ACCCUUCACAUUUAAGACCtt Non-hit 0,196 0,424 
PRKD1 5587 NM_002742 103397 GGUAAUUCAGACCACACCCtt Non-hit 0,490 0,369 
PRR5-
ARHGAP8  23779 NM_181334 202491 AUCGUUCUCAACGUAUUGGtc Non-hit -0,183 0,961 
PRR5-
ARHGAP8  23779 NM_181334 213040 CGUGCUCAGCGCAGGAUCCtg Non-hit 0,842 0,108 
PRR5-
ARHGAP8  23779 NM_181334 213042 GUCGUCAAAGUUCACGGGCtt Non-hit -0,289 0,836 
PRR5-
ARHGAP8  23779 NM_181334 213201 AGUUUUCAUUAGAAGGUUCtg Non-hit -1,206 0,061 
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PTEN 5728 NM_000314 45927 CAAAGUACAUGAACUUGUCtt Strong hit -2,230 0,038 
PTEN 5728 NM_000314 142044 CAUUACACCAGUUCGUCCCtt Strong hit -1,124 0,174 
PTK2 5747 NM_005607 103596 GCAAGCUCAUACUUCUCCCtc Non-hit -1,423 0,449 
PTK2 5747 NM_153831 103649 CAUAUAAUCGCUCUUCACCtg Non-hit -0,923 0,239 
PTK2 5747 NM_153831 103698 AGAUCCAAACUGUAUUUCCtt Non-hit -0,558 0,602 
PTK2 5747 NM_153831 142859 UCUUAGUACUCGAAUUUGGtg Non-hit -0,518 0,607 
PTPN1 5770 NM_002827 4264 UGGGUAAGAAUGUAACUCCtt Strong hit -1,570 0,040 
PTPN1 5770 NM_002827 104533 CCAUGAUGAAUUUGGCACCtt Strong hit -1,004 0,785 
PTPN11 5781 NM_002834 4361 GGGUUACUUUUACUAGGCCtt Strong hit -1,863 0,005 
PTPN12 5782 NM_002835 4270 AUCAAAUGGCAGUAUGUCCtt Mild hit -1,214 0,084 
PTPN12 5782 NM_002835 142400 AACCAUAUGCAACACUGGCtt Mild hit -0,891 0,005 
PTPRA 5786 NM_080840 4271 UGGAUUUGAAGUUUUGGCCtc Non-hit -0,687 0,125 
PTPRA 5786 NM_080840 4363 CAUUCUCCGGUUAAUUUCCtc Non-hit 0,107 0,290 
PTPRA 5786 NM_080841 104563 AGGGUUACAGGCCUUCACCtt Non-hit -1,279 0,085 
PTPRA 5786 NM_080841 104566 AUACUGAGGGUUACAGGCCtt Non-hit -0,596 0,217 
PTPRA 5786 NM_080841 104569 AUAUUAAAGGCAAUCCUCCtg Non-hit 0,734 0,312 
PTPRA 5786 NM_080841 114285 UCUUUAACUGGUUCUGCCGtt Non-hit -0,806 0,071 
PTPRF 5792 NM_002840 4274 AUCAUCAAACUCAAUGACCtc Non-hit 0,201 0,261 
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PTPRF 5792 NM_130440 4366 GUCUACAGGAAGGAAGUCCtt Non-hit -0,907 0,039 
PTPRF 5792 NM_130440 4454 AAAAAACAUUGAGUUUCCCtg Non-hit -0,848 0,100 
PTPRF 5792 NM_130440 104588 AUACAUGAUGAUCCGCUCCtg Non-hit -0,099 0,803 
PXN 5829 NM_002859 12157 GAAGAGGUUGUGGUAGUCCtt Mild hit -1,064 0,085 
PXN 5829 NM_002859 12253 GAACAUGUCGAAGUAGUCCtt Mild hit 0,133 0,352 
RAC1 5879 NM_006908 27408 UUUUACAGCACCAAUCUCCtt Non-hit 0,856 0,131 
RAC1 5879 NM_018890 45358 AGACAGUAGGGAUAUAUUCtc Non-hit -0,132 0,267 
RAC1 5879 NM_006908 120600 UGAGCAAAGCGUACAAAGGtt Non-hit -0,647 0,356 
RAC1 5879 NM_006908 120601 AAUAAGGCUUUAAGAAGGCtt Non-hit -0,508 0,321 
RAC1 5879 NM_006908 120602 UAAAGAGGGUCAGUAUUGGtc Non-hit -0,168 0,861 
RAC1 5879 NM_006908 242587 AAGGAAAGCACUUAUUAGCtc Non-hit 0,012 0,493 
RAC2 5880 NM_002872 43342 UGUCCACCAUCACAUUGGCtg Non-hit -0,784 0,027 
RAC2 5880 NM_002872 43438 UUCUCAUAAGAGGCUGGGCtg Non-hit -0,656 0,098 
RAC3 5881 NM_005052 41918 CCACUUGGCACGAACAUUCtc Mild hit 0,737 0,375 
RAC3 5881 NM_005052 42005 GUAUUUCACAGAGCCAAUCtc Mild hit -1,221 0,033 
RACGAP1 29127 NM_013277 20189 ACGGAAAUCCUCAAAGUCCtt Non-hit -0,409 0,707 
RACGAP1 29127 NM_013277 20283 CCACUUUUUACGGAAAUCCtc Non-hit -0,494 0,287 
RALBP1 10928 NM_006788 18602 CCUGAAAGGCUGCAUAGCCtt Mild hit 0,088 0,997 
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RALBP1 10928 NM_006788 18693 CAUUUUUGUUUCCAGUUCCtt Mild hit -1,192 0,004 
RASGRF1 5923 NM_002891 12181 GAGAUUCUUAAAUCUGCCCtc Non-hit -0,187 0,569 
RASGRF1 5923 NM_153815 120291 CUCAUGGAGACUUCUGAGCtc Non-hit 0,163 0,704 
RASGRF2 5924 NM_006909 120492 GGUCGCAUUCGUUCUUUGGtt Mild hit -1,016 0,183 
RASGRF2 5924 NM_006909 120493 AACCAUCCUCGCAUGAAGCtc Mild hit -0,990 0,011 
RDX 5962 NM_002906 12193 ACCAACUGUUUUCACCACCtg Non-hit -0,247 0,544 
RDX 5962 NM_002906 142472 UAUCAUUAGCCAGGUAGCCtg Non-hit -0,388 0,223 
RGNEF 64283 BC012946 288687 GUUUUGUUUUCAAUCUUAUtt Mild hit -0,358 0,332 
RGNEF 64283 BC012946 288688 CAUAUAACAGAGUCCUUUCtt Mild hit -1,179 0,136 
RHOA 387 NM_001664 2808 UACCUGCUUUCCAUCCACCtc Non-hit -0,381 0,681 
RHOA 387 NM_001664 120211 UUUUCUAAACUAUCAGGGCtg Non-hit 0,909 0,081 
RHOB 388 NM_004040 41889 AAUGUCGGCCACAUAGUUCtc Non-hit -0,767 0,495 
RHOB 388 NM_004040 120361 CAGACAAGGGAUAUCAAGCtc Non-hit -0,436 0,927 
RHOBTB1 9886 NM_014836 43848 GCCUGAGAGAAACACUCACtt Non-hit -0,159 0,859 
RHOBTB1 9886 NM_014836 43944 CAAAGCCUGAGAGAAACACtc Non-hit -0,180 0,740 
RHOBTB1 9886 NM_001032380 44031 UAAAGGUUUCUGGACUUUCtt Non-hit -1,200 0,294 
RHOBTB1 9886 NM_001032380 138464 GCCUGGCUCGAUUAACAGCtt Non-hit -0,666 0,581 
RHOBTB1 9886 NM_198225 138465 CCAAACUGGUCAAACACGCtt Non-hit -0,437 0,871 
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RHOBTB1 9886 NM_198225 138466 GUCCAAUUUAAAUGUCACGtc Non-hit -0,151 0,249 
RHOBTB2 23221 NM_015178 22631 AUCUUCUGCCAUCUCUUCCtg Mild hit -1,251 0,013 
RHOBTB2 23221 NM_015178 136812 GCUGACAUCAUCUACCACGtc Mild hit -0,667 0,338 
RHOC 389 NM_175744 44091 GACCUCCGGAAACUGAUCCtt Non-hit -0,017 0,916 
RHOC 389 NM_175744 44189 GAUCAUAGUCUUCCUGCCCtg Non-hit -0,318 0,607 
RHOD 29984 NM_014578 21520 GGUCAUAGUCAUCUUGCCCtg Non-hit -0,038 0,644 
RHOD 29984 NM_014578 21613 CACGACGAUGAUGGGUACCtt Non-hit -0,443 0,101 
RHOF 54509 NM_019034 27700 AAAAAAAAUUCCCAGACCCtc Non-hit 0,005 0,741 
RHOF 54509 NM_019034 27796 AUGCUUGUUUUAAAAGUCCtg Non-hit 0,091 0,694 
RHOG 391 NM_001665 10243 CACUUCCUUGACACCAUCCtg Mild hit 0,600 0,111 
RHOG 391 NM_001665 45990 UUAGUCCUUAAGGCACAGCtg Mild hit -1,448 0,057 
RHOH 399 NM_004310 5062 CUCCUUCUGUUUCGUCUCCtg Non-hit -0,102 0,435 
RHOH 399 NM_004310 120805 AUUGCUAAGGGCUGAGCACtc Non-hit 0,217 0,828 
RHOJ 57381 NM_020663 28549 CAAAAACCGCUUUGAGACCtt Mild hit -0,023 0,552 
RHOJ 57381 NM_020663 28644 UCCGUGCAAAGGGAGUUCCtt Mild hit -1,089 0,792 
RHOQ 23433 NM_012249 19665 CAGACGGUCAUAGUCUUCCtg Non-hit 0,394 0,064 
RHOQ 23433 NM_012249 19755 AUUGGGUAAGAUAAAGGCCtc Non-hit -0,304 0,574 
RHOU 58480 NM_021205 29108 CAGCUUGUCAAAUUCAUCCtg Non-hit -0,067 0,748 
207 
 
Gene Symbol 
1 
Gene ID1 RefSeq  
Accession 
Number2 
siRNA ID3 Antisense (target) siRNA Sequence3 Hit gene4 Z-score 5 P-value 5 
RHOU 58480 NM_021205 29197 GAUGGCUGCAUCAAAGACCtc Non-hit 0,093 0,727 
RHOV 171177 NM_133639 36445 AAGUCGGUCAAAAUCCUCCtg Mild hit -1,300 0,008 
RHOV 171177 NM_133639 120713 AGUACGUUGACAUCGUCCCtc Mild hit -0,039 0,450 
RND1 27289 NM_014470 21295 GGUCUCUGGAUAGCAAUCCtt Non-hit -0,369 0,881 
RND1 27289 NM_014470 21389 UAUCGUAGUAGGGAGAUCCtg Non-hit 0,120 0,590 
RND2 8153 NM_005440 16082 UAUCAUAGUAAGAGGAACCtg Strong hit -1,686 0,044 
RND2 8153 NM_005440 16252 UGUGUAACAGGGAUAAGCCtc Strong hit 0,541 0,444 
RND3 390 NM_005168 15798 AAAAUUCCUGGAUUUCACCtt Non-hit 0,439 0,317 
RND3 390 NM_005168 15891 GGUAUUUGGACAAAAUUCCtg Non-hit -0,340 0,779 
RNF5 6048 NM_006913 18776 CCCAUAAAGCGGGACAACCtt Mild hit -0,835 0,198 
RNF5 6048 NM_006913 46173 CUUUACAUACUGGACACUCtt Mild hit -1,086 0,394 
ROCK1 6093 NM_005406 681 ACCUUUUAAAUUGUCUGCCtc Mild hit -1,246 0,024 
ROCK1 6093 NM_005406 142844 ACACCAUUUCGCCCUAACCtc Mild hit 0,669 0,211 
ROCK2 9475 NM_004850 595 GCACUUCACCAAAAGCACCtc Mild hit -0,796 0,284 
ROCK2 9475 NM_004850 110865 UUUCCGUAAGGUAAUCUCCtc Mild hit -1,453 0,098 
SDC4 6385 NM_002999 12434 CUCAAAGUCAUCAGAUUCCtg Strong hit -1,784 0,003 
SDC4 6385 NM_002999 12529 CACCUUGUUGGACACAUCCtc Strong hit -1,075 0,100 
SDCBP 6386 NM_001007067 16556 CUUUAUCAGAGCUCCAUCCtg Non-hit -0,524 0,477 
208 
 
Gene Symbol 
1 
Gene ID1 RefSeq  
Accession 
Number2 
siRNA ID3 Antisense (target) siRNA Sequence3 Hit gene4 Z-score 5 P-value 5 
SDCBP 6386 NM_001007068 16651 GUGCCGUGAAUUUUAAACCtc Non-hit 0,139 0,126 
SDCBP 6386 NM_001007067 16742 AUGUAAGAUAGAAAGGUCCtc Non-hit 1,418 0,189 
SDCBP 6386 NM_001007070 121549 UGGCUUUUAGUCUAGAUGCtt Non-hit -0,604 0,104 
SDCBP 6386 NM_001007070 121550 UAAGCAGCUAUGCUAUAGCtc Non-hit -0,448 0,918 
SDCBP 6386 NM_001007070 121551 GGCUAGUGUACAUUUCAGGtt Non-hit 0,055 0,736 
SDCBP 6386 NM_001007070 288578 GAGGGAUAGGAGCAGAAGCtt Non-hit -0,255 0,211 
SDCBP 6386 NM_001007070 288579 GGGAGUCAAAAGUUUAUCCtg Non-hit -0,572 0,258 
SDCBP 6386 NM_005625 288580 AAUUGCUGGAUUGGCAGGGtt Non-hit -0,189 0,724 
SDCBP 6386 NM_005625 288581 CCAUCCCAAAGUAGCUAGGtt Non-hit -1,111 0,115 
SH3BP1 23616 NM_018957 27462 GCCUGAAUUCUUGGUUGCCtg Non-hit 0,201 0,241 
SH3BP1 23616 NM_018957 27556 UUUCCUCUUCAGCUCCUCCtc Non-hit 0,981 0,854 
SIRPA 140885 NM_080792 43659 UGACAUUCACCUGGUUCUCtg Non-hit -0,544 0,323 
SIRPA 140885 NM_080792 112326 CCACAAUAUAGAUGUUCCGtt Non-hit -0,307 0,719 
SORBS1 10580 NM_006434 22706 AGGUGAGGUGGGUUUUUCCtg Non-hit 0,292 0,390 
SORBS1 10580 NM_001034957 22801 UGCUCUUUUUUCAAUAGCCtt Non-hit 0,258 0,398 
SORBS1 10580 NM_015385 22895 UUCUCCAUAUUCCAAAACCtg Non-hit -0,926 0,141 
SORBS1 10580 NM_015385 136917 UUGCUUUCGUGUUGCCGGGtt Non-hit 0,418 0,538 
SORBS1 10580 NM_001034957 136918 GGAAACAUCGCUUAAGUCCtg Non-hit -0,753 0,044 
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SORBS1 10580 NM_001034957 136919 GGCUGAUAUUCGUAAAUGCtc Non-hit -1,577 0,040 
SORBS1 10580 NM_024991 288594 GUUUUUCACCAGUGGUCGCtt Non-hit -1,201 0,009 
SORBS1 10580 NM_006434 288595 UCUCUUUAUCAUCAUGACGtc Non-hit 1,264 0,083 
SORBS1 10580 NM_024991 288596 GCUACUGAGUCGUUUUUGCtg Non-hit 0,149 0,263 
SORBS1 10580 NM_015385 288597 CUAGCUGUAUUUAAAGAGGtg Non-hit -1,167 0,100 
SORBS1 10580 NM_015385 288598 AUGUCUGCAUAGGACAUGCtc Non-hit -0,252 0,621 
SORBS1 10580 NM_006434 288599 GGUUGAGUGAGGGAUUUGGtc Non-hit 0,488 0,588 
SORBS1 10580 NM_006434 288600 GUGAGUUAUUUGGAAUUCCtt Non-hit -0,916 0,412 
SORBS1 10580 NM_024991 288601 GAAAUUUCCGGAGUAGGGCtg Non-hit -0,242 0,807 
SORBS3 10174 NM_001018003 16824 GAAGGGUAGACAAAGUCCCtc Non-hit -0,711 0,005 
SORBS3 10174 NM_001018003 16920 CUCUUCUUCUCUUCCCUCCtg Non-hit -0,282 0,850 
SORBS3 10174 NM_005775 17014 UUUCUCUUCUUCUCUUCCCtc Non-hit -0,696 0,087 
SORBS3 10174 NM_001018003 126654 GUCUGGUCUCAAUAAGGCCtg Non-hit -0,923 0,304 
SOS1 6654 NM_005633 16561 ACUUUUUUGAACACGUUCCtc Mild hit -0,491 0,233 
SOS1 6654 NM_005633 142883 UUUAUAACCUAGGACCUCCtt Mild hit -1,300 0,449 
SOS2 6655 NM_006939 143048 UCUUUUCGUAUACAGAAGGtt Non-hit -0,524 0,493 
SOS2 6655 NM_006939 143049 AAGGACAUAACGAACUGCCtc Non-hit -0,619 0,145 
SPATA13 221178 NM_153023 39762 CAGAAGAUUGUCCAGUUCCtc Non-hit -0,658 0,200 
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SPATA13 221178 NM_153023 129604 UGUGGUCCUACUGACGAGCtt Non-hit 0,132 0,595 
SRC 6714 NM_198291 103333 CUUGCCAAAAUACCACUCCtc Non-hit -0,339 0,828 
SRC 6714 NM_198291 103417 CCUCAGCUUCUUCAUGACCtg Non-hit 0,124 0,836 
SRC 6714 NM_198291 142855 GCCUCCGACGAAUUGUUGGtt Non-hit -0,871 0,131 
SRC 6714 NM_198291 288644 CUAUGUCUGCUUGAUUGCCtc Non-hit -1,660 0,210 
SRGAP1 57522 NM_020762 148766 AACUCGCAUCUCCGUUUGCtg Mild hit -0,244 0,681 
SRGAP1 57522 NM_020762 148767 ACCAGAUCUCCCAAUUUGCtt Mild hit -1,326 0,061 
SRGAP2 23380 NM_015326 261179 UACCGAUUUACCAAUUUGCtt Non-hit -0,538 0,276 
SRGAP2 23380 NM_015326 261180 CCUUUAAUCUAACUAAGGCtc Non-hit 0,062 0,512 
SRGAP3 9901 NM_001033116 22081 GAAGGCAUCAUCCAUGUCCtg Strong hit -0,826 0,014 
SRGAP3 9901 NM_001033117 138476 CAAGUAGUCAUUCCGGGCCtt Strong hit 1,405 0,038 
SRGAP3 9901 NM_014850 22273 AAUAGAAACCUUUCAUCCCtt Strong hit -0,582 0,660 
SRGAP3 9901 NM_001033117 138477 GAGUAAAUCGUGCUUGGCCtg Strong hit -0,376 0,331 
SRGAP3 9901 NM_014850 138478 UAUAUACACUUAGUAUGCGtg Strong hit -1,112 0,042 
SRGAP3 9901 NM_014850 288609 UUAUAGCUGCGUUGGUGGCtg Strong hit -2,238 0,058 
STARD13 90627 NM_052851 288666 UCCAAAAGAUCUCCUGUGCtg Non-hit -0,170 0,543 
STARD13 90627 NM_178007 288668 GAGAAAGGUCUCACUGAGCtt Non-hit -0,494 0,980 
STARD13 90627 NM_052851 35407 GUGACCCAUUUCUGUCUCCtc Non-hit 0,340 0,736 
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STARD13 90627 NM_178007 35499 AAUGAUUUGGCCCUAGCCCtc Non-hit 0,200 0,849 
STARD13 90627 NM_178007 35584 UUAUGGAUUUACUGCUUCCtt Non-hit -0,624 0,524 
STARD13 90627 NM_178007 202336 GAUGGGAAAUUGUGAAUCCtc Non-hit 0,182 0,173 
STARD13 90627 NM_052851 202362 UUCAACGUAUUUAGUCGUCtg Non-hit 0,274 0,811 
STARD13 90627 NM_178008 131863 UGUUCAACGUAUUUAGUCGtc Non-hit 0,439 0,978 
STARD8 9754 NM_014725 21799 GAUGGUACACUGCUCUUCCtc Non-hit -0,613 0,322 
STARD8 9754 NM_014725 138366 UGGCCCUGUAAAAUCCAGCtg Non-hit 0,266 0,755 
STARD9 57519 AK122666 251250 UAUCUCAUUUACUCGUGGCtt Non-hit -0,852 0,170 
STARD9 57519 AK122666 251251 CUGAUUUCCAGUCUUCUGCtc Non-hit -0,743 0,110 
SYDE1 85360 NM_033025 34994 AGCAAGCGCGAGAACUACCtt Non-hit 0,196 0,309 
SYDE1 85360 NM_033025 125786 CUAAAGAGGUGUCCUCAGCtg Non-hit -0,876 0,906 
TENC1 23371 NM_198316 22677 AGGUUUCUUCCGGAAAACCtt Non-hit -0,640 0,127 
TENC1 23371 NM_198316 22773 UGUCCCAUCGAUGGUCACCtt Non-hit -0,842 0,090 
TENC1 23371 NM_170754 22868 AUGUUACCAUGACAUCGCCtt Non-hit -0,568 0,436 
TENC1 23371 NM_198316 136884 UUUUCUGUGCGUCGCCACCtt Non-hit -0,280 0,291 
TENC1 23371 NM_170754 136885 CAUUCCUAAGGGAGGGUGCtt Non-hit 0,253 0,429 
TENC1 23371 NM_198316 136886 GCAGUAUAGUACGACCACGtg Non-hit -1,244 0,096 
TES 26136 NM_152829 23211 AGAAGUGCAGUUCGAAUCCtt Non-hit -0,116 0,559 
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TES 26136 NM_152829 23307 UUUUCCCACUUUUCGAUCCtc Non-hit -1,557 0,002 
TES 26136 NM_152829 134609 UUUCGAUCCUCUUCAUUGCtc Non-hit 0,160 0,209 
TES 26136 NM_152829 134610 CACUUUGGAUAGCUAUGGCtc Non-hit -0,751 0,583 
TGFB1I1  7041 NM_015927 23481 CUGAGUGGCAUUAAGUUCCtg Non-hit -0,927 0,003 
TGFB1I1  7041 NM_015927 23577 AUCUUCAGACUGGUCCUCCtt Non-hit -0,434 0,032 
TIAM1 7074 NM_003253 4716 AAUGUCAUCAAAUAUUCCCtc Non-hit -0,909 0,761 
TIAM1 7074 NM_003253 138877 AGUCAGUGUAAGACACAGGtc Non-hit 0,684 0,623 
TIAM2 26230 NM_012454 20229 UGGGUCAGUGACAGUGUCCtt Non-hit -0,017 0,341 
TIAM2 26230 NM_012454 258554 UACUAUGAUUUUCCGUGGCtc Non-hit -0,748 0,555 
TIAM2 26230 NM_001010927 258555 AAACACGGUCCCAUAAUCCtc Non-hit 0,884 0,228 
TIAM2 26230 NM_001010927 258556 AGAUGGUUUCUGGCCGUCCtt Non-hit 0,470 0,088 
TLN1 7094 NM_006289 5379 AGCCUCCAGCCAUAUACCCtt Non-hit -0,982 0,174 
TLN1 7094 NM_006289 5467 GGUCCCUGUUAUUUCCUCCtt Non-hit -0,940 0,322 
TLN2 83660 NM_015059 5622 UCCAGCCAAAUCCCUUUCCtc Non-hit 0,937 0,048 
TLN2 83660 NM_015059 5717 UUUUGAGUGUGCCCGUUCCtt Non-hit -0,869 0,006 
TNS1 7145 NM_022648 30149 UGAACAGCAGGUAGUUGCCtc Non-hit 0,071 0,864 
TNS1 7145 NM_022648 30244 CCAGCCAAAUUCCAGUACCtt Non-hit -0,639 0,430 
TPM1 7168 NM_001018004 8333 CAGUUCAUCUUCGGUGCCCtt Non-hit -0,983 0,255 
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TPM1 7168 NM_001018020 8429 CUCACUCUCAUCUGCUGCCtt Non-hit 0,237 0,944 
TPM1 7168 NM_001018004 8523 UUCCUCAUAUCUGUCUUCCtt Non-hit -0,711 0,902 
TPM1 7168 NM_001018004 118352 UCAGAGAAGCUACGUCGGCtt Non-hit -0,608 0,088 
TPM1 7168 NM_001018008 118353 UCCAAUUUAGUUACUGACCtc Non-hit -0,919 0,130 
TPM1 7168 NM_001018005 118354 UUACAUGGAAGUCAUAUCGtt Non-hit 0,064 0,658 
TPM1 7168 NM_001018008 288545 UCUCAAUGACUUUCAUGCCtc Non-hit -0,640 0,955 
TPM1 7168 NM_001018008 288546 CUCUUUCAGUUGGAUCUCCtg Non-hit -0,621 0,387 
TPM2 7169 NM_003289 12962 AUACUUUUCCACCUCAUCCtc Non-hit -1,428 0,592 
TPM2 7169 NM_003289 13058 UUCAGAAUACUUUUCCACCtc Non-hit -0,960 0,007 
TPM2 7169 NM_213674 13149 UUUCGAUGACCUUCAUUCCtc Non-hit -0,468 0,413 
TPM2 7169 NM_213674 118375 CAGCUUGCUUCUUGUCGGCtt Non-hit -0,110 0,707 
TPM3 7170 NM_153649 43886 UUUCAAUAACCUUCAUACCtc Non-hit -0,645 0,089 
TPM3 7170 NM_153649 43982 GGCCCGGUUUUCAAUAACCtt Non-hit -0,604 0,003 
TPM3 7170 NM_152263 46535 UUUUUCAGCUUCUUCCAGCtt Non-hit -0,380 0,519 
TPM3 7170 NM_153649 288634 AAGAAUCUUGAUUUCUUCCtc Non-hit -0,632 0,930 
TPM4 7171 NM_003290 12963 UUUCUAUCACCUUCAUUCCtc Non-hit -0,295 0,654 
TPM4 7171 NM_003290 13059 GGCCCGGUUUUCUAUCACCtt Non-hit -0,444 0,730 
PTPN11 5781 NM_080601 4449 GAAAACUACCAUGUUUUCCtt Strong hit -1,781 0,001 
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TRIO 7204 NM_007118 849 GAUAUGUUCAUAUAUUCCCtg Non-hit 0,066 0,930 
TRIO 7204 NM_007118 103343 AAUGAGUCUCCUGAGAUCCtc Non-hit 0,578 0,948 
TRIP6 7205 NM_003302 12968 AAACUUCCUGUGAAAGUCCtc Non-hit -0,875 0,212 
TRIP6 7205 NM_003302 13155 AACAAUUCUCACAGUCUCCtc Non-hit -0,686 0,048 
TRPM7 54822 NM_017672 1490 AAGGCAUCUGUGAGGGUCCtt Strong hit -1,565 0,001 
TRPM7 54822 NM_017672 212797 AGUAAAACAAGCAUGUUGCtt Strong hit -1,608 0,115 
TSPAN4 7106 NM_001025234 12769 CAGGAGGCACUUGUUCUCCtt Non-hit 0,158 0,424 
TSPAN4 7106 NM_003271 12860 GUUCUCCUGAAGCCACACCtt Non-hit 0,013 0,537 
TSPAN4 7106 NM_003271 46050 GAAAGUGAGCAGGAGGCACtt Non-hit -0,178 0,679 
TSPAN4 7106 NM_003271 138895 ACCACUUGGCAGUACAUGGtc Non-hit -0,508 0,111 
TSPAN4 7106 NM_003271 138896 GCCCACUAUGGAAUGUAGGtg Non-hit -0,619 0,788 
TSPAN4 7106 NM_001025239 288553 GCCUUUCUUCAGGUCUUGCtg Non-hit -0,234 0,849 
TSPAN4 7106 NM_003271 288554 UUUUUUUCAAGGUUGCUGCtc Non-hit 0,237 0,232 
TSPAN4 7106 NM_001025238 288555 UACCUGUCAAUCUUGUCCGtg Non-hit -1,093 0,112 
TSPAN4 7106 NM_001025238 288556 UACAUGGUCAUGGCGAAGGtc Non-hit 0,983 0,329 
TSPAN4 7106 NM_001025235 288557 AACCUGUUUUCCAGGAGGCtg Non-hit -0,356 0,425 
TSPAN4 7106 NM_001025239 288558 UCGAACCAGUCAGUGUAGUtg Non-hit -1,064 0,214 
TSPAN4 7106 NM_001025239 288559 ACGGGCCCACUAUGGAAUGta Non-hit -0,540 0,415 
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TSPAN4 7106 NM_003271 288560 CCUGUCAAUCUUGUCCGUGta Non-hit -0,889 0,243 
TSPAN4 7106 NM_003271 288561 UGCUCACACUUUAUUAAGAtg Non-hit -0,798 0,042 
TSPAN6  7105 NM_003270 12768 GUAAUUCUCCAGGCUCACCtt Non-hit -0,222 0,543 
TSPAN6  7105 NM_003270 138892 AUCUUGUCUACUGCAUGGCtt Non-hit 0,257 0,251 
TUBA1B  10376 NM_006082 42130 UCUCAAGGGCAGCCAUAUCtt Non-hit 0,628 0,015 
TUBA1B  10376 NM_006082 42217 UGGAUAAUUAGUAUUCCUCtc Non-hit -0,311 0,618 
TUBB 203068 NM_178014 120764 GACUCCUCCAGAGUAGAGCtt Mild hit -1,083 0,015 
TUBB 203068 NM_178014 120844 GUUGGUUCUAAAUGGGAUCtg Mild hit -1,028 0,182 
LOC441930 441930 XM_497745 271492 UAGGAAAACCUGGUGGUCCtc Non-hit 0,136 0,738 
LOC441930 441930 XM_497745 271493 AGGACACCAUCCUUAUCCCtt Non-hit -0,921 0,343 
VASP 7408 NM_003370 13013 UCCUGCUUGCUGACUUUCCtg Non-hit 0,034 0,902 
VASP 7408 NM_003370 13105 CCAACUUGCGUGGCUUUCCtt Non-hit -0,830 0,108 
VASP 7408 NM_003370 13195 GUUACAGCAUCUUAUUUCCtc Non-hit -0,565 0,384 
VASP 7408 NM_003370 288562 ACUUUGAAGGCAUUAAGCGtt Non-hit 0,700 0,147 
VAV1 7409 NM_005428 2839 GAUGACCUUGCCAAAAUCCtg Non-hit -0,898 0,006 
VAV1 7409 NM_005428 2933 AGACAGGGUGUAGAUGACCtt Non-hit 0,310 0,789 
VAV2 7410 NM_003371 13014 UCAAACAGCUCGCUGUUCCtt Mild hit -1,259 0,006 
VAV2 7410 NM_003371 138981 CCUUAAUCCAAAUUUAUCGtg Mild hit -0,225 0,700 
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VAV3 10451 NM_006113 17378 CAGGCCGUGAGAAAUGUCCtt Mild hit -0,396 0,677 
VAV3 10451 NM_006113 107954 CACAUAUUGUGCCAAGUCCtt Mild hit -1,121 0,345 
VCL 7414 NM_003373 20480 UCUCUUCAAAAUCUGAUCCtc Mild hit -1,187 0,008 
VCL 7414 NM_014000 20570 GGUGCAAGCAUUCUCAACCtt Mild hit -0,772 0,144 
VCL 7414 NM_014000 108453 AAUUUUACGGACCUCAGCCtc Mild hit -0,590 0,235 
VCL 7414 NM_014000 108454 UGGCCAUCUUAGUCAUUCCtg Mild hit -1,012 0,364 
VIM 7431 NM_003380 13019 AAAUCCUGCUCUCCUCGCCtt Non-hit -0,362 0,433 
VIM 7431 NM_003380 13111 CAGAGAAAUCCUGCUCUCCtc Non-hit -0,506 0,106 
YES1 7525 NM_005433 690 UUAAAAAAUCAAUGCAACCtc Non-hit 0,511 0,121 
YES1 7525 NM_005433 691 GAAAUUAACUGCUGUUCCCtt Non-hit 0,437 0,564 
ZYX 7791 NM_003461 13054 AUACUGCUCACCUUCUCCCtg Non-hit -0,597 0,099 
ZYX 7791 NM_003461 13145 CAAAUCAAUACUGCUCACCtt Non-hit 0,091 0,655 
ZYX 7791 NM_003461 115435 CAUAGGUGAAGCUGGGAGGtt Non-hit 0,159 0,379 
ZYX 7791 NM_003461 139068 AUCCCUAGACCAUGUUGGGtc Non-hit -0,605 0,968
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Appendix III. Expression of kinesins in HeLa cells 
Gene ID and gene information is given according to http://www.ncbi.nlm.nih.gov/gene/ 
Gene Symbol Gene ID Expression in HeLa Forward primer 
Sequence (5'->3') 
Reverse primer 
Sequence (5'->3') 
Expected 
fragment 
length, b.p. 
KIFC1  3833 + GAGTGGGTGGTGGCCGTTGG GCACCCAGGCCTCTGTCCG 334 
KIFC2 90990 + GAGACGGAGCAGAACTGCAGGCG AGGTCTTCCCGGTGCCTGTCTGG 526 
KIFC3  3801 + GTCGGCTCTGGGGGACGTCAT ACTTCCCCGAGGGCTGCAGCTTC 373 
KIF1A 547 - CAGTGAGGACCAGCAGGCTATGCTC AGAGCCGAGTGTCACCCCTCACCC 1000 
GCTGGAGGCCCCGGAGTGACA GGGGCAAGTGGAGGGAGGGGGTGAG 440 
TCCCAACTTGTTCCACCAGAGCAC GACGAGTCCTGGACAGATCTGTGGCCTAT 1275 
KIF1B 23095 + CCTGCAACTTCTCACCCACACTT AGGCCGACGGACGACAACAAAAT 407 
KIF1C 10749 + ATGGCGTCACCAGGGTCGGC GCTGGGCAGACCACAGCGTT 586 
KIF2A 3796 + GGGGTGTGGGGAGTTCCCCT GGCACGGGGTCTCTTCGGGT 373 
KIF2C 11004 + AGTTGGGCCTGGAAGTCTATGTGA ACGGGGTGTGAGCCTTGTTCTG 440 
KIF3A 11127 + AACTGGAGCTACTGGACAGCGCC CGAAGCTCCCGGCTAAGTTGCCG 981 
KIF3B 9371 + GAGCCGTCTGAGGGCCTTCATGC GCGCCCTTGGTCATGGAGGTGTG 322 
KIF3C 3797 + CCCGCCGGAGGaGAAGAACAAGAT GGAAGGTGGAGGCCGCTGAGGACT 405 
KIF4A 24137 + GAACCGCCAGCAAGGCAAGGATAG TCTGGACCTGGAGGCTAAGGCCCA 526 
KIF5A 3798 - TCTGGAGGAGACAGTTGCCCGG AGAATGGCCCCGTTTGCCCG 399 
AGAAATGGAGCCCGAAGACAGTGG TAGGGGTTGGTGGGTGAGGATGCT 345 
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KIF5B 3799 + CGGTCGTGATCGCGTCCAAGC ACAAAACGCTCTGTGCACCCC 405 
KIF5C 3800 + CATTCAGCCCAGATCGCCAAGCC TCTGCCTCCACGGCACTTGGTTG 506 
KIF6 221458 - TGGAAGACAGCATCCCCAAGAGGC AACCAGAGCACGGGCCAAGG 581 
   GCCGTGCCTCTGATGCCAGAC TGGCCTCTTGGGGATGCTGTC 458 
KIF9 64147 - TTCAAAGAGCCACTCAGGCCCGAC GCAGGCGGTGGCGACACTGATC 403 
GGCCCATTCCCGGACCTTATCA CCTCAAGAAGCAGTACCGCAGCGA 356 
KIF11 3832 + TCCCAACAGGTACGACACCACAG TGGGCTCGCAGAGGTAATCTGC 397 
KIF13A 63971 + GTACACTCGAGGCGTGCTGCAGG GGCATGCTCTCCTGGCTTAGAAGAGG 449 
KIF15 56992 + CTCCATGCGGGCGTCAACGT CCTGAGCCAGTCTGTCCATATGCA 483 
KIF16B 55614 + AGGAACCACCACAGCAGTG AATATAGCCAGCCACATGG 429 
KIF17 57576 + CTGGCCCGTCTGCAGCTGTTGG AGGCTGGTTTTTGTGATGACGGGATG 491 
KIF18A 81930 + CCTTGTTGCTCATCTTCAGGTGGAA TGGCACCATGCTTGGTACAGGC 512 
KIF19 124602 - GCGGGAGGACTCTAAGGGGGTGAT TGAGCTTGCTGTCGCGATAGTTGA 397 
CATCGCCCAGTACACCAGCATCAT CCCTGTCCCCTAAACCCACTCTCC 554 
KIF20A 10112 + GGAGTTGGCTGCTGAAGCCTCAAG GGGCAGCCAGGTCCGAAGACG 407 
KIF22 3835 + TGCTCCGGCCCCTTTCACAT CTCCCGCCAGCCCACGATTAG 337 
KIF23 9493 + TCTCCATCACCTGTGCCTCTTTCT CGGAGACGAATTGGTGGTGCGT 374 
KIF24 347240 + GAGCACAGGGGGCCCAGTTGTG ATGACCACCTGCTGCGCTTGCTC 636 
KIF26B 55083 - TGCTGCGGGAGTCTCTGGGGAACA GCAGGGCTGGCACGATAGGGACAA 387 
GGG GCT GGG CAA GGT GAA AGT GAG GTA CAC GCC CGG GGA CT 549 
CGCCCTACAGCAAGATCACGCCC CACATGGCCTCCTTGCTGGCACC 493 
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Appendix IV. Results of the validation experiments 
1  Gene name and Gene ID according to  http://www.ncbi.nlm.nih.gov/gene/  
2  Manufacturer's SiRNA ID. The IDs starting with SI... belong to siRNAs purchased from Qiagen. The numeric siRNA IDs belong 
to siRNAs purchased from Ambion. 
3 Target mRNA accession number according to  http://www.ncbi.nlm.nih.gov/nuccore/ 
4 ND = „No Data“ 
Gene 
Symbol 1
Gene 
ID1 
siRNA_ID2 Target sequence 2 Target 
transcript 3 
Mean 
integrin 
endocytosis, 
% of 
control 
Integrin 
endocytosis
, SEM 
Mean 
integrin 
expression, 
% of 
control 
Integrin 
expression, 
SEM 
Mean cell 
count, % 
of control
Cell 
count, 
SEM 
Negative 
control 
siRNA 
 251283 ACGUGACACGUUCGGAGAAtt  100  100  100  
CAV1 857 SI00299635 AAGCATCAACTTGCAGAAAGA NM_001172895 
NM_001172896 
NM_001172897 
NM_001753 
31,68 13,03 95,86 10,14 105,46 16,8 
CAV1 857 SI00299642 AAGCAAGTGTACGACGCGCAC NM_001172895 
NM_001172896 
NM_001172897 
NM_001753 
28,78 15,9 79,83 1,33 65,79 12,04 
CLTC 1213 SI00299880 TAATCCAATTCGAAGACCAAT NM_004859 26,16 0,72 ND4 ND ND ND 
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, SEM 
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integrin 
expression, 
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control 
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expression, 
SEM 
Mean cell 
count, % 
of control
Cell 
count, 
SEM 
DNM2 1785 SI02654687 CTGCAGCTCATCTTCTCAAAA NM_001005360 
NM_001005361 
NM_001005362 
NM_004945 
27,2 6,63 82,45 13,77 98,56 6,88 
DNM2 1785 SI04224591 CTCATACGTGGCCATCATCAA NM_001005360 
NM_001005361 
NM_001005362 
NM_001190716 
NM_004945 
21,14 6,2 95,58 10,07 99,15 10,83 
ABL2 27 SI02634499 CCCAAGTGTAATAAGCCTACA NM_001100108 
NM_001136000 
NM_001136001 
NM_001168236 
NM_001168237 
NM_001168238 
NM_001168239 
NM_005158 
NM_007314 
88,09 26,92 96,83 0,59 49,15 14,98 
ABL2 27 SI02660287 AACCCTGTCCTTAATAACTTA NM_001100108 
NM_001136000 
NM_001168236 
NM_001168237 
NM_001168238 
NM_001168239 
NM_005158 
NM_007314 
52,78 9,94 56,84 4,49 72,05 18,60 
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, SEM 
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expression, 
SEM 
Mean cell 
count, % 
of control
Cell 
count, 
SEM 
ABR 29 SI00290388 AAGCGTTTGTCGATAACTATA NM_001092 
NM_001159746 
NM_021962 
13,16 2,19 60,22 1,30 83,70 2,79 
ABR 29 SI04334841 CACCAGCAATAAAGACGACGA NM_001092 
NM_001159746 
NM_021962 
203,25 41,01 124,51 2,55 71,65 16,27 
ARF1 375 SI00299250 ACGTGGAAACCGTGGAGTACA NM_001024226 
NM_001024227 
NM_001024228 
NM_001658 
35,77 3,32 68,00 13,80 186,80 55,70 
ARF1 375 SI02654470 CACCATAGGCTTCAACGTGGA NM_001024226 
NM_001024227 
NM_001024228 
NM_001658 
49,17 7,43 99,11 17,67 99,16 37,85 
ArhGAP
18 
93663 SI00302169 CAGGGAGTGATTCGAGTGCAA NM_033515 20,64 228,66 89,45 4,98 57,93 5,46 
ArhGAP
18 
93663 SI03238522 TGGCTTAAAGAGGCCGGTTTA NM_033515 43,52 11,40 96,35 4,02 76,57 7,99 
ARHGA
P6 
395 SI04173302 CAGGGCCTATAAACTCAAGCA NM_006125 
NM_013423 
NM_013427 
42,03 6,35 43,14 4,33 75,59 7,24 
ARHGA
P6 
395 SI04283888 CAGAAACACCGAATGAGTCAA NM_006125 
NM_013423 
NM_013427 
81,09 22,14 ND 4 ND 99,68 5,92 
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Gene 
ID1 
siRNA_ID2 Target sequence 2 Target 
transcript 3 
Mean 
integrin 
endocytosis, 
% of 
control 
Integrin 
endocytosis
, SEM 
Mean 
integrin 
expression, 
% of 
control 
Integrin 
expression, 
SEM 
Mean cell 
count, % 
of control
Cell 
count, 
SEM 
ArhGEF
1 
9138 SI00302680 CAGCAGCTCTGAGAACGGCAA NM_004706 
NM_198977 
NM_199002 
110,75 29,06 87,84 8,40 76,58 5,66 
ArhGEF
1 
9138 SI04266171 CCCAATGAGCCTGGAGTCCTT NM_004706 
NM_198977 
NM_199002 
109,26 19,10 61,61 0,04 57,37 6,88 
CHN1 1123 SI04145456 ATCCTCGAAGAATTACCTGTA NM_001025201 
NM_001822 
22,33 4,00 71,46 0,35 ND ND 
CHN1 1123 SI04248531 TTGGGCATATAACCAGATTAA NM_001025201 
NM_001822 
163,74 18,39 122,51 7,03 ND ND 
CRK 1398 146743 GAGGCAAGAUACCUAUCCCtt NM_016823 149,34 27,24 88,29 14,33 77,42 12,50 
CRK 1398 146745 UCGCCAUUUGAUAGUAUGGtt NM_005206 208,24 14,32 132,02 25,79 104,42 13,39 
CRK 1398 SI00073787 CAGCAGCTAACTAGAGTCCTA NM_005206 
NM_016823 
107,84 8,14 95,99 39,81 74,26 5,69 
CRK 1398 SI00299929 AATCCGGGACAAGCCTGAAGA NM_005206 
NM_016823 
106,10 12,61 78,83 6,35 94,01 10,46 
ITGB1 3688 SI00300573 AAAAGTCTTGGAACAGATCTG NM_002211 
NM_033666 
NM_033667 
NM_033668 
NM_033669 
NM_133376 
7,38 3,40 54,12 7,10 ND ND 
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Gene 
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siRNA_ID2 Target sequence 2 Target 
transcript 3 
Mean 
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Integrin 
endocytosis
, SEM 
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expression, 
% of 
control 
Integrin 
expression, 
SEM 
Mean cell 
count, % 
of control
Cell 
count, 
SEM 
ITGB1 3688 SI02662590 ACAGATGAAGTTAACAGTGAA NM_002211 
NM_033666 
NM_033667 
NM_033668 
NM_033669 
NM_133376 
0,67 0,67 50,76 7,44 ND ND 
KIF11 3832 SI02653693 ACGGAGGAGATAGAACGTTTA NM_004523 101,80 11,85 ND ND 50,89 14,78 
KIF11 3832 SI02653770 GCCGATAAGATAGAAGATCAA NM_004523 101,02 15,56 ND ND 41,46 6,48 
KIF13a 63971 29651 GCAGGACCGUUUGAUUCCCtt NM_022113 125,23 0,80 155,04 23,06 102,02 21,26 
KIF13a 63971 29745 AAUACCUUGGGAGGUUUCCtt NM_022113 79,48 21,32 81,32 11,12 99,14 48,11 
KIF13a 63971 SI00462322 AACCTATGAAATAGTATCCAA NM_001105566 
NM_001105567 
NM_001105568 
NM_022113 
59,84 10,30 73,65 1,58 106,45 38,18 
KIF13a 63971 SI03019800 CTGGCGGGTAGCGAAAGAGTA NM_001105566 
NM_001105567 
NM_001105568 
NM_022113 
55,56 9,29 68,60 11,87 84,40 4,12 
KIF15 56992 118474 AGUUCUGCUCUCCAUCAGCtg NM_020242 86,31 6,06 88,59 8,34 125,79 2,11 
KIF15 56992 28246 AAACUUUGAUGGCAUCACCtt NM_020242 27,80 4,45 96,50 2,30 106,44 7,75 
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Cell 
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SEM 
KIF15 56992 SI02643914 TTGAGATTGACCAACTTTCAA NM_020242 129,74 18,17 116,20 8,96 74,13 3,99 
KIF15 56992 SI03029390 AACGAGCAGATATATGATCTA NM_020242 47,85 0,25 76,53 4,62 87,27 6,49 
KIF16b 55614 288693 UGUGAAACGUAAUCUGGGCtt BX647572 101,58 3,79 110,16 17,06 ND ND 
KIF16b 55614 288694 UGUUGAUGAUGUUUUUGGCtc BX647572 125,12 12,31 107,39 18,49 96,00 12,03 
KIF16b 55614 SI00287280 AACGAACGTGTGAGAGATCTA NM_001199865 
NM_001199866 
NM_024704 
78,23 5,27 ND ND 100,34 4,62 
KIF16b 55614 SI00287301 TTGCATCGTGTGATTAGTGAA NM_001199865 
NM_001199866 
NM_024704 
97,09 12,00 100,43 5,72 82,43 4,12 
KIF17 57576 SI00462364 CAGCAACTACTTCCGATCTAA NM_001122819 
NM_020816 
NM_020816 
NM_020816 
83,80 10,06 ND ND 92,39 6,73 
KIF17 57576 SI03099243 CTGGGTGCTGCTTAACGTCTA NM_001122819 
NM_020816 
NM_020816 
NM_020816 
78,47 4,37 ND ND 122,96 24,44 
KIF18a 81930 118492 CUUUAUGAAAUCCAGCUGCtt NM_031217 51,12 9,54 97,64 16,74 98,64 31,44 
KIF18a 81930 32973 UCAGUGGGAUGUUGUGUCCtg NM_031217 43,54 12,65 75,91 8,52 72,72 11,26 
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KIF18a 81930 SI00140238 CAGGTGGAACTAATCTGGTTA NM_031217 196,97 27,07 109,63 18,38 71,58 13,37 
KIF18a 81930 SI03090941 CTCGAAGTGTAAATTACCCGA NM_031217 145,65 36,36 90,72 1,60 52,54 21,05 
KIF1b 23095 118460 GAAGGACUUUGGAGCUUCCtt NM_183416 99,67 21,32 112,96 4,75 114,10 16,39 
KIF1b 23095 22400 AAUGAUGCAUUUGGAUUCCtt NM_183416 55,78 7,70 85,19 14,08 93,70 3,23 
KIF1b 23095 SI03078040 CCCGCGGATATCAACTACGAT NM_015074 
NM_183416 
69,03 7,80 75,15 4,01 83,24 7,80 
KIF1b 23095 SI03103345 GAGGAAGCTATTGAACGTTTA NM_015074 
NM_183416 
79,65 7,92 82,83 7,05 80,32 4,39 
KIF1c 10749 SI02655401 AAGAAGCGAAAGTCGGATTTT NM_006612 93,32 12,95 ND ND 81,27 17,25 
KIF1c 10749 SI02781331 CTGGAGAATCAGTACCGGAAA NM_006612 132,85 9,95 ND ND 111,27 10,80 
KIF20a 10112 SI00300601 AAGGCCAGGTTTCTGCCAAAA NM_005733 102,97 13,36 ND ND 102,84 47,17 
KIF20a 10112 SI02654064 AACGAACTGCTTTATGACCTA NM_005733 101,51 0,16 ND ND 65,63 15,29 
KIF22 3835 118450 CGAGUAGCUCCAAUCUUGCtt NM_007317 
AB017430.2 
BC004352.1 
BT007259.1 
AK223431.1 
DC370294.1 
AK312234.1 
141,74 2,68 110,58 1,13 46,90 7,25 
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AK294380.1 
AK316050.1 
KIF22 3835 19353 CUGGUAUUUGAGAGUCUCCtg NM_007317 
AB017430.2 
BC004352.1 
BT007259.1 
AK223431.1 
DC370294.1 
AK312234.1 
AK294380.1 
AK316050.1 
211,43 52,25 109,23 19,10 19,65 4,34 
KIF22 3835 SI02638713 CAGGACATCTATGCAGGTTCA NM_007317 82,69 13,68 82,69 13,68 84,31 20,34 
KIF22 3835 SI03019856 ACAGATGGAGTCCTTCCTGAA NM_007317 87,55 3,65 87,55 3,65 107,64 4,30 
KIF23 9493 118501 CUUAUAGUCUCCAUUUCGGtt NM_138555 25,40 6,36 92,69 33,23 49,11 22,74 
KIF23 9493 36749 AAAUGAAUACUGAGUCUCCtt NM_138555 50,89 6,86 79,80 5,06 81,46 28,84 
KIF23 9493 SI02653483 AAGGCTGAAGATTATGAAGAA NM_004856 
NM_138555 
107,33 17,74 79,72 11,24 73,41 5,47 
KIF23 9493 SI02653910 CAGAAGTTGAAGTGAAATCTA NM_004856 
NM_138555 
168,49 28,47 81,22 30,62 61,16 12,62 
KIF24 55265 26683 CUGUGGCAUUCAGAAUUCCtg NM_018278 212,10 13,90 66,58 8,24 ND ND 
KIF24 55265 26777 AAAUAACUUAUUGUCACCCtg NM_018278 83,99 16,67 100,12 28,11 ND ND 
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KIF24 55265 SI03019926 ACCCTATTCTATCATCATATA NM_194313 72,35 11,01 60,11 2,94 86,77 7,82 
KIF24 55265 SI04714192 TACGTCGTGGAGAAATTAATA NM_194313 100,54 7,45 88,49 21,51 96,49 10,05 
KIF2a 3796 14669 CCAGGUCAAUCUCUUUGCCtt NM_004520 352,91 41,60 163,11 5,33 ND ND 
KIF2a 3796 14762 GUCUAUAAUCCAAACUUCCtc NM_004520 59,52 22,00 57,50 6,59 108,71 9,22 
KIF2a 3796 SI02781310 CAGCAAGCAAATCAACCCGAA NM_001098511 
NM_001243952 
NM_001243953 
NM_004520 
119,74 19,07 82,63 8,97 90,76 10,59 
KIF2a 3796 SI03019751 AAGAACCAAGATTGTTCTAAA NM_001098511 
NM_001243952 
NM_001243953 
NM_004520 
49,07 7,06 66,53 13,13 84,94 2,73 
KIF2a 3796 SI04435613 AAGCGCAGCGATGGCCGAATA NM_001098511 
NM_004520 
NM_004520 
NM_004520 
105,93 9,71 84,81 11,05 74,84 6,95 
KIF3a 11127 SI02655415 AAGACCTGATGTGGGAGTTTA NM_007054 77,48 7,77 ND ND 147,18 9,58 
KIF3a 11127 SI04438847 CAAGAACGCTTGGATATTGAA NM_007054 79,25 6,72 ND ND 95,85 24,00 
KIF3b 9371 SI02655303 AATCCGTGGTGACCCTGAAAA NM_004798 104,20 5,31 ND ND 93,09 24,22 
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KIF3b 9371 SI03019772 CAGAAATGCATGGGTAAGGTA NM_004798 122,71 8,94 ND ND 105,80 18,48 
KIF4a 24137 288675 UGUUCUUGAUUUUUCUUGCtc AF071592 87,74 22,89 103,93 20,87 105,81 10,65 
KIF4a 24137 288676 UUAGAUGAUUAAGUUCAGCtg AF071592 102,58 28,96 143,48 29,66 84,09 8,55 
KIF4a 24137 SI00099232 CAGGTCCAGACTACTACTCTA NM_012310 87,97 11,14 68,54 2,96 ND ND 
KIF4a 24137 SI03030699 AACTGTGGAACCATCAGAGAA NM_012310 60,63 0,68 ND ND ND ND 
KIF5b 3799 SI02654848 AAACCGAGTTCCCTATGTAAA NM_004521 88,96 20,66 ND ND 111,34 14,24 
KIF5b 3799 SI02781317 AACGTTGCAAGCAGTTAGAAA NM_004521 72,77 1,53 ND ND 72,81 14,13 
KIF5c 3800 SI04916394 TCCCACGAATTGCCCATGATA NM_004522 128,43 2,08 ND ND 101,41 24,92 
KIF5c 3800 SI04916401 CCGACACGTGGCTGTGACAAA NM_004522 85,04 7,82 ND ND 116,13 33,27 
KIFC1 3833 43827 UCCUCUUGAGUCUGCUUCCtg NM_002263 153,12 14,88 104,06 17,18 89,11 5,46 
KIFC1 3833 43923 UGUCCGUUUCUUCUCAGGCtc NM_002263 114,42 12,99 84,57 15,25 ND ND 
KIFC1 3833 SI02653210 TGGGACTTAAAGGGTCAGTTA NM_002263 102,34 25,41 83,57 83,57 74,67 20,29 
KIFC1 3833 SI02653336 TCGGGAAACACAGGCCATTAA NM_002263 49,10 2,59 95,42 14,80 87,80 8,64 
KIFC2 90990 SI03019884 CCAGATGGATCCACATCCCAA NM_145754 113,19 0,44 ND ND 84,09 1,54 
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KIFC2 90990 SI03092250 CTCGTTGCTCATCTACATCTT NM_145754 70,39 13,93 ND ND 77,34 7,83 
KIFC3 3801 SI00078722 CAGCGCTGCGGAGATCTACAA NM_001130099 
NM_001130100 
NM_005550 
NM_001130100 
NM_005550 
NM_001130100 
NM_005550 
93,62 9,99 ND ND 88,60 17,75 
KIFC3 3801 SI03082583 CCGGGCGCAGATTGCCATGTA NM_001130099 
NM_001130100 
NM_005550 
NM_001130100 
NM_005550 
NM_001130100 
NM_005550 
124,21 7,18 ND ND 89,98 14,40 
LIMS1 3987 SI00071043 TAGGAAATAGAGGCTTTCAAA NM_004987 122,97 6,52 109,72 19,67 ND ND 
LIMS1 3987 SI03031609 AAGACTTAAGAAACTAGCTGA NM_004987 74,54 2,53 96,57 2,08 ND ND 
Myo1a 4640 SI00653268 CTGGATAGTGAATCGAATCAA NM_005379 165,23 8,59 95,64 12,65 85,23 8,92 
Myo1a 4640 SI04242917 GCCCGAAAGAATTATCGCAAA NM_005379 72,02 13,87 81,00 4,18 91,59 9,90 
Myo1a 4640 16050 AAACGGCUUGUUUUGGGCCtc NM_005379 36,43 12,58 67,95 4,19 126,42 46,71 
Myo1a 4640 144012 GCGAUAAUUCUUUCGGGCCtt NM_005379 42,19 37,93 74,17 15,61 116,50 32,84 
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NF2 4771 202366 GGCAGUAGAUCUUUUCAUCta NM_181825 41,67 7,87 79,04 9,90 136,65 0,51 
NF2 4771 288641 CUCUUGAGAGAGCUGAAGCtc NM_181834 35,59 3,10 95,89 13,64 85,77 3,19 
NF2 4771 SI02664137 CACCGTGAGGATCGTCACCAT NM_000268 
NM_016418 
NM_181825 
NM_181828 
NM_181829 
NM_181830 
NM_181831 
NM_181832 
NM_181833 
129,73 18,86 87,57 2,92 74,82 7,62 
NF2 4771 SI02664452 CCGGGTCGCGCCTGCACCGAA NM_000268 
NM_016418 
NM_181825 
NM_181828 
NM_181829 
NM_181830 
NM_181831 
NM_181832 
NM_181833 
86,42 7,07 93,48 18,76 90,87 9,88 
PRKCA 5578 SI00301308 AACCATCCGCTCCACACTAAA NM_002737 101,02 23,33 73,18 4,75 62,52 11,79 
PRKCA 5578 SI00605934 TACAAGTTGCTTAACCAAGAA NM_002737 65,43 7,28 102,95 4,25 99,24 32,08 
PTEN 5728 SI00301504 AAGGCGTATACAGGAACAATA NM_000314 88,20 9,65 89,61 3,21 123,54 56,29 
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PTEN 5728 SI03116092 TCGACTTAGACTTGACCTATA NM_000314 118,43 13,79 123,71 4,74 67,57 20,36 
PTPN11 5781 SI02225902 CAGAAGCACAGTACCGATTTA NM_002834 132,87 7,40 99,67 16,31 84,74 3,62 
PTPN11 5781 SI02225909 CCGCTCATGACTATACGCTAA NM_002834 39,15 5,19 76,83 3,72 66,07 28,10 
TRPM7 54822 SI03048465 ATCGGAGGTCTGGCCGAAATA NM_017672 79,52 8,29 61,59 3,63 108,13 13,59 
TRPM7 54822 SI03079468 CCCTGACGGTAGATACATTAA NM_017672 179,54 58,91 70,97 3,62 51,40 5,43 
 
 
